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ABSTRACT 
 
Oncological diseases remain one of the major worldwide Public Health 
concerns. Despite this, the therapeutic options for many cancer patients are still limited and 
disappointing, mainly due to chemoresistance and severe side effects. On the other hand, 
the development of new anticancer therapies has shown to be a slow and highly unreliable 
process.  
Compelling evidence has demonstrated that inactivation of the p53 pathway underlies 
tumor development and maintenance. In fact, in the majority of human cancers, the p53 
function is compromised, either by mutation or by inhibition through interaction with negative 
regulators, such as murine double minute (MDM)2 and MDMX. Based on this, the inhibition 
of the p53 interaction with MDMs and the restoration of wild-type (wt)-like function to mutant 
p53 have been recognized as hopeful strategies in anticancer treatment. However, despite 
all the efforts made to find new small molecule activators of p53, to date, few entered into 
clinical trials and none has reached the clinic.  
Hence, with the present thesis, we intended to find new pharmacological options 
against cancer by targeting p53, focusing on inhibitors of the p53 interaction with 
MDM2/MDMX (MDMs) and reactivators of mutant p53. For that, a drug screening strategy, 
based on yeast, tumor cell lines and animal models, was used to test several chemical 
libraries, comprising compounds with scaffolds previously reported to be promising in the 
search for modulators of p53 activity, namely containing indole and/or isoindolinone 
moieties. With this approach, an enantiopure phenylalaninol-derived oxazolopyrrolidone 
lactam (oxazoloisoindolinone 3a) was identified as new inhibitor of the p53-MDM2 
interaction with potent in vitro p53-dependent tumor growth-inhibitory effect through 
stimulation of apoptosis and cell cycle arrest.  However, a dual inhibition of the p53 
interaction with MDM2 and MDMX is the most effective strategy for a full activation of wt 
p53, particularly against MDMX-overexpressing tumor cells that are highly resistant to 
MDM2-only inhibitors. Therefore, this thesis was also focused on the identification of dual 
inhibitors of p53-MDMs interactions. In fact, a dual inhibitor of p53-MDMs interactions, the 
compound OXAZ-1, was identified from the chemical family of tryptophanol-derived 
oxazolopiperidone lactams. This compound activated a p53-dependent mitochondrial 
apoptotic pathway, and presented promising p53-dependent synergistic effects with 
conventional chemotherapeutic drugs, in human tumor cells. However, the modest in vitro 
tumor growth-inhibitory activity of OXAZ-1 led us to pursue our search for more potent dual 
inhibitors. This conducted to the second inhibitor of p53-MDMs interactions found in this 
thesis, the tryptophanol-derived oxazoloisoindolinone DIMP53-1. Besides its higher in vitro 
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growth-inhibitory effect, DIMP53-1 exhibited potent p53-dependent in vivo antitumor activity 
with no apparent toxic side effects. With these results, DIMP53-1 became the first small 
molecule dual inhibitor with in vivo anticancer properties described to date. 
In order to streamline the identification of reactivators of mutant p53, a new yeast-
based screening assay was developed encompassing human mutant p53 R280K and 
Y220C. Using the developed cell system, the first reactivator of mutant p53 R280K, the 
compound SLMP53-1, an enantiopure tryptophanol-derived oxazoloisoindolinone, was 
discovered. This compound also activated wt p53, and exhibited a potent p53-dependent in 
vivo antitumor activity with no apparent toxic side effects. Furthermore, SLMP53-1 inhibited 
tumor cell migration and presented synergistic effects with conventional 
chemotherapeutics.  
In conclusion, an efficient and reliable screening approach to search for new 
reactivators of mutant p53 emerged from this thesis. Most importantly, four new activators 
of p53 were discovered, two of them (DIMP53-1 and SLMP53-1) revealing to be promising 
anticancer drug candidates. Besides the incontestable impact of this thesis to the advance 
of p53 pharmacology and targeted drug discovery strategy, it gave rise to new hopes and 
therapeutic opportunities in anticancer treatment.  
 
 
 
 
 
 
 
 
 
Key words: Anticancer agents; Cancer; p53; MDM2/MDMX; Yeast targeted screening 
assays. 
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RESUMO 
 
As doenças oncológicas continuam a ser uma das maiores preocupações de Saúde 
Pública. Apesar disso, as opções terapêuticas existentes para muitos doentes oncológicos 
permanecem limitadas e com resultados insatisfatórios devido, nomeadamente, à 
quimioresistência e aos seus graves efeitos secundários. Por outro lado, o 
desenvolvimento de novas terapias anticancerígenas tem-se demonstrado um processo 
lento e muito falível. 
Vários estudos têm indicado que a inativação da via da p53 está na base do 
desenvolvimento e subsistência tumoral. De facto, na maioria dos cancros humanos, a 
função da p53 está comprometida, tanto por mutações como por inibição através da 
interação com reguladores negativos, como as proteínas Murine Double Minute (MDM)2 e 
MDMX. Desta forma, a inibição da interação da p53 com as proteínas MDMs e o 
restabelecimento da função nativa às mutantes da p53 têm sido consideradas estratégias 
promissoras no tratamento do cancro. Contudo, até à data, apesar de todos os esforços 
realizados no sentido de encontrar novas pequenas moléculas ativadoras da p53, apenas 
um número reduzido de moléculas seguiu para ensaios clínicos e nenhuma se encontra 
aprovada para tratamento oncológico.  
Deste modo, a presente tese teve como objetivo encontrar novas opções 
farmacológicas no tratamento cancro tendo como alvo a proteína p53, nomeadamente 
através da descoberta de inibidores da interação da p53 com MDM2/MDMX (MDMs) e de 
reativadores das mutantes da p53. Com este objetivo, usou-se uma estratégia de pesquisa 
farmacológica baseada em modelos de levedura, células tumorais humanas e animais para 
testar várias bibliotecas químicas, que compreendem compostos com estruturas químicas 
previamente descritas como promissoras na alteração da atividade da p53, nomeadamente 
moléculas contendo os grupos indole e/ou isoindolinona. 
Com esta abordagem foi identificado um novo inibidor da interação p53-MDM2, uma 
oxazolopirrolidona lactama derivada do fenilalaninol (oxazoloisoindolinona 3a), com efeito 
inibidor do crescimento tumoral, dependente da p53 e associado à indução de apoptose e 
retenção do ciclo celular. Contudo, a dupla inibição da interação da p53 com MDM2/MDMX 
é uma estratégia mais eficaz para uma completa ativação da p53 nativa, nomeadamente 
em células tumorais que sobreexpressam MDMX, resistentes aos inibidores seletivos do 
MDM2. Assim, esta tese teve também como objetivo, a identificação de novos inibidores 
duais das interações p53-MDMs. De facto, a partir da família química de oxazolopiperidona 
lactamas derivadas do triptofanol foi identificado um inibidor dual das interações p53-
MDMs, o composto OXAZ-1. Este composto ativou uma via apoptótica mitocondrial 
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dependente da p53 e apresentou efeitos sinérgicos promissores, também dependentes da 
p53, com quimioterápicos convencionais em células tumorais humanas. Porém, a modesta 
inibição do crescimento tumoral do OXAZ-1 levou à pesquisa de inibidores duais mais 
potentes. Tal facto, conduziu à identificação do segundo inibidor das interações p53-MDMs, 
a oxazoloisoindolinona derivada do triptofanol DIMP53-1. Este composto, para além do 
marcado efeito inibidor do crescimento tumoral in vitro, apresentou uma potente atividade 
anti-tumoral in vivo dependente da p53, sem efeitos secundários aparentes. Com estes 
resultados, DIMP53-1 torna-se a primeira pequena molécula inibidora dual, com 
propriedades anticancerígenas in vivo, descrita até à presente data.   
De forma a agilizar a identificação de reactivadores das mutantes da p53, foi 
desenvolvido um novo ensaio de pesquisa farmacológica baseado em células de levedura 
expressando as mutantes humanas da p53 R280K ou Y220C. Com a utilização deste 
sistema de pesquisa farmacológica foi descoberto o primeiro reactivador da mutante 
p53R280K, o composto SLMP53-1, uma oxazoloisoindolinona derivada do triptofanol. Este 
composto foi também capaz de ativar a p53 nativa tendo demonstrado atividade antitumoral 
dependente da p53 in vivo, sem sinais aparentes de efeitos adversos. Além disso, o 
composto SLMP53-1 inibiu a migração das células tumorais humanas e apresentou efeitos 
sinérgicos com quimioterápicos convencionais. 
Em conclusão, com esta tese, foi desenvolvida uma nova abordagem eficaz de 
pesquisa farmacológica de reactivadores de mutantes da p53. Adicionalmente, no âmbito 
da mesma, foram descobertos quatro novos ativadores da p53, dois dos quais (DIMP53-1 
e SLMP53-1) representam promissores candidatos a fármacos anticancerígenos. De uma 
forma geral, para além do impacto incontestável no avanço farmacológico da p53 e na 
estratégia de descoberta de fármacos dirigidos a um alvo específico, com esta tese 
surgiram novas esperanças e oportunidades na terapia oncológica.  
 
 
 
 
 
 
 
Palavras-chave: Agentes anticancerígenos; Cancro; Ensaios alvo-dirigidos utilizando 
células de levedura; p53; MDM2/MDMX. 
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1.1. Cancer: General concepts 
 Epidemiology of cancer 
Cancer is a worldwide public health concern, particularly in developed countries 
(Ferlay et al., 2015).  In fact, in 2012, it was reported 14.1 million new cancer cases, 8.2 
million cancer deaths and 32.6 million people living with cancer (within 5 years of diagnosis) 
worldwide (Ferlay et al., 2015). In Portugal, cancer is the second cause of death 
(https://www.ine.pt) and, following the worldwide trend, it is predicted an increase in the new 
cancer cases, mainly due to an ageing population, human lifestyle, and infections (mostly 
in developing countries). Accordingly, it is predicted 20 million new cancer cases for 2025 
worldwide, and in Portugal it is expected 53 thousand new cases (Ferlay et al., 2013; Bray 
et al., 2013; Ferlay et al., 2015).  
Lung cancer is one of the most common cancers in the world, associated with high 
incidence (due to tobacco consumption and pollution) and mortality (1.8 million cases, 1.6 
million deaths; Figure 1.1), mostly because of its aggressiveness, invasion capacity and 
treatment resistance (Ferlay et al., 2015). The breast cancer is the second most common 
overall, but ranks fifth as cause of death (1.7 million cases, 522,000 deaths; Figure 1.1) 
because of the relatively favorable prognosis. Colorectal (1.4 million cases, 694,000 
deaths), prostate (1.1 million cases, 307,000 deaths), stomach (951,000 cases, 723,000 
deaths) and liver (782,000 cases, 745,000 deaths) cancers are the following more common 
in worldwide (Figure 1.1). These six cancers represent more than 50% of the global 
incidence burden in 2012 (Ferlay et al., 2015; Figure 1.1). In Portugal, although lung cancer 
is the most lethal, it ranks fourth in terms of incidence. The large bowel, prostate and breast 
cancers are more incident, following this order (Ferlay et al., 2013; https://www.ine.pt). 
 
 
Figure 1.1. Estimated incidence and mortality of different types of cancer worldwide in 2012 
[Graphs from GLOBOCAN 2012: Estimated cancer Incidence Mortality and Prevalence Worldwide 
in 2012 (http://globocan.iarc.fr/Pages/fact_sheets_population.aspx)]. 
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Early diagnosis, universal access to health care and new therapies has resulted in a 
significant improvement of cancer survival. Despite this, the high incidence and mortality 
can justify the intense research conducted around cancer, especially towards finding more 
efficient therapeutic strategies. 
 
 Hallmarks of cancer 
Nowadays, cancer is considered more than masses of proliferating cells, 
characterized by complex tissues composed by distinct cell types involved in heterotypic 
interactions between them (Hanahan and Weinberg, 2011). Furthermore, beyond tumor 
biology with all cross-talking pathways inside and between cells, the “tumor 
microenvironment” is also a fundamental part, contributing to tumor progression and 
maintenance (Figure 1.2).  
The tumor microenvironment reinforces the recognition of tumors as complex organs 
that are constructed during the course of multistep tumorigenesis. There are many cells, 
molecules and blood vessels that surround and feed the tumor (Figure 1.2). Due to the 
hyperproliferation and genetic instability, tumors are heterogeneous, containing different 
types of subclonal populations (Hanahan and Weinberg, 2011). Cancer stem cells are very 
common in tumors and are responsible for its poor prognosis. They are classified as stem 
cells due to their ability to efficiently seed new tumors upon inoculation in mice, and because 
they share transcriptional profiles with normal tissue stem cell populations (Cho and Clarke, 
2008; Lobo et al., 2007). These cells initiate tumors and are essential for its progression 
(Hanahan and Weinberg, 2011), contributing to tumor heterogeneity due to their different 
stages of differentiation. On the other hand, their heterogenic profiles contribute to the 
chemotherapeutic resistance and tumor recurrence (Singh and Settleman, 2010; Creighton 
et al., 2009). 
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Figure 1.2. Tumor microenvironment: representation of the different cell types constituints of 
solid tumors. 
 
 
In some tumors, fibroblasts are the preponderant cells. They can be found in both 
forms, as a similar form to the normal fibroblasts supporting epithelial cells, and as 
myofibroblasts with different functions compared to the normal ones (Figure 1.2). In chronic 
inflammation, myofibroblasts may lead to the pathological fibrosis in tissues such as lung, 
kidney and liver (Hanahan and Weinberg, 2011).  
The angiogenic process is crucial to feed, oxygenate and maintain tumor cells. In 
“angiogenic switch”, quiescent endothelial cells are activated, inducing them to enter into a 
cell biological program that allows the construction of new blood vessels (Baeriswyl and 
Christofori, 2009). This process is coordinated by signaling proteins that bind to endothelial 
cell surface receptors that either stimulate (such as vascular endothelial growth factor-A, 
VEGF-A, and fibroblast growth factor, FGF), or inhibit (such as thrombospondin-1, TSP-1) 
angiogenesis (Baeriswyl and Christofori, 2009). Moreover, although pericyte cells (Figure 
1.2) are known for supporting mechanically and physiologically the endothelial cells, in 
tumor context, they are fundamental pieces in the maintenance of the tumor structure and 
in the construction of new blood vessels (Raza et al., 2010; Hanahan and Weinberg, 2011).  
The presence of inflammatory cells is well-established in tumor microenvironment 
(Figure 1.2), in which they can have different functions. They can either antagonize the 
tumor progression, such as natural killer (NK) cells and cytotoxic T lymphocytes (CTLs), or 
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to promote its progression, such as macrophages, mast cells, neutrophils, and T and B 
lymphocytes (DeNardo et al., 2010; Hanahan and Weinberg, 2011; Murdoch et al., 2008). 
The tumor promoting inflammatory state is also characterized by the presence of some 
signaling molecules released by inflammatory cells, such as tumor epidermal growth factor 
(EGF), VEGF, FGF2, chemokines, and cytokines (Qian and Pollard, 2010; Murdoch et al., 
2008). Additionally, other pro-invasive enzymes are released, and all together contribute to 
tumor angiogenesis, proliferation, invasion and metastasis (Mantovani, 2010; Hanahan and 
Weinberg, 2011; Murdoch et al., 2008).  
In 2000, the complexity of tumor biology and their surrounding microenvironment led 
to the identification of six hallmarks of cancer (Hanahan and Weinberg, 2000). For the 
development and metastatic dissemination of a tumor, the following requirements were 
determined: 1) sustaining proliferative signaling to support a chronic proliferation; 2) evading 
growth suppressors, such as the known retinoblastoma-associated (RB1) and the TP53 
tumor suppressor genes; 3) resisting cell death by down-regulation of pro-apoptotic 
signaling, autophagic and necrotic death; 4) enabling replicative immortality by abolishment 
of senescence and crisis events, and telomerase overexpression; 5) inducing angiogenesis; 
and 6) activating invasion and metastasis through a complex cascade initiated by some 
cellular modifications, such as the loss of cell-to-cell adhesion molecule E-cadherin (Figure 
1.3; Hanahan and Weinberg, 2000). In 2011, two other emerging hallmarks were included: 
7) the deregulation of cellular energetics, through modification of cellular metabolism to 
most effectively support neoplastic proliferation; and 8) avoiding immune destruction 
particularly by NK cells and CTLs (Figure 1.3; Hanahan and Weinberg, 2011). Moreover, 
considering the tumor microenvironment, two more enabling characteristics, that promote 
the achievement of both core and emerging hallmarks, the genome instability and mutation 
and the tumor-promoting inflammation, were established (Figure 1.3; Hanahan and 
Weinberg, 2011). 
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Figure 1.3. The hallmarks of cancer. Schematic representation of the eight core and emerging 
hallmark capabilities currently proposed, and two more enabling characteristics. [Adapted from 
(Hanahan and Weinberg, 2011)]. 
 
 
 Anticancer therapeutic strategies 
At the beginning of the 20th century, the only treatment recognized for cancer was 
surgery. To date, surgery is the most effective treatment for localized primary tumors. 
However, for advanced cancers, the ineffectiveness of this approach led, in the 1920s, to 
the use of radiation therapy (Urruticoechea et al., 2010). In the 1940s, the first anticancer 
drug was discovered, through serendipity, based on bone marrow depletion effects of sulfur 
mustard gas on victims of World Wars I and II (Cheung-Ong et al., 2013; DeVita and Chu, 
2008). Nevertheless, nitrogen mustard compounds revealed to be not enough to a complete 
remission of tumor, with the development of drug resistance. However, this discovery 
motivated the search for new anticancer chemotherapeutic alternatives (Cheung-Ong et al., 
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2013; DeVita and Chu, 2008). Actually, after that, the scenario of cancer treatment has been 
dramatically changed over the last decades.  
In spite of the great advances in biomedical research, which have contributed to our 
deeper understanding of cancer hallmarks, the success of anticancer drug development 
remains low. In fact, even though anticancer drugs represent a substantial proportion of 
total new drug approvals, their success in clinical trials remains unsatisfactory (7% from 
phase I and <50% from phase III) (Hay et al., 2014).  
In anticancer drug development, the major challenge is to kill tumor cells without 
affecting the healthy ones. Based on this, due to the underlying toxicity of the traditional 
DNA-damaging drugs on non-tumor cells, the attempt to replace these compounds by 
targeted anticancer drugs has been carried out. Despite this, although the targeted therapy 
has gained strength, the traditional cytotoxic drugs remain the most widely used in cancer 
therapy.   
In this thesis, the two types of anticancer chemotherapy, the conventional 
chemotherapeutic drugs and the targeted anticancer drugs, will be briefly described and 
some examples of each class will be presented.    
 
 Conventional chemotherapeutic drugs 
The conventional chemotherapy, mostly including DNA-damaging agents, usually 
affects cell division/DNA integrity, not directly interfering with the invasion capacity, the loss 
of differentiation or the tendency to metastization. When cell cycle checkpoint proteins 
detect high levels of damaged DNA, cell cycle arrest is induced to prevent the transmission 
of damaged DNA during mitosis. If the damaged DNA is irreparable, cell death may occur 
(Rang et al., 2015). Cancer cells are known for their ability to ignore cell cycle checkpoints 
and to have an undemanding DNA repair system, allowing high cell proliferation rates. 
Therefore, a weaker DNA repair makes cancer cells more susceptible to cell death induced 
by DNA damaging agents (Rang et al., 2015). These cytotoxic drugs affect rapidly dividing 
cells, targeting both tumor and all normal cells that are in accelerate division. Therefore, 
they are commonly associated with a high toxicity, being responsible for depress bone 
marrow, impair wound healing, depress growth in children, alopecia, damage to 
gastrointestinal epithelium (including oral mucous membranes), sterility, teratogenicity and 
carcinogenicity (www.cancer.org; Rang et al., 2015).  Consequently, these drugs are often 
administrated in single doses, or short courses of therapy, at the highest concentrations 
possible without no life-threatening levels of toxicity (Maximum Tolerated Dose – MTD). 
Besides, these high doses require subsequent treatment-free periods for recovery of patient 
normal cells (Venkatakrishnan et al., 2014).  
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The conventional chemotherapeutic anticancer drugs are divided into several groups 
taking into account their mechanism of action: alkylating agents, antimetabolites, 
topoisomerase inhibitors, mitotic inhibitors and glucocorticoids (Table 1.1). 
 
Table 1.1. Conventional chemotherapeutic anticancer drugs grouped according to their 
mechanism of action. 
Group 
(mechanism of action) 
Classes (examples) 
Therapeutic 
applications 
Observations References 
     
Alkylating agents 
(directly damage DNA - 
intercalation between 
bases, DNA 
crosslinking) 
Nitrogen mustards (cyclophosphamide) 
Nitrosoureas (carmustine, lomustine) 
Alkyl sulfonates (busulfan) 
Triazines (temozolomide) 
Ethylenimines (altretamine) 
Platinum drugs (cisplatin, carboplatin) 
Leukemia, 
lymphoma, multiple 
myeloma, sarcoma 
and lung, breast, 
ovary and testicular 
cancers 
Long-term damage 
to the bone 
marrow (except 
platinum drugs) 
Cheung-Ong 
et al., 2013; 
Rang et al., 
2015; 
Kelland, 
2007. 
     
Antimetabolites 
(block the synthesis of 
DNA and/or RNA) 
Folate antagonists (methotrexate, 
pemetrexed) 
Pyrimdine pathway (cytarabine, decitabine, 
5-fluorouracil, gemcitabine) 
Purine pathway (fludarabine, 6-
mercaptopurine, pentostatin, tioguanine) 
Leukemia, breast, 
ovary, 
gastrointestinal and 
other cancers 
Potent 
myelosuppression 
Rang et al., 
2015; 
Cheung-Ong 
et al., 2013. 
     
Topoisomerase 
inhibitors 
(dysregulation of DNA 
topology with induction 
of DNA cleavage) 
Topoisomerase I inhibitors (topotecan, 
irinotecan) 
Topoisomerase II inhibitors (etoposide, 
teniposide) 
Leukemia, lung, 
ovarian, 
gastrointestinal, and 
other cancers 
Topotecan and 
irinotecan have low 
toxicity 
Rang et al., 
2015; 
Cheung-Ong 
et al., 2013. 
     
Mitotic inhibitors 
(bind tubulin, 
stabilize microtubules) 
Vinca alkaloids (vinblastine, vincristine, 
vinorelbine) 
Taxanes (paclitaxel, docetaxel) 
Others (ixabepilone, estramustine) 
Breast and lung 
cancers, myelomas, 
lymphomas, and 
leukemias 
Cumulative 
neurotoxicity, and 
in some cases 
hypersensitivity  
Rang et al., 
2015; 
www.cancer.o
rg 
     
Glucocorticoids 
(inhibit lymphocyte 
proliferation) 
Prednisolone, dexamethasone Leukemia and 
lymphoma 
Also used to 
prevent side 
effects (nausea, 
vomiting and 
hypersensitivity) of  
chemotherapeutics 
Rang et al., 
2015. 
     
Antibiotics 
(inhibit topoisomerase 
II, interfere with helicase 
activity, intercalate 
DNA, crosslink DNA, 
and other mechanisms)  
Anthracyclines (doxorubicin, daunorubicin) 
Others (dactinomycin, bleomycin, 
mitomycin) 
Breast cancer, small-
cell lung tumors, soft 
tissue sarcomas, 
lymphomas, and 
acute lymphoblastic 
or myeloblastic 
leukemias 
High cardiotoxicity Minotti et al., 
2004; 
Rang et al., 
2015 
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 Targeted anticancer drugs  
These less toxic anticancer drugs inhibit the growth, progression and dissemination 
of cancer by interfering with specific molecules involved in its pathobiology (Urruticoechea 
et al., 2010; Chessum et al., 2015). The recognition of the hallmarks of cancer has opened 
the way to the identification of promising molecular targets in anticancer therapy. These 
targets include growth factors, signaling molecules, modulators of cell cycle and apoptosis, 
as well as molecules involved in angiogenesis (Hanahan and Weinberg, 2011). Currently, 
there are already several targeted therapies in the clinic for the treatment of many cancer 
types, and many others are in clinical trials waiting for approval (Hay et al., 2014).   
 Considering the molecular target and the type of agent, anticancer targeted 
therapies can be divided into several groups: hormone therapies, monoclonal antibody 
therapies, protein kinase inhibitors, proteasome inhibitors, histone deacetylase inhibitors, 
and poly (ADP-ribose) polymerase (PARP) inhibitors (Table 1.2).  
 Hormone therapies are usually used in hormone-sensitive tumors. They can reduce 
or completely abolish the tumor cell growth by acting as physiological agonists, antagonists 
or hormone synthesis inhibitors (Table 1.2). The antioestrogen tamoxifen is widely used in 
the treatment of breast cancer. However, tamoxifen is not devoid of side effects, causing 
menopause-like symptoms. More severe effects are hyperplastic events in the 
endometrium, which may progress to cancer and the risk of thromboembolism (Kreipe and 
von Wasielewski, 2007). Aromatase inhibitors are other class of hormone therapy used in 
the treatment of breast cancer, which act by suppressing the synthesis of oestrogen from 
androgens in the adrenal cortex (Rang et al., 2015).  
As mentioned above, the overexpression of growth factors is widely frequent in tumors 
to support tumor growth. The therapeutic monoclonal antibodies can prevent the survival 
pathways and promote apoptosis by interaction with growth factors (e.g. VEGF), or with the 
extracellular domain of the growth factors receptors (Table 1.2; Figure 1.4; Rang et al., 
2015; Urruticoechea et al., 2010). Furthermore, they can act directly on lymphocyte cell 
surface proteins as CD20 or CD52, to cause lysis and elimination of lymphocytes in 
lymphoma and leukemia cases (Rang et al., 2015; Kreipe and von Wasielewski, 2007). 
Although monoclonal antibodies have less severe side effects, their high cost is still a 
limitation (Rang et al., 2015; www.cancer.org). Alternatively, the protein kinase inhibitors 
may inhibit protein kinases preventing the downstream signaling cascade triggered by 
growth factors (Table 1.2; Figure 1.4). The side effects of this group of drugs differ 
depending on the drug and the target, but are less aggressive compared to the ones 
described for the conventional therapy.  
 
11 
 
Table 1.2. Anticancer targeted therapies grouped according to the molecular target and type 
of agent. 
Group Classes/targets (examples) Therapeutic applications References 
    
Hormone 
therapies 
Gonadotrophin-releasing hormone antagonist 
(degaralix) 
Prostate cancer 
 
Rang et al., 2015 
Oestrogen receptor antagonists (tamoxifen, 
toremifene and fulvestrant)  
Hormone-dependent breast 
cancer 
Androgen antagonists (flutamide, cyproterone and 
bicalutamide) 
Prostate cancer 
 
Aromatase inhibitors (anastrozole, letrozole and 
exemestane) 
Breast cancer in 
postmenopausal women  
    
Monoclonal 
antibodies 
VEGF (bevacizumab) Colorectal cancer Rang et al., 2015; 
Urruticoechea et al., 
2010 EGF receptor (panitumumab, cetuximab)   
HER-2 receptor (trastuzumab) Breast cancer 
CD20 (rituximab) 
CD52 (alemtuzumab) 
Leukemia and  
lymphoma 
Rang et al., 2015; Kreipe 
and von Wasielewski, 
2007 
    
Protein kinase 
inhibitors 
Bcr/Abl, c-kit and PDGF kinases (imatinib, nilotinib) Chronic myeloid leukaemia Chessum et al., 2015; 
Kreipe and von 
Wasielewski, 2007; Rang 
et al., 2015; 
Urruticoechea et al., 
2010 
EGF receptor (erlotinib, gefitinib)  Non-small-cell lung carcinoma 
HER-2 and EGF receptors (lapatinib) Breast cancer 
VEGF receptor (axitinib) Renal cell carcinoma  
JAK1 and JAK2 kinases (ruxolitinib) Myelofibrosis 
Pan-kinase inhibitors (sorafenib, dasatinib, sunitinib) 
Different types of cancer mTOR kinase, also classified as pan- 
kinase inhibitors (everolimus, temsirolimus)  
    
Proteasome 
inhibitor 
Bortezomib Myeloma Rang et al., 2015 
    
Histone 
deacetylase 
inhibitors 
Vorinostat and romidepsin  
Refractory cutaneous T-cell 
lymphoma 
West and Johnstone, 
2014 
Panobinostat Multiple myeloma 
www.ema.europa.eu/ema
/index 
    
PARP inhibitor Olaparib BRCA mutated advanced 
ovarian cancers 
www.fda.gov 
 
 
The proteasome inhibitor bortezomib selectivelly affect rapidly dividing cells, with 
small impact on normal cells, making it a useful anticancer agent. The bortezomib inhibits 
the proteasome by destroying proteins such as growth regulatory proteins, promoting tumor 
cell death (Rang et al., 2015). The histone deacetylases are critical regulators of gene 
expression (West and Johnstone, 2014). Thus histone deacetylases inhibitors exert their 
antitumor effect by changing the expression profile of oncogenes and tumor suppressor 
genes, through modulation of the histones acetylation state. PARP is involved in DNA repair 
and its inhibitors cause multiple double strand breaks. In tumors with mutations on DNA 
reparatory proteins (like BRCAs), these double strand breaks induced by PARP inhibitors 
cannot be efficiently repaired, what conducts to tumor cell death (Liu et al., 2014b).  
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Figure 1.4. Mechanism of action of anticancer monoclonal antibodies and protein kinase 
inhibitors. Therapeutic monoclonal antibodies can prevent the overexpression of growth factors as 
EGFR, HER-2 and VEGFR by interacting directly with the receptor itself (e.g. cetuximab, 
trastuzumab) or with the ligand (e.g. bevacizumab). Protein kinase inhibitors prevent downstream 
signaling triggered by growth factors by inhibiting protein kinases (e.g. gefitinib, lapatinib, axitinib and 
imatinib). EGFR, epidermal growth factor receptor; HER, human epidermal growth factor; P, 
phosphate group; PDGFR, platelet-derived growth factor receptor; VEGFR, vascular endothelial 
growth factor receptor [adapted from (Rang et al., 2015)]. 
 
 
However, although targeted therapies are a promising way to personalize cancer 
treatment, leading to less severe side effects and to more effective treatments than the 
standard chemotherapy, they are currently associated with increased tumor resistance. This 
resistance can be attributed to the occurrence of mutations on the molecular target and/or 
to the adoption by cancer cells of alternative growth pathways that are independent of the 
molecular target. Combination therapy may overcome this limitation, as demonstrated by 
some clinical studies (Chessum et al., 2015). Actually, targeted therapies have gained 
strength in combination either with other therapies that target different parts of the cell 
signaling pathway, or with conventional chemotherapeutic drugs.  
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The development of targeted therapies requires the identification of targets with a key 
role in cancer development and mantainance. Proteins expressed by cancer cells, but not 
by normal cells, would be potential targets, especially if they are involved in cell growth and 
survival. Another approach to identify potential targets is to determine whether cancer cells 
express mutant proteins that drive cancer progression. One of such promising target is the 
p53 tumor suppressor protein.  
 
 
1.2. The p53 tumor suppressor proteins 
In 1979, the p53 protein was discovered in a complex with the simian virus 40 (SV40) 
large T-antigen (Linzer and Levine, 1979; Lane and Crawford, 1979). At that time the 
importance of this protein was far from being imagined. Initially, p53 was classified as an 
oncogene due to the association between the high levels of this protein and the occurrence 
of tumors (DeLeo et al., 1979; Rotter, 1983). This incorrect idea was supported by other 
publications during almost ten years (Freed-Pastor and Prives, 2012). Currently, 
accumulated data clearly demonstrate the tumor-suppressing properties of p53. A very 
plausible explanation for the first contradictory findings is attributed to the fact that the p53 
highly expressed in those tumors was actually a mutant form (Levine and Oren 2009; Freed-
Pastor and Prives, 2012).  
As a transcription factor, the p53 tumor suppressor protein is able to induce the 
transcription of many genes controlling crucial stress responses with a major role in 
preventing malignant transformation. p53 has been recognized as the most frequently 
inactivated protein in cancer (in about 80% of cancers) (Olivier et al., 2004). In fact, the 
TP53 gene is mutated or deleted in approximately half of tumors, and in tumors that retain 
a wild-type (wt) form, p53 is inactivated due to diverse mechanisms, including the 
overexpression of endogenous inhibitors, such as the murine double minute (MDM)2 and 
MDMX proteins (Shadfan et al., 2012; Selivanova, 2014). These findings, together with 
other evidences from innumerous studies, strongly support the idea that p53 inactivation is 
a required condition for tumor development and maintenance (Zawacka-Pankau and 
Selivanova, 2015). Based on this, the p53 protein has been subject of intensive research 
over the last 30 years. Despite this, many aspects concerning the p53 biology and 
pharmacology remain unclear.  
With the discovery of the p53 family, composed by p53, p63 and p73, with high 
structural homology, many functions initially attributed to p53 only are now shared by the 
other family members (Kaghad et al., 1997; Schmale and Bamberger, 1997; Yang et al., 
1998; Trink et al., 1998). Still, p53 remains the family member with the highest impact on 
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tumorigenesis, as demonstrated by knockout mouse models. In fact, while the knockout of 
p53 leads to increased tumor susceptibility (Donehower et al., 1992), the knockout of p63 
or p73 leads to severe developmental abnormalities, but not to increased spontaneous 
tumors (Yang et al., 1999; Yang et al., 2000). Actually, in the absence of stress, the most 
important role of p63 and p73 seems to be the regulation of cell differentiation and tissue 
development (Moll and Slade, 2004). Despite this, it is well-established that p63 and p73 
cooperate with p53 in the regulation of tumorigenesis, either in a p53-synergistic or in a 
p53-antagonistic nature (Moll and Slade, 2004). 
 
 
 Structure of p53 
The TP53 gene is located at the short arm of the chromosome 17p13.1 region. It 
encodes the p53 protein composed by 393 amino acids (a.a.) with different functional 
domains encompassing well-defined and natively unfolded regions that form tetramers in a 
reversible equilibrium (Bell et al., 2002; Veprintsev et al., 2006). The structure of p53 
comprises two N-terminal transcriptional activating domains (TAD)1 (1-42 a.a.) and TAD2 
(43-63 a.a.), a proline-rich domain (64-97 a.a.), a DNA binding domain (DBD, 102-292 a.a.), 
an oligomerization domain (OD, 323-356 a.a.), and a basic or regulatory domain (363-393 
a.a.) (Figure 1.5; Millau et al., 2009).  
The TADs are critical for the regulation of p53 activity, because they interact with 
regulatory proteins such as MDM2 (Momand et al., 1992), components of the transcription 
initiation complex as human TATA-binding-protein-associated factor TAFII31 (Lu and 
Levine, 1995), and with acetyltransferases, such as p300 and CBP, which act as co-
activators and regulate the p53 function via acetylation (Grossman, 2001). The proline-rich 
domain contains five PXXP motifs and seems to also have an important role in the 
regulation of p53 activity, as evidenced by a mice model expressing a truncated p53 (without 
proline-rich domain) (Toledo et al. 2006). This truncated p53 showed increased sensitivity 
to MDM2-dependent degradation and decreased transactivation capacity, associated with 
deficient cell cycle arrest and reduced apoptotic response (Toledo et al. 2006). The DBD is 
highly conserved and specifically binds to a double-stranded target DNA, allowing the 
transcription of several target proteins. This region presents a high homology (~60%) to that 
of p63 and p73 (Wei et al., 2012), what justifies the resemblance of the transcription targets 
and functions between p53 family proteins. Additionally, the majority of p53 missense 
mutations occur in this region (Muller and Vousden, 2014). Contrary to the unfolded N-
terminal, the DBD and OD adopt a well-defined conformation. The OD at the C-terminal is 
essential for the formation of tetramers, which are organized as dimers of p53 (Jeffrey et 
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al., 1995). The structure of the tetramerization domain has been solved by X-ray 
crystallography and by nuclear magnetic resonance (NMR) (Jeffrey et al., 1995; Mittl et al., 
1998; Clore et al., 1995). These tetramers are known to be the most active transcriptional 
form of p53. Additionally, the regulatory domain (consisting of a lysine-rich region) is 
involved both in the positive (by post-translational modifications involving acetylation, 
methylation, phosphorylation and sumoylation) and negative (by ubiquitination or 
neddylation) regulation of p53 (Wahl, 2006).  
The p53 protein also contains three nuclear localization signals (NLS) at C-terminal 
that specifically bind to nuclear receptors (Shaulsky et al., 1990; Liang and Clarke, 1999), 
and two nuclear export signal (NES) regions, one localized at TAD and other at C-terminal 
(Stommel et al., 1999; Zhang and Xiong et al., 2001). Both NLS and NES are involved in 
the regulation of the p53 transcriptional activity through the p53 nuclear/cytosolic shuttling.  
 
 
 
 
Figure 1.5. Structure of p53 protein and respective isoforms. The structure of p53 comprises two 
transcriptional activating domains (TAD)1 and TAD2, a proline-rich domain, a DNA binding domain 
(DBD), an oligomerization domain (OD) and a regulatory domain. Three different N-terminal isoforms 
Δ40p53, Δ133p53 and Δ160p53 can be combined with C-terminal isoforms α, β, γ, δ, ε, ζ, ΔE6. 
 
 
A large variety of p53 transcripts can be found as result of alternative splicing and of 
the action of different promoters (P1, P1’ or P2). Some examples of Δp53 isoforms (without 
part of the N-terminal) are Δ40p53, Δ133p53 and Δ160p53, lacking the first 40, 133 and 
160 a.a., respectively (Figure 1.5). Δ40p53, produced by alternative splicing of intron 2 or 
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internal initiation of translation from codon 40, does not complex with MDM2, but it is able 
to oligomerize with full-length p53, inhibiting its transcriptional activity (Yin et al, 2002; 
Courtois et al., 2002). Δ133p53 and Δ160p53 are both regulated by P2, located in intron 4 
of the TP53 gene (Marcel et al., 2011). Moreover, it was described that Δ133p53 expression 
induces tumor growth progression and angiogenesis in full-length p53-expressing tumors 
(Bernard et al., 2013). Instead, its knockdown increases apoptosis, cell cycle arrest and 
senescence, what demonstrated the oncogenic properties of Δ133p53 (Fujita et al., 2009; 
Aoubala et al., 2011). However, in clinic, high Δ133p53 expression levels resulted in a risk 
reduction of 43% for recurrence and of 64% for death, when compared with low Δ133p53 
expression levels in mutant p53-expressing serous ovarian cancers (Hofstetter et al., 2011). 
Additionally, the clinical relevance of Δ40p53 has been investigated, and its presence has 
been associated with a favorable prognostic in the mucinous histological subtype of ovarian 
cancer (Hofstetter et al., 2012). This may be explained by the fact that the in vivo effects of 
these isoforms depend on the p53 status (wt/mutant). In fact, this may indicate that the 
heteroligomer formation with the isoforms inactivates the p53 function (the p53 wt anti-
tumoral or the p53 mutant pro-tumoral effects).  
Moreover, the alternative splicing at C-terminal originates a diversity of transcripts 
referred by Greek alphabet letters, leading to seven variants for p53 (α, β, γ, δ, ε, ζ, ΔE6) 
(Figure 1.5; Wei et al., 2012). Some of these truncated proteins, which lack the 
oligomerization domain, fail to bind DNA and for this reason are transcriptionally deficient 
(Murray-Zmijewski et al., 2006). As for TAD truncated isoforms, it was reported that patients 
whose tumors expressed both mutant p53 and p53γ had a prognosis as good as the wt 
p53-expressing tumors, while tumors only expressing mutant p53 demonstrated poor 
prognosis (Bourdon et al., 2011). This suggested that the expression of p53γ may abrogate 
the poor prognosis commonly associated with TP53 mutations. However, exception made 
for α, β and γ, very few studies addressed the other transcripts (Wei et al., 2012).  
Despite this, more studies about the biology and tumorigenesis of these isoforms, 
particularly taking into consideration different cellular contexts, isoforms expression levels 
and p53 status, are required.     
 
 
 Functional aspects of p53 
Under no stress conditions, p53 is maintained at low levels not interfering with the cell 
fate. Nevertheless, as transcription factor, p53 regulates the cell homeostasis, acting on 
biological processes such as metabolism, cell differentiation, immune response, among 
others (Aylon and Oren, 2011; Suzuki and Matsubara, 2011). 
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In response to stress signals, such as DNA damage and oxidative stress, the 
activation of p53 leads to the transcription of several genes involved in apoptosis, DNA 
repair, cell cycle arrest or senescence (Figure 1.6), in order to suppress genetic mutations 
and to prevent the accumulation of abnormal cells that can lead to tumors (Vousden and 
Prives, 2009; Aylon and Oren, 2011; Martinez et al., 2010). However, beyond triggering 
classical responses, p53 can modulate several additional cellular processes that are 
relevant to suppress tumor development. This includes opposing oncogenic metabolic 
reprogramming and stem cell self-renewal, and limiting the invasion, metastasis and 
angiogenesis, promoting communication within the tumor microenvironment and 
immunosurveillance (Figure 1.6; Vousden and Prives, 2009). 
 
 
 
Figure 1.6. Overview of p53-activating stress signals and key cellular responses promoted by 
p53 for tumor suppression [adapted from (Bieging et al., 2014)]. 
 
 
The p53 response depends on the type, severity and persistence of the stress 
(Maddocks and Vousden, 2011). Indeed, under low stress levels that cause reparable 
damage, p53 induces cell cycle arrest and activates the DNA repair machinery to promote 
cell survival. However, in case of irreparable damage caused by high stress levels, p53 
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drives cellular senescence or irreversible apoptosis (Maddocks and Vousden, 2011). This 
justifies that in tumors with inactivated p53, cells are resistant to apoptosis and able to 
survive (Amaral et al., 2010). It should be noted that for certain types of cellular stresses, 
such as starvation and metabolic stress, the p53 activation triggers different cellular 
pathways such as the antioxidant response and autophagy (Mollereau and Ma, 2014). One 
of the first mechanisms proposed to determine cell fate was the amount of p53 after stress 
induction. Actually, it was demonstrated that low p53 levels correlate with cell cycle arrest, 
while high p53 levels with apoptosis (Chen et al., 1996; Kracikova et al., 2013). Thereafter, 
it was revealed different p53 DNA binding affinities for the different target genes (Resnick-
Silverman et al., 1998). Taken together, it was proposed that under low levels of p53, this 
protein preferentially binds to high-affinity target genes (involved in cell cycle arrest). 
Conversely, under high p53 levels, more p53 is available to bind to low-affinity target genes 
(involved in apoptosis) (Resnick-Silverman et al., 1998; Inga et al., 2002; Weinberg et al., 
2005). Additionally, it seems that the binding to apoptosis-inducing genes requires the 
cooperative p53 DNA binding to multiple binding sites (Schlereth et al., 2010; Timofeev et 
al., 2013). This justifies that some mutant p53 only induce cell cycle arrest and senescence 
and not apoptosis (Schlereth et al., 2010; Timofeev et al., 2013). Another mechanism of 
regulation is mediated by p53 recruited cofactors through the differential transcription of 
downstream genes. For example, p53 recruits the cofactor ASPP1 (apoptosis-stimulating 
of p53 protein 1), which can promote the p53 binding to the promoters of the pro-apoptotic 
Bcl-2 associated X (BAX) or p53-inducible protein 3 (PIG3), but not to the Cyclin-Dependent 
Kinase Inhibitor 1A (CDKN1A; responsible for cell cycle arrest) promoter (Samuels-Lev et 
al., 2001). By contrast, the p53 binding to the protein inhibitor of ASPP (iASPP) activates 
genes that mediate cell cycle arrest (Bergamaschi et al., 2006).  
The regulation of cell fate by p53 post-translational modifications, such as 
phosphorylation, acetylation and ubiquitination, has been also shown to be determinant.  
For example, in response to DNA damage, the phosphorylation of p53 at Ser46 seems to 
promote the transcription of pro-apoptotic genes, such as p53-regulated apoptosis-inducing 
protein (p53AIP) (Oda et al., 2000).  
Additionally, p53 has an important role in the regulation of the expression of several 
microRNAs that contribute to cell fate decision, either promoting cell cycle arrest (e.g. 
miR107; Böhlig et al., 2011) or apoptosis (e.g. miR-200c; Schickel et al., 2010). In turn, 
some microRNAs may control the expression levels and activity of p53, both directly, such 
as miR-125b that suppresses apoptosis by blocking the expression of p53 (Le et al., 2009), 
or indirectly, such as miR-143/145 that regulates the MDM2 expression (Zhang et al., 2013; 
Otsuka and Ochiya, 2014).  
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Despite all these data, the molecular mechanism responsible for the switch between 
survival (cell growth arrest) and death (apoptosis) is still not well understood. Therefore, 
more studies, particularly around the regulatory transcriptional pathways of p53 target 
genes, are still required.  
 
 
 The p53 function under reparable stress 
As described above, under low stress conditions, the cell tends to follow cell cycle 
arrest with activation of the DNA repair machinery to preserve its viability. The inhibition of 
cell cycle progression is one of the most important functions of p53.  
The cell cycle is a highly controlled process composed by four phases: Mitosis (M), 
Gap1 (G1), Synthesis (S), and Gap2 (G2). This process allows cell division, with DNA 
replication (S phase), and the duplication of cell population (Nurse, 2000). To prevent the 
transmission of DNA errors to the daughter cells, cell cycle is regulated by three principal 
checkpoints: one between G1 and S phases, other in the S phase, and the last one between 
G2 and M phases. Cyclin-dependent kinase (CDK) complexes are responsible for the 
regulation of G1/S and G2/M checkpoints, and their activity is regulated by the respective 
cyclins (Nurse, 2000). One important regulator of the cell cycle is the family of E2F 
transcription factors, which control the expression of many key proteins required for 
proliferation. In G1 phase, the E2F protein is linked to the hypophosphorylated 
retinoblastoma protein (Rb). After G1 restriction point, cyclin E/CDK2 and cyclin D/CDK4/6 
complexes start the Rb phosphorylation and, when hyperphosphorylated, E2F is 
dissociated from Rb in order to promote the progress of cell cycle to the next phase (S) by 
activation of the E2F transcriptional program (Amundson et al., 1998; Chellappan et al., 
1991). 
Depending on the type of cellular stress, p53 can induce either G1 arrest or G2/M 
transition arrest. p53 promotes the transcription of the CDKN1A gene, which encodes p21, 
a CDK inhibitor. The overexpressed p21 binds to cyclin E/CDK2 complex, inhibiting the Rb 
phosphorylation and the subsequent cell cycle progression at G1 phase (Figure 1.7; Adams 
et al., 1996; Chen et al., 1996). Additionally, p21 is involved in the inhibition of cyclin 
D/CDK4/6 complexes, which also prevents the Rb phosphorylation (Figure 1.7; el-Deiry, 
1998). On the other hand, p53 is able to inhibit the cyclin E by induction of hCDC4b, an F 
box protein component of the Skp1–Cul1–F-box-protein (SCF) ubiquitin ligase complex that 
promotes the ubiquitin-mediated degradation of phosphorylated cyclin E (Kimura et al., 
2003). The p21 protein has also an important role in p53-mediated G2/M arrest. This protein 
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also interacts with cyclin B/CDK1 complex, blocking the phosphorylation and subsequent 
activation of CDK1 (Smits et al., 2000).  
Additionally, p53 induces the overexpression of Growth Arrest and DNA Damage 
inducible 45 (GADD45) and 14-3-3σ proteins (Figure 1.7). GADD45 binds to CDK1, 
inhibiting the cyclin B/CDK1 complex formation and its subsequent kinase activity (Zhan et 
al., 1999). Moreover, high levels of 14-3-3σ remove the cyclin B/CDK1 from the nucleus, 
physically separating cyclin B/CDK1 from its target proteins (Hermeking et al., 1997). As 
such, these two proteins promote the inhibition of cyclin B/CDK1 function, inducing G2/M 
cell cycle arrest.  
 
 
 
Figure 1.7. Regulation of cell cycle by p53. Under normal conditions, the cyclin/CDK complexes 
are functional and Rb is hyperphosphorylated, leading to the release and activation of the E2F 
transcriptional factor, and to G1 and G2 progression. When activated, p53 induces (red lines) the 
transcription of p21 and hCDC4b, which inhibit cyclin/CDK complexes, resulting in the accumulation 
of hypophosphorylated Rb and in the subsequent inhibition of E2F activity, resulting in G1-phase 
arrest. In G2/M arrest, p53 directly downregulates the expression of cyclin B and promotes the 
expression of p21, GADD45, Reprimo and 14-3-3s, which inhibit the cyclin B/CDK1 complex 
formation. p53 also controls the G2 arrest by inhibition of Cell division cycle 25 homolog C (Cdc25C) 
and by induction of B99 and MCG10; P: phosphorylation. 
 
 
There are other genes regulated by p53, whose induction promotes G2/M arrest, like 
MCG10 (encodes a RNA-binding protein), Reprimo (encodes a glycosylated protein that 
promotes the cytoplasmic localization of cyclin B/CDK1) and B99 (encodes a protein that 
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may cause G2/M arrest independently of CDK1) (Figure 1.7; Zhu and Chen, 2000; Ohki et 
al., 2000; Utrera et al., 1998). Moreover, it was reported that p53 represses the expression 
of important proteins involved in the progression of cell cycle from G2 to M phase, like 
CDK1, cyclin B and Cdc25c (Taylor et al., 2001; Krause et al., 2000; Yun et al., 1999). In 
addition to the repression of the expression of Cdc25C (a mitosis promoting phosphatase 
that activates the cyclin B1/CDK1 complex) by p53, the Cdc25C activity can be inhibited via 
phosphorylation by checkpoint kinases, Chk1 and Chk2, both activated by p53. This, in turn, 
generates a consensus binding site for 14-3-3σ protein, allowing this protein to exert its 
negative effect (Figure 1.7; Taylor and Stark, 2001). 
After entered in a cell cycle arrest stage, p53 is able to promote the DNA repair 
through transcriptional activation of GADD45 and p53R2 genes (Smith et al., 1996; 
Yamaguchi et al., 2001). Together, GADD45 and p53R2 proteins, assist the DNA repair 
response contributing to the p53-mediated genetic stability.  
 
 
 The p53 function under irreparable stress 
Under severe DNA damage, cells may be eradicated via activation of programmed 
cell death pathways, particularly apoptosis. However, high stress conditions can also lead 
to senescence (permanent cell cycle arrest that can culminate in phagocytosis) (Xue et al., 
2007). 
Apoptosis is considered a “clean” death that does not stimulate an inflammatory 
response. It is typically characterized by chromatin condensation and fragmentation, 
membrane blebbing and mitochondrial swelling. The dying cell or cell body is finally 
recognized and engulfed by phagocytosis (Edinger and Thompson, 2004). There are two 
primary apoptotic pathways, the extrinsic and the intrinsic, although both converge into the 
same terminal or execution pathway. The extrinsic pathway starts with the binding of 
external ligands to death receptors, such as type 1 of tumor necrosis factor receptor 
(TNFR1), Fas (also called CD95/Apo-1), and TNF-related apoptosis-inducing (TRAIL) (Jin 
and El-Deiry, 2005; Guicciardi and Gores, 2009). These receptors send signals that activate 
caspase 8, with the induction of apoptotic events (Figure 1.8; Ryan, 2011). Inflammatory 
states, and others extracellular events, are responsible for the stimulation of this pathway. 
In contrast, the intrinsic mitochondrial pathway is dependent on intracellular stimulus, like 
genotoxic stress and the unfolded protein response (Ryan, 2011). In this pathway, members 
of the Bcl-2 family, with an important role in mitochondria membrane permeability, are 
responsible for the regulation of cytochrome c (cyt c) release from mitochondria. The 
released cyt c interacts with apoptosis protease-activating factor 1 (Apaf-1), forming a 
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complex recognized as apoptosome that leads to caspase-9 activation, followed by the 
subsequent activation of caspases 3, 6 and 7 (Figure 1.8; Yip and Reed, 2008).  
The crucial role of p53 in apoptosis regulation was first demonstrated in vivo, in a 
choroid plexus epithelial tumor model (Symonds et al., 1994). In this model, they showed 
that the inactivation of p53 abolished apoptosis and promoted tumor growth. Some genes 
that are regulated by p53 transcriptional activity are essential for triggering extrinsic and 
intrinsic apoptotic pathways (Figure 1.8). Regarding to extrinsic pathway, p53 increases the 
expression levels of Fas, death receptor 5 (DR5/Killer, a TRAIL receptor), and of p53-
induced protein with a death receptor domain (PIDD) (Amaral et al., 2010). p53 can also 
trigger this pathway enhancing the cell surface levels of Fas, by promoting its traffic from 
Golgi complex (Bennett et al., 1998).  
In the intrinsic mitochondrial apoptotic pathway, p53 is responsible for the increase of 
the expression levels of several proteins of the Bcl-2 family, as BAX and Bcl-2-
antagonist/killer (BAK; Figure 1.8). Other p53 transcription target proteins are p53 
upregulated modulator of apoptosis (PUMA) and NOXA, which are involved in apoptosis 
incitation. PUMA binds to mitochondrial anti-apoptotic proteins, such as Bcl-2, Bcl-XL, Bcl-
W, Mcl1 and Bcl-2-related protein A1 (Bcl-2A1), inhibiting their activities. Instead, NOXA 
only binds to Mcl1 and Bcl-2A1 (Khoo et al., 2014). p53 can also stimulate the intrinsic 
apoptotic pathway via activation of factors, like Scotin, that causes cellular perturbations 
such as endoplasmic reticulum stress, which ultimately leads to an intrinsic cell death 
response (Figure 1.8; Bourdon et al., 2002). Additionally, p53 can activate the apoptosome 
via induction of Apaf-1 expression (Moroni et al., 2001).  
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Figure 1.8. Regulation of intrinsic and extrinsic apoptotic pathways by p53. The p53 protein 
regulates the apoptotic process by inducing and repressing the transcription of pro-apoptotic and 
anti-apoptotic proteins, respectively. Additionally, p53 has a transcriptional-independent function in 
both apoptotic pathways. In the extrinsic pathway, p53 induces the expression of FAS, DR5 and 
PIDD, promoting the recruitment of the adaptor molecule, which binds to procaspase-8 leading to 
caspase-8 activation. Activated caspase-8 directly activates the executioner caspases 3, 6, and 7, 
with subsequent BH3 interacting-domain death agonist (Bid) cleavage. Additionally, p53 promotes 
the translocation of FAS from Golgi complex to cell surface. In the intrinsic pathway the stress-
induced mitochondrial translocation of p53 results in interactions between several anti- and pro-
apoptotic members of the Bcl-2 family to induce mitochondrial outer membrane permeabilization 
(MOMP) and cyt c release. Indeed, p53 interacts with Bcl-XL/Bcl-2 blocking their inhibitory effect on 
BAX. Besides, p53 upregulates the transcription of proteins, such as PUMA and NOXA that bind to 
and inhibit the activity of Bcl-2. The release of cyt c from mitochondria results in the formation of the 
apoptosome that activates caspase-9. The activation of the executioner caspases 3, 6 and 7 by 
caspase 9 leads to cell death.  
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Many other proteins involved in apoptosis are transcriptionally regulated by p53, the 
majority of them are pro-apoptotic being overexpressed, such as PIG3 and tumor p53 
regulated apoptosis inducing protein 1 (p53AIP1; Figure 1.8). Some examples of anti-
apoptotic proteins downregulated by p53 are Bcl-2, Bcl-XL and survivin (Figure 1.8; Harms 
et al., 2004; Riley et al., 2008; Hoffman et al., 2002). Another relevant p53 transcriptional 
target is Bid, which is responsible for the link between the extrinsic and intrinsic apoptotic 
pathways. In fact, the cleavage of Bid by caspase 8 promotes its translocation to 
mitochondria, where it triggers the intrinsic apoptosis by activation of BAX and BAK, and by 
inhibition of Bcl-2 and Bcl-XL (Figure 1.8; Sax et al., 2002). 
Despite the relevance of its transcriptional activity, p53 has also crucial 
transcriptional-independent pro-apoptotic functions. In fact, besides its nuclear localization, 
p53 can be also found in cytoplasm and mitochondria. Several factors can influence the 
localization of p53, namely its tetramerization, which prevents the nuclear exportation of 
p53 by masking its C-terminal NES (Stommel et al., 1999). Furthermore, post-translational 
modifications and protein-protein interactions have been demonstrated to be crucial to p53 
mitochondrial translocation, such as the MDM2-mediated p53 multi-mono-ubiquitylation 
and the p53 phosphorylation at Ser46 (Marchenko et al., 2007; Sorrentino et al., 2013). 
After activation, p53 translocates to mitochondria, where it induces BAX and BAK 
oligomerization, physically interacts with Bcl-XL and Bcl-2 inhibiting their anti-apoptotic 
effects, and forms a complex with cyclophilin D, leading to mitochondrial outer membrane 
permeabilization (MOMP) (Wolff et al., 2008). Moreover, in cytoplasm, p53 can induce 
homo-oligomerization of BAX, followed by BAX mitochondrial translocation (Chipuk et al., 
2004).  
Moreover, p53 can directly affect the executioner caspases 3 and 6 (Figure 1.8). In 
fact, it was shown that p53 induces caspase-6 expression, and it interacts with pro-caspase-
3 enhancing caspase 3 activation (MacLachlan and El-Deiry, 2002; Frank et al., 2011). 
Although numerous studies about the role of p53 in apoptosis have been published in the 
last years, the contribution of p53 transcription-dependent and -independent activities to the 
cell fate needs further elucidation.   
Despite the reported antioxidant properties of p53 (Sablina et al., 2005), when p53 is 
overexpressed in a stress-induced apoptotic pathway, an increase of reactive oxygen 
species (ROS) can also be found. In fact, high levels of ROS have been detected before 
MOMP and cyt c release (Fleury et al., 2002). Additionally, besides its role in apoptosis 
induction, the p53 transcriptional target PIG3 has been implicated in the accumulation of 
ROS (Polyak et al., 1997).  
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Multiple factors, such as the type and intensity of the cellular stress, tissue type, and 
cellular microenvironment, may determine if a cell stays in cell cycle arrest as a permanent 
form, or if it follows apoptotic death. Cellular senescence is another mechanism of tumor 
suppression, characterized by an irreversible cell cycle arrest by blocking malignant 
transformation (at the initial step of tumorigenesis) and by clearance of cancer cells (at the 
late stage of tumor progression) (Rufini et al., 2013). The p53 activity in senescence is 
mainly mediated by its transcription targets p21, plasminogen activator inhibitor 1 (PAI-1), 
promyelocytic leukemia protein (PML) and embryo chondrocyte expressed 1(DEC1) (Rufini 
et al., 2013; Kortlever et al., 2006; Barboza et al., 2006). However, other proteins were 
described to be involved in this process. For instance, due to the accumulation of p53 and 
p16, the expression of the oncogene ras results in cellular senescence (Serrano et al., 
1997). Despite the involvement of senescence in tumor suppression, targeting this effect is 
opposed by the cost of accelerated aging. Actually, the challenge to develop senescence-
based cancer therapy is to disclose the targets and pathways that control the balance 
between cancer and longevity (Qian and Chen, 2013). 
 
 
 Regulation of p53 by MDM2 and MDMX 
The p53 inactivation can lead to tumor development, or the own tumor can provide 
the perfect conditions to the inactivation of p53. In tumors that retain wt p53, this protein 
can be inactivated by overexpression of its negative regulators MDM2 and MDMX (also 
called MDM4) (Zawacka-Pankau and Selivanova, 2015). In fact, transgenic mice 
overexpressing MDM2/MDMX (MDMs), either globally or in a specific tissue, develop 
spontaneous tumors, what established a connection between the overexpression of these 
two proteins and tumor onset (Jones et al., 1998; Ganguli et al., 2000; Xiong et al., 2010). 
The overexpression of MDMs occurs in at least 10% of total human tumors (Toledo and 
Wahl, 2006). The degree of overexpression of these two proteins differs among the different 
types of tumors, and their expression is not related, what suggests specific roles for MDM2 
and MDMX in tumorigenesis (Toledo and Wahl, 2006). For example, MDM2 is 
overexpressed in 24% to 56% of osteosarcomas, 45% to 75% of brain glioblastomas, 33% 
to 41% of prostate cancers, while MDMX is overexpressed in 65% of cutaneous 
melanomas, 60% of retinoblastomas, 50% of hepatocellular carcinomas, 5% of breast 
cancers, and 4% of glioblastomas (Rayburn et al., 2005; Riemenschneider et al., 1999; 
Danovi et al., 2004; Laurie et al., 2006; Gembarska et al., 2012). Importantly, the deletion 
of MDM2 and MDMX results in embryonic lethality, which is completely rescued, in both 
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cases, by concomitant p53 loss (Jones et al., 1995; Parant et al., 2001). These data confirm 
the MDMs function and show the significance of these two negative regulators of p53. 
The MDM2 gene encodes a 491 a.a. protein with several domains (Figure 1.9). The 
MDM2 protein contains an N-terminal domain that comprises the p53 binding site, an acidic 
domain capable of interacting with the tumor suppressor p14/ARF (that inhibits the MDM2-
mediated degradation of p53), a zinc finger domain that mediates MDM2's interaction with 
ribosomal proteins and its ability to degrade p53, and a RING finger domain with the E3-
ligase activity responsible for p53 ubiquitination (Lee and Gu, 2010). MDM2 also contains 
the NLS and NES regions, responsible for shuttling MDM2 between the nucleus and 
cytoplasm (Iwakuma and Lozano, 2003).  
 
 
 
 
Figure 1.9. Structure of MDM2 and MDMX proteins. Domains: p53 binding, acidic, zinc finger, and 
RING finger. NLS, nuclear localization signal; NES, nuclear export sequence. 
 
 
Under normal conditions, there is an auto-regulatory feedback loop between p53 and 
MDM2 (Figure 1.10). Actually, p53 promotes MDM2 expression by binding to the P2 
promoter of the MDM2 gene. In turns, MDM2 binds to the N-terminal transactivation domain 
of p53 inhibiting its transcriptional activity and promoting its monoubiquitination. The p53 
monoubiquitination enhances the nuclear export of p53 and can also endorse the 
polyubiquitination and subsequent degradation by proteasome (Figure 1.10; Michael and 
Oren, 2003; Zawacka-Pankau and Selivanova, 2014). In addition, MDM2 may negatively 
affect the p53 mRNA translation (Ofir-Rosenfeld et al., 2008).   
Under stress conditions, the p53 stabilization can result from an inefficient p53-MDM2 
binding, or from the inhibition of the MDM2 E3-ligase activity by stress-induced interactions 
of MDM2 with other proteins. For example, p14/ARF, whose expression increases in 
response to oncogenic stress, can bind to MDM2 inhibiting its ubiquitin ligase activity on 
p53 (Honda and Yasuda, 1999). Similarly, ribosomal proteins L5, L11 and L23 can also 
interact with MDM2 inhibiting its E3 function (Lohrum et al., 2003; Dai and Lu, 2004; Dai et 
al., 2004).  
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MDMX is an MDM2-related protein with high homology to MDM2, particularly in the 
N-terminal (Shvarts et al., 1996). However, MDMX has no NLS and NES domains (Figure 
1.9). Like MDM2, MDMX binds with high affinity to the N-terminal transactivation domain of 
p53, inhibiting its transcriptional activity (Figure 1.10). However, contrary to MDM2, MDMX 
does not target p53 for degradation, because the RING domain lacks the E3-ligase activity 
(Stad et al., 2001). Despite this, the hetero-oligomerization of MDMX with MDM2, through 
RING finger domains, increases the efficiency of MDM2 E3-ligase activity towards p53 
(Figure 1.10; Wade et al., 2013). Interestingly, in mice with MDMX RING domain alterations, 
it was shown that the MDM2 interaction with MDMX through this RING domain is required 
for modulating the p53 activities, in embryonic stages. However, it has shown to be 
dispensable for MDM2 and p53 stabilization in adult mouse (Pant et al., 2000; Huang et al., 
2011). Upon DNA damage stimuli, MDM2 degrades itself and can also directly ubiquitinate 
and degrade MDMX (Nag et al., 2013).  
 
 
 
 
Figure 1.10. Regulation of p53 by MDM2 and MDMX. p53 is responsible for the regulation of MDM2 
and MDMX transcription levels (yellow arrows). In turn, MDM2 and MDMX cooperate to inhibit the 
p53 transcriptional function. MDM2 also promotes p53 nuclear export to the cytoplasm for ubiquitin-
mediated degradation by proteasome. Additionally, MDM2 can promote the nuclear degradation of 
p53 (polyubiquitination), MDMX ubiquitination and its own ubiquitination and degradation. Ub: 
ubiquitin.    
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Recently, it was discovered that, similarly to MDM2, also MDMX can establish an 
auto-regulatory feedback loop with p53 (Figure 1.10). The p53 protein can bind to a 
functional p53-binding site in MDMX intron 1, increasing the MDMX expression (Li et al., 
2010a). Furthermore, it was discovered that, like MDM2, also MDMX contains a P2 
promoter that is regulated by p53. Activated p53 induces the expression of a MDMX 
transcript from the P2 promoter that encodes a novel “long-form” of the protein. Curiously, 
this long-form of MDMX appears to function with MDM2 promoting p53 ubiquitination during 
recovery from stress (Phillips et al., 2010).  
The overexpression of MDM2 in tumor cells can result from gene amplification, 
increased mRNA stability, enhanced translation, altered post-translational modification, or 
from the presence of a single nucleotide polymorphism at position 309 (SNP309) in the P2 
promoter of MDM2 (creating an additional binding site for the transcriptional activator Sp1 
enhancing MDM2 expression) (Li and Lozano, 2013; Bond et al., 2004). 
Similar mechanisms of overexpression to those described for MDM2 have been found 
for MDMX. However, no corresponding of SNP has been observed in MDMX (Schlaeger et 
al., 2008; Valentin-Vega et al., 2007; Laurie et al., 2006).  
In addition to the overexpression of MDMs, the expression of more stable isoforms 
can be also observed. For example, the MDM4-S transcript produces a MDMX isoform 
containing the p53-binding domain, but lacking the negative regulatory sites, which are 
more stable and oncogenic than the full-length MDMX. Thus, the overexpression of MDMX-
S has been associated with decreased survival and poor prognosis in cancer patients (Li 
and Lozano, 2013). 
Although the major functions of MDM2 and MDMX are associated with p53, emerging 
data have suggested that these two proteins may also have p53-independent roles, namely 
in the regulation of genomic instability, apoptosis and metastasis, contributing to tumor 
formation and progression (Li and Lozano, 2013).  
Taking into consideration that MDMs overexpression correlates with poor clinical 
prognosis and with poor response to current cancer therapies (Zhao et al., 2015), it is 
important to develop new therapeutic alternatives targeting both MDM2 and MDMX, for a 
full reactivation of p53 tumor cells. 
 
 
 Mutant p53 
The TP53 gene is the most commonly mutated gene in human cancers (Kandoth et 
al., 2013). Although p53 mutations can be found in all regions of the protein, only the most 
frequent mutations has been deeply studied (Leroy et al., 2013). In fact, more than 80% of 
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somatic and germline TP53 mutations are missense that lead to stable mutant proteins 
(Soussi and Wiman, 2015). The missense mutations, characterized by the substitution of a 
single amino acid in the p53 protein, commonly occur within the DBD region, particularly in 
six hotspot residues (175, 245, 248, 249, 273, 282) (Figure 1.11). The frameshift or 
nonsense mutations occur with less frequency, and in some cases, they result in the loss 
of p53 protein expression (Muller and Vousden, 2014). It is important to note that more than 
90% of p53 mutations are located in the core domain of the protein, affecting all p53 protein 
isoforms (Leroy et al., 2014). Due to the high fragility of the core domain, which can be 
easily destabilized by amino acid substitutions, at least five occurrences of each mutation 
and up to 2,000 for hotspot mutations can be observed in independent tumors (Figure 1.11; 
Leroy et al., 2014; Soussi, 2011).   
 
 
Figure 1.11. Distribution of somatic mutations by codon in p53. The peaks indicate the relative 
frequency of cancer-associated mutations for each residue according to IARC TP53 Database. 
Missense mutations, at hotspot codons located in the DNA binding domain of p53, are the most 
frequent alterations in human cancers [adapted from (version R17 2013; Petitjean et al., 2007b)]. 
 
 
The missense p53 mutations can be classified as structural (e.g., R175H, Y220C) or 
DNA contact (e.g., R273H, R280K), based on whether they lead to a protein conformational 
change, or simply affect its DNA binding ability with no profound structural alterations, 
respectively (Khoo et al., 2014). Nuclear magnetic resonance, circular dichroism and X-ray 
diffraction analyses have confirmed and expanded this description, suggesting that multiple 
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thermodynamic stages may be associated with the various mutations depending on their 
position (Wong et al., 1999; Bullock et al., 1997; Cho et al., 1994). Interestingly, these 
studies also confirmed that even some contact mutants are unfolded to some degree 
(Bullock et al., 1997). Despite the differences, both types of mutations modify the ability of 
p53 to interact with DNA, leading to the loss of wt p53 transcriptional activity (Khoo et al., 
2014; Zawacka-Pankau and Selivanova, 2015).  
Different tumor types show different spectra of TP53 mutations. For example, in high-
grade serous ovarian cancer, the frequency of TP53 mutation is higher than 90%, in 
colorectal, head and neck cancers it ranges from 50% to 70%, while in haematopoietic 
malignancies it is lower than 10% (Leroy et al., 2014; Soussi and Wiman, 2015; Olivier et 
al., 2010). The different mutation rates can be related with the mutagenic event that leads 
to tumor development or with geographic factors. The frequency of missense mutations also 
differs in different subclasses of tumors of the same organ. For example, almost all basal 
breast tumors carry p53 truncations, while luminal breast cancers frequently carry point 
mutations in TP53 (Dumay et al., 2013).  
Whereas somatic TP53 mutations contribute to sporadic cancer, germline mutations 
cause a rare type of cancer predisposition, known as Li–Fraumeni Syndrome. In this 
syndrome, the residues 248 and 273 are the most commonly mutated, and it is 
characterized by the early onset of tumors as sarcomas, osteosarcomas, breast carcinomas 
and leukaemias (Malkin et al., 1993). Patients with this disease and heterozygous for 
mutant TP53 allele have a 50% risk for developing tumors by the age of 30, and a 90% risk 
after 70 years old (Malkin et al., 1993). Importantly, both somatic and germline TP53 
mutations are usually followed by loss of heterozygosity during tumor progression, which 
suggests that a selective force inactivates the remaining wt allele (Brosh and Rotter, 2009). 
 Under unstressed conditions, the wt p53 is a very short-lived protein, while p53 
mutations provide a prolonged half-life. For this reason, wt p53 appears at lower levels in 
heterozygous cells. The hyperstability of mutant p53 can be attributed to its inability to act 
as a transcription factor and to induce sufficient levels of MDM2 for p53 ubiquitination and 
degradation (Li et al., 2011b). In fact, a complete lack of ubiquitination of mutant proteins 
was demonstrated in a large survey of tumor cells expressing wt and mutant p53, leading 
to mutant protein stabilization (Li et al., 2011b).  
However, beyond this loss-of-function (LOF), that is based on the loss of normal 
transcriptional activity, accumulating evidence supports that some of these mutant p53 have 
additional oncogenic activities, collectively referred as mutant p53 dominant-negative effect 
(DNE) and gain-of-function (GOF) (Figure 1.12). Despite the complexity to study each of 
these valences, it is important to considerer that different mutants show a distinct profile 
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towards them (Halevy et al., 1990; Petitjean et al., 2007b). Moreover, DNE and GOF events 
are usually associated with more aggressive tumor profiles, characterized by increased 
metastasis and resistance to anticancer treatments, and, consequently, with poor prognosis 
(Muller and Vousden, 2014). 
 
 
 Functional activities of mutant p53: LOF, DNE and GOF  
In 1997, tumor suppressor genes were defined as genes that sustain LOF mutations 
in the development of cancer (Haber and Harlow, 1997). Today, although LOF is still being 
the main characteristic of tumor suppressor genes, we know that this definition is not 
complete. The Haber and Harlow definition does not take into account the heterogeneity of 
the different protein variants, or other activities such as DNE on wt protein or GOF. 
Numerous studies about LOF of mutant p53 have been carried out. The majority of 
them are based on the analysis of p53 transcriptional activity. In fact, the transcriptional 
analysis of 2500 mutant p53 on 8 different target genes, representative of different TP53 
functions, demonstrated heterogeneous prevalence of the various mutant p53 with more 
than 50% presenting only partial loss of activity (Kawaguchi et al., 2005; Kakudo et al., 
2005; Shiraishi et al., 2004; Kato et al., 2003). However, the most prevalent mutant p53 
demonstrated a completely loss of their transcriptional function.  
Besides LOF, in a p53 heterozygous environment, many stable mutant p53 are able 
to exert a DNE on the remaining wt p53, preventing its normal activity. The DNE can be 
observed through formation of mutant/wt p53 cotetramers (Chan et al. 2004), by the 
incorporation of wt p53 into mutant p53 supratetrameric aggregates (Xu et al. 2011), or by 
preventing wt p53 from binding to the promoter of its target genes (Willis et al., 2004; Figure 
1.12). The DNE has been experimentally studied in yeast, human cells and mouse models. 
To date, there is information about DNE for over 200 mutants. These studies supported the 
notion that DNE property is correlated with cancer occurrence, being DNE promoter- and 
cell-type dependent (Dearth et al., 2007).  
The first systematic study to evaluate the DNE of mutant p53 was performed in yeast, 
and measured the ability of 35 mutants to inhibit the transcriptional activity of wt p53 on its 
consensus response element (RE) (Brachmann et al., 1996). Latter, it was found that 80% 
of the most common mutant p53 have the capacity to exert DNE over wt p53, compared to 
only 45% of the less frequent mutants studied. This suggests that DNE plays a role in the 
selection of mutant p53 in sporadic cancers (Petitjean et al. 2007a). Interestingly, it was 
observed a correlation between LOF and DNE (Dearth et al., 2007), which was in 
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accordance with the finding that mutant p53 alleles with partial-function have not a DNE 
over wt p53 (Shi et al., 2002).  
Importantly, it was demonstrated that the inactivation of wt p53 by DN mutants depends on 
several factors: the wt to mutant subunit ratio within the heterotetramers, the conformation 
of the mutant protein, the DNA affinity of mutant subunits present in the heterotetramers, 
and the DNA binding site (Chène, 1998).  
The DNE is correlated with some types of cancer and with some aggressive tumor 
profiles. For example, DN mutation of the TP53 gene was related to serous 
adenocarcinoma (Sakuragi et al., 2001), to early recurrence of oral cancer (Hassan et al., 
2008), and to accelerated development and/or growth of glioblastomas (Marutani et al., 
1999). Despite the relevance of the DN classification of mutant p53 to the clinical outcome 
of some types of cancer, in carriers of germline p53 mutations, the transactivation-based 
classification of p53 alleles seems to be more important for genotype/phenotype 
correlations than the DN classification (Monti et al., 2011). The GOF was firstly suggested 
in 1993 with the observation of a new phenotype with the induction of mutant p53 expression 
in p53-null cells (Dittmer et al., 1993). Since then, many GOF have been described for 
different mutant p53. In vivo evidences, namely from mutant p53-expressing mice, have 
shown a tumor profile that is more aggressive and metastatic than p53-null or wt p53 mice 
(Doyle et al., 2010; Lang et al., 2004; Morton et al., 2010; Olive et al., 2004).  
Contrary to what happens for DNE, no systematic studies have been performed to 
distinguish mutant p53 with GOF properties. In fact, current studies about GOF have only 
considered one or a small group of mutant p53 proteins and a GOF property. Although 
some mechanisms of GOF may be shared by a group of mutant p53 proteins, it has become 
clear that each individual mutant p53 may act on its own specific way, while they may 
converge to affect the same pathway (Muller and Vousden, 2014). According to different 
works published to date, some examples of mechanisms by which mutant p53 may exert 
their GOF are: genomic instability, the activation of genes normally unaffected or repressed 
by wt p53, the interference with other transcription factors, the interaction with other 
proteins, and the modification of miRNAs expression (Figure 1.12; Oren and Rotter 2010). 
These GOF activities contribute to tumor development by enhancing cell proliferation, 
migration, invasion, angiogenesis, metabolic changes and chemoresistance (Figure 1.12; 
Muller and Vousden, 2014).  
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Figure 1.12. Functional activities of mutant p53: dominant-negative effect (DNE), loss-of-
function (LOF) and gain-of-function (GOF).  
 
 
Although mutant p53 proteins are generally characterized by LOF due to their 
incapacity to bind to consensus p53 DNA binding regions in target gene promoters, it seems 
that they have the ability to regulate the gene expression by binding to DNA with some 
degree of selectivity (Weisz et al., 2007; Brázdová et al., 2013; Göhler et al., 2005; Quante 
et al., 2012). One example is the transcription activation of the multidrug resistance 1 
(MDR1) gene, responsible for drug resistance in mutant p53-expressing cancers (Lin et al., 
1995). Additionally, mutant p53 has been involved in the regulation of genes, such as FAS, 
Bcl-XL and VEGF, which are key proteins in apoptosis and angiogenesis (Zalcenstein et 
al., 2003; Bossi et al., 2008; Khromova et al., 2009). Besides the direct regulation of gene 
expression, mutant p53 is able to interact with transcription factors as p63 and p73 (Liu et 
al., 2014a). These interactions deplete the p63 and p73 transcriptional activity and, 
consequently, their ability to prompt growth suppression and apoptosis. Additionally, these 
interactions seem to be highly involved in migration, invasion, metastasis and 
chemoresistance (Di Como et al., 1999; Strano et al., 2002; Gaiddon et al., 2001; 
Bergamaschi et al., 2003; Liu et al., 2014a). In fact, the p63 inhibition by mutant p53 triggers 
a pro-invasive transcription program involving the expression of Dicer, DEPDC1, Cyclin G2 
(through interaction with Smad), and Sharp1 (through interaction with Pin1) (Adorno et al., 
34 
 
2009; Girardini et al., 2011). However, it was shown that the loss of TAp63 alone is less 
potent in inducing metastases compared to the effect of mutant p53 expression in the 
presence of TAp63 in a mouse model of pancreatic ductal adenocarcinoma. This suggests 
additional functions of mutant p53 besides inhibiting p63 (Tan et al., 2014). Moreover, 
mutant p53 may interact with other proteins, such as the MRE11-Rad51-NSB complex 
(recruit ATM kinase to double-strand breaks) and SP-1, impairing their activities to induce 
proliferation, genomic instability, or chemoresistance (Chicas et al., 2000; Song et al., 
2007). The genomic instability was further supported in a recent analysis of 3000 tumors 
showing that TP53 mutations were strongly associated with a high frequency of copy 
number changes (Ciriello et al., 2013). Additionally, numerous studies using xenograft 
mouse models demonstrated that mutant p53 enhances invasion and motility, through 
modification of the signaling of receptors such as transforming growth factor  (TGF-), 
EGF, and MET (Adorno et al., 2009; Grugan et al., 2013; Muller et al., 2009; Muller et al., 
2013; Wang et al., 2013). Moreover, a recent report highlights an important function of 
mutant p53 in promoting the inflammatory environment of colorectal tumors, by protracting 
NF-kB activation and cell survival (Cooks et al., 2013). Other important GOF property of 
mutant p53 is the contribution to tumor initiation via enhanced generation and expansion of 
cell populations with stem cell/cancer stem cell properties (Yallowitz et al., 2015; Hanel et 
al., 2013; Sarig et al., 2010). In the last years, a new mechanism of GOF has been 
described, which consists in the ability of mutant p53 to regulate the expression of certain 
miRNAs to gain new oncogenic activities. For example, mutant p53 binds to the promoter 
of miR-130b and inhibits its transcription. As negative regulator of ZEB1, miR-130b 
promotes epithelial-mesenchymal transition and cancer cell invasion in endometrial cancer 
(Dong et al., 2013).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
In conclusion, accumulated data have demonstrated the relevant contribution of 
mutant p53 to tumor proliferation, survival, limitless replication, cell death resistance, 
evading growth suppression, sustained proliferative signaling, genomic instability, 
inflammation, migration, invasion, angiogenesis, and metastasis. This provides to mutant 
p53 a central role in tumorigenesis, with impact on all cancer hallmarks (Solomon et al., 
2011; Freed-Pastor and Prives, 2012; Girardini et al., 2014). Moreover, the high frequency 
of TP53 mutation, the poor prognostic of patients with mutant p53-expressing cancers, and 
the high amount of mutant p53 in tumors, make mutant p53 a promising target for the 
development of new anticancer therapies. Besides this, the TP53 status can give relevant 
clinical information about patient’s prognosis. In fact, in clinical studies, p53 mutation is 
found to be associated with resistance to radiotherapy and chemotherapy and with poor 
survival rates (Robles and Harris, 2010). 
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1.3. Targeting the p53 pathway  
Several mouse models have demonstrated that the reactivation of p53 results in tumor 
regression with no evidence of toxicity in normal tissues (Xue et al., 2007; Martins et al., 
2006; Ventura et al., 2007; Zawacka-Pankau and Selivanova, 2015). This together with the 
correlation between inactive p53 pathways and aggressive tumor phenotypes and poor 
prognosis, as well as the key role of p53 in central processes related to tumor development 
and progression has become p53 one of the most appealing therapeutic targets in cancer, 
Actually, in contrast with the majority of anticancer therapies, acting on p53 will allow to 
attack all cancer hallmarks (Luo et al., 2009; Solomon et al., 2011; Hanahan and Weinberg, 
2011). Additionally, the high protein levels of mutated p53 in tumors and the high frequency 
of the inactive p53 pathway in cancer, makes this protein a selective target in cancer 
treatment (Zawacka-Pankau and Selivanova, 2015). 
Moreover, the functional integrity of the p53 pathway showed to be essential for the 
action of several conventional chemotherapies, particularly for the chemotherapeutics that 
act on DNA, such as doxorubicin, etoposide, and cisplatin. In fact, several reports have 
demonstrated the increased resistance of tumors with deleted or mutated p53 to this type 
of conventional anticancer therapies (Do et al., 2012; Dunkern et al., 2003; Chee et al., 
2013). Considering that the therapeutic outcome of many tumors is highly dependent on 
these chemotherapeutics (the only therapeutic option for many types of tumors) the 
reestablishment of the normal status of p53 is therefore an effective strategy to overcome 
this chemoresistance.  
After p53 has been recognized as an ideal anticancer therapeutic target, several 
strategies to reactivate the p53 pathway have emerged, including: wt p53 delivery or 
oncolytic gene therapy, elimination of p53 mutant-expressing cells by p53-based vaccines, 
therapies based on elimination of mutant p53, activation of p53 by inhibiting histone 
deacetylases, synthetic lethality, inhibition of p53-MDMs interactions, and restoration of wt 
function to mutant p53 (Figure 1.13; Hong et al., 2014). Actually, in last years, an impressive 
number of p53-based therapies have emerged, with several drugs in clinical trials and new 
lead compounds under development.   
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Figure 1.13. Different strategies for activation of the p53 pathway.  
 
 
Gene therapy is a recent approach that has been explored for the treatment of many 
diseases. The delivery of wt p53 by adenovirus into cancer cells has been shown to be a 
promising strategy to rescue the p53 activity in cancer (Hong et al., 2014). This approach 
uses virus as vector, which maintain the capacity to allow the input of new genetic material 
into the cell but lacking, at the same time, certain early proteins for replication (preventing 
the infection). In China (Gendicine) and in USA (ADVEXIN), this therapy was tested in 
clinical trials for the treatment of several cancers, demonstrating to be advantageous when 
combined with radiotherapy in the treatment of hepatocellular carcinoma and 
nasopharyngeal carcinoma (Yang et al., 2010; Pan et al., 2009). However, this approach 
has some limitations, namely the incapacity to infect all cancer cells due to the limitation of 
virus delivery, and the reduction of adenovirus infectivity by host antibodies (Hong et al., 
2014). Currently, just China approved the Gendicine for clinical use in combination with 
radiotherapy. FDA did not approve the ADVEXIN due to some cases of tumor resistance 
(Golubovskaya and Cance, 2013). Other gene therapy approach was developed to 
eliminate tumor cells with deleted or mutated p53, the oncolytic therapy. One example is 
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the E1B-deleted adenovirus, designated as ONYX-015, which selectively replicates in p53-
deficient cancer cells and subsequently lyses the cells (Bischoff et al., 1996). Despite the 
efficiency of this treatment, particularly in combination with other chemotherapies, FDA did 
not approve ONYX-015 due to its hepatotoxicity and to difficulties to assess p53-dependent 
responses versus non-specific effects of virus on tumor (Khuri et al., 2000; Golubovskaya 
and Cance, 2013).  
Taking advantage from tumor specificity and high expression levels in cancer cells, a 
vaccine was developed against mutant p53. In fact, antibodies against p53 have been found 
in patients with different types of cancer, which indicates that the human immune system 
can recognize and respond to tumor-associated p53 (Chada et al., 2003). Two different 
types of vaccines entered in phase I/II of clinical trials, the p53-SLP (a p53 synthetic long 
peptide vaccine) for colorectal cancer and the INGN-225 (a p53-modified adenovirus-
transduced dendritic cell vaccine) for small cell lung cancer (Speetjens et al., 2009; 
Chiappori et al., 2010). Both vaccines demonstrated specific anti-p53 immune response 
without toxicity, and INGN-225 also showed synergistic effects when conjugated with 
chemotherapy (Speetjens et al., 2009; Chiappori et al., 2010). 
The DNE and GOF properties of mutant p53, together with the high expression levels 
of mutant p53 in tumor cells, led to the development of strategies to eliminate mutant p53. 
For example, arsenic trioxide, a drug for the treatment of acute promyelocytic leukemia, 
was found to degrade mutant p53 (Yan et al., 2011). Other strategy to eliminate mutant p53 
is based on the inhibition of their conformational stabilizing chaperones. For example, the 
17AAG is an inhibitor of HSP90 (a chaperone that interacts with mutant p53), which can 
decrease mutant p53 levels by destroying the complex of mutant p53 and HSP90 to release 
mutant p53 for its degradation (Li et al., 2011a). In addition, the SAHA is an inhibitor of 
histone deacetylase, HDAC6 (a positive regulator of HSP90 chaperone activity), with 
preferential cytotoxicity for mutant p53-expressing cancer cells due to its ability to degrade 
mutant p53 by inhibition of the HDAC6-HSP90 chaperone axis (Li et al., 2011b).  
Using a yeast genetic screen, tenovins 1/6 were identified as activators of p53 through 
inhibition of SirT (sirtuin 1 and 2; histone deacetylases) (Lain et al., 2008). The inhibition of 
SirT1 and 2 by tenovins results in increased acetylation of p53, at lysine-382, and in p53 
subsequent activation. Despite the potent in vivo antitumor activity of tenovins, the 
mechanism of action may be independent of p53 (Lain et al., 2008). 
An alternative strategy is the exploration of cell-specific vulnerabilities imposed by 
alterations in p53 status. In fact, several studies have reported that cells that have lost 
functional p53 exhibit specific functional dependencies on several secondary pathways that 
could be targeted in therapy. In this way, in cells with deleted or mutated p53, it is possible 
38 
 
to inhibit crucial proteins regulators of vital pathways, in order to cause cell death (synthetic 
lethality). A well-studied example of synthetic lethal interactions involves p53 and the 
ATR/Chk1 pathway. Cancer cells deficient on p53 become dependent on G2/M cell cycle 
arrest for DNA repair and survival. Therefore, targeting the ATR/Chk1 pathway that 
regulates G2/M progression with small-molecule inhibitors, the synthetic lethality can be 
conducted in p53 null or mutant p53-expressing cancer cells (Nghiem et al., 2001; Gurpinar 
and Vousden, 2015). Actually, the combination of the selective Chk1 inhibitor AZD7762 with 
irinotecan (a topoisomerase I inhibitor), in early-passage human-in-mouse (HIM) models of 
triple-negative breast cancer, significantly enhanced the therapy response and prolong 
survival in mice bearing p53-deficient tumors (Ma et al., 2012). Although the synthetic 
lethality has been already applied in clinic for other proteins, as PARP inhibitors in the 
treatment of breast cancer with mutated BRCAs, concerning to p53, clinical studies with this 
principle has not been performed yet.  
The other two approaches, inhibition of p53-MDMs interactions and restoration of wt 
function to mutant p53, since they are the basis of this thesis, will be discussed in the 
following subsections. 
 
 
 Inhibition of MDMs and of their interactions with p53 
Until now, several approaches to inhibit MDM2 and MDMX have been described. 
Using anti-sense oligonucleotides to decrease MDM2 expression, it was possible to reduce 
xenograft tumors in mouse models (Sato et al., 2000; Zhang et al., 2005). Despite these 
promising results, the high promiscuity of siRNAs, as well as problems related with delivery 
and cellular uptake, made this approach not feasible to apply in clinical studies. However, 
the recent identified benzofuroxan derivative XI-066 (NSC207895) and the pseudourea 
derivative XI-011 (NSC146109), which inhibit the MDMX expression by MDMX promoter 
inhibition, increased the expectations around this strategy (Wang et al., 2011b, Wang and 
Yan, 2011).  
Other group of agents that inhibit the MDM2-dependent ubiquitination of p53, 
preventing the p53 degradation, was also developed. The first compound identified was the 
HDM2 ligase inhibitor 98 class (HLI98), a 7-nitro-5-deazaflavin, that inhibits the E3-ligase 
activity of MDM2, leading to p53 stabilization and apoptosis in tumor cells. Later, an 
optimized derivative, HLI373, was identified, showing improved solubility and potency. 
Additionally, the natural compounds Lissoclinidine B (Clement et al., 2008) and 
Sempervirine (Sasiela et al., 2008) were also identified as inhibitors of the MDM2 E3 
ubiquitin ligase activity. The JNJ-26854165 (Serdemetan), a p53 activating tryptamine 
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derivative, was initially described as an E3 ubiquitin ligase inhibitor (Arts et al., 2008). Due 
to its potent antitumor activity, JNJ-26854165 entered into phase I clinical trials, but it is no 
longer in clinical development (Yu et al., 2014).  
However, the most explored approach, due to its high efficacy and safety, has been 
the development of chemical agents that inhibit the p53-MDMs interactions. Particularly, the 
inhibition of the p53 interaction with MDM2 has been the most extensively studied strategy. 
The characterization of the crystal structure of the p53-MDM2 interaction was fundamental 
to the structure-based design of small molecule inhibitors of this interaction. Moreover, with 
the characterization of the crystal structure, three critical a.a. in the p53-MDM2 interaction 
(LEU26, TRP23 and PHE19) were identified, which were the focus of chemical library 
screens from which emerged Nutlin-3a (Vassilev et al., 2004).  
Nutlin-3a, a cis-imidazoline, is a potent and selective p53-MDM2 interaction inhibitor, 
which binds to the deep hydrophobic p53-binding pocket of MDM2 (Vassilev et al., 2004). 
The disruption of the p53-MDM2 interaction by Nutlin-3a increases the p53 expression and 
functional activity, leading to cell cycle arrest and apoptosis in both human tumor cells and 
xenograft mouse models (Vassilev et al., 2004). Nutlin-3a does not bind to MDMX; therefore 
it fails to activate p53 in MDMX-overexpressing tumor cells (Hu et al., 2006; Patton et al., 
2006). Later, the optimized compound RG7112, from Nutlin family, was identified as a 
potent and selective p53-MDM2 interaction inhibitor with oral bioavailability (Tovar et al., 
2013). In human xenograft models, RG7112 inhibits the tumor growth in a wt p53-
dependent manner (Tovar et al., 2013). RG7112 is currently in phase I of clinical trials 
(Table 1.3; Yu et al., 2014).  
Together with Nutlin-3a, the Sulfonamide I (NSC279287) was the first described p53-
MDM2 interaction inhibitor. This compound was a fairly weak inhibitor of the p53-MDM2 
interaction, with a low impact on p53 transcriptional function even for high concentrations 
(Galatin and Abraham, 2004).  
The benzodiazepinediones are benzodiazepine derivatives that disrupt the p53-
MDM2 interaction in a similar manner to nutlins, by binding to the p53-pocket of MDM2 
(Grasberger et al., 2005). The optimized benzodiazepinediones TDP521252 and 
TDP665759 show to stabilize p53 and to increase the p53 transcriptional activity, leading 
to the reduction of proliferation of wt p53-expressing tumor cells (Grasberger et al., 2005; 
Koblish et al., 2006; Parks et al., 2006). Additionally, TDP665759 showed in vivo antitumor 
activity (Koblish et al., 2006). 
The spiro-oxindoles (MI compounds) were design to interact with MDM2, mimicking 
the p53 a.a. side chains to interact with the p53-binding pocket of MDM2 (Ding et al., 2006). 
One of the most potent MI inhibitors initially described was MI-63, and its optimization 
40 
 
resulted in MI-219, which inhibited the tumor growth in vivo by oral administration (Shangary 
et al., 2008). The followed derivative of MI-219 was MI-319 that shows efficient tumor growth 
suppression of lymphoma cells (Mohammad et al., 2009). Several optimizations of MI-319 
led to SAR405838, currently in phase I of clinical trials for patients with advanced wt p53-
expressing cancers (Table 1.3).  
The isoindolinones represent other family of p53-MDM2 interaction inhibitors that 
block the p53-binding pocket of MDM2 (Hardcastle et al., 2006). The compound 74a was 
the most potent isoindolinone described to date. Despite this, it exhibited a lower binding 
affinity to MDM2 than Nutlin-3a (Hardcastle et al., 2011). The piperidinone AM-8553 also 
demonstrated to inhibit the p53-MDM2 interaction (Bernard et al., 2012). A further 
optimization of this compound led to AMG 232 with improved potency, in vivo antitumor 
activity in mice, and pharmacokinetic profile (Sun et al., 2014). The substitution of the 
piperidinone core by a morpholinone led to compounds with further improved antitumor 
activity and better pharmacokinetics, such as AM-8735 (Gonzalez et al., 2014). 
In 2013, the compound RG7388, with a pyrrolidine core, was identified as p53-MDM2 
interaction inhibitor (Ding et al., 2013). This compound binds to MDM2 and induces cell 
cycle arrest and cell death in both human tumor cells and mice. Due to its high efficacy, this 
compound is under clinical trials (Table 1.3; Ding et al., 2013). The optimized molecules 
RO5353 and RO2468 were identified as more potent, selective and orally active in the 
treatment of human osteosarcoma xenografts in mice (Zhang et al., 2014b).   
RITA (reactivation of p53 and induction of tumor cell apoptosis) was identified as an 
inhibitor of the p53-MDM2 interaction that binds to p53, causing a consequent 
conformational change (Issaeva et al., 2004), although crystal structures failed to confirm 
this (Krajewski et al., 2005). Besides its effect on wt p53, RITA also suppresses the growth 
of different tumors with mutant p53 (Zhao et al., 2010). In fact, it remains unclear how RITA 
can activate both wt and mutant p53.  
Many other small molecules have been described as inhibitors of the p53-MDM2 
interaction, such as terphenyl compounds 2 and 6 (Chen et al., 2005), the quinolinole 
NSC66881 (Lu et al., 2006), the chromenotriazolopyrimidine 1 (Allen et al., 2009), the 
isoquinolinones PXN727 and PXN822 with in vivo antitumor activity by oral administration 
(Yuan et al., 2011), the pyranoxanthone 1 (Leão et al., 2013c), the dihydroisoquinolinone 
derivative NVP-CGM097 that is under clinical trials (Table 1.3; Holzer et al., 2015), the 
spirooxadiazoline oxindole 1a (Ribeiro et al., 2015), the chalcone 2 (Leão et al., 2015b) and 
the fluspirilene (Patil et al., 2015). Finally, some peptides have been described that bind to 
the p53-binding pocket on MDM2 thereby preventing the interaction of p53 with MDM2 with 
subsequent p53 activation (Bernal et al., 2007; Baek et al., 2012). However, despite the 
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huge number of small molecule inhibitors of the p53-MDM2 interaction that have been 
described so far, only few have reached clinical trials (Table 1.3). 
Although adressed in much less studies, the inhibition of the p53-MDMX interaction 
is currently recognized as important as the inhibition of the p53-MDM2 interaction. 
Additionally, due to differences in their p53-binding pockets, small molecule MDM2 
inhibitors have shown very low binding affinity to MDMX (Li and Lozano, 2013). 
Interestingly, high expression levels of MDMX are known to confer tumor cell resistance to 
MDM2-inhibitors. Just recently, the first small molecule inhibitor of the p53-MDMX 
interaction, called SJ-172550, was identified (Reed et al., 2010). This compound 
establishes a reversible covalent complex with MDMX and induces p53-dependent 
cytotoxic effects in tumor cell lines (Reed et al., 2010).  
However, the simultaneous inhibition of the p53 interaction with MDM2 and MDMX 
(p53-MDMs) showed to be the most successful strategy for a full reactivation of wt p53 in 
tumors. Despite this, very few dual inhibitors of p53-MDMs interactions have been reported. 
The pyrrolopyrimidine-based compound 3a, which increases p53 and p21 expression levels 
and triggers apoptosis through a p53-dependent pathway in tumor cells (Lee et al., 2011), 
and the cis-imidazoline derivative H109, which reactivates a p53-dependent pathway in 
tumor cell lines (Qin et al., 2014), showed to inhibit the p53-MDMs interactions through 
binding to both MDMX and MDM2. Graves and colleagues (2012) identified the high soluble 
indolyl hydantoin RO-5963, which binds to the p53-binding pockets of both MDM2 and 
MDMX, by inducing the formation of dimeric protein complexes, and leads to p53-
dependent cell cycle arrest and apoptosis in wt p53-expressing tumor cells overexpressing 
MDMX (Graves et al., 2012). The imidazoyl-indole WK298 was also identified to share 
similar binding modes for MDMX and MDM2, but cause only minimal induced-fit changes 
in the structures of both proteins (Popowicz et al., 2010). Nevertheless, WK298 
demonstrated a moderate binding affinity to MDMX (Popowicz et al., 2010), and no data 
are available about its antitumor activity. Additional studies are still required to clarify 
whether or not WK298 is a dual p53-MDMs inhibitor. Recently, the 2,3’-bis(1’H-indole) 
scaffold demonstrated to be active as dual inhibitor of p53–MDMs interactions with high 
affinities, however there are no available data about its antitumor activity (Neochoritis et al., 
2015). 
Many peptide derivatives have been described as dual inhibitors. However, for most 
of them, their efficacies in tumor cell lines remain to be elucidated (Hu et al., 2007; Czarna 
et al., 2009; Kallen et al., 2009; Pazgier et al., 2009; Li et al., 2010b). However, recently two 
peptide derivatives dual inhibitors of p53-MDMs interactions, SAH-p53-8 and ATSP-7041, 
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demonstrated in vivo antitumor effects with low toxicity to normal tissues (Bernal et al., 2010; 
Chang et al., 2013). 
 
 
 Restoration of wt p53 function to mutant p53 
Targeting p53 protein has been shown to be a very difficult task, even more 
challenging when a diversity of mutations can be found in this protein. The first described 
reactivator of mutant p53 with antiproliferative effects in mutant p53-expressing human 
tumor cells was the alkaloid ellipticine and its derivative 9-hidroxy ellipticine (Shi et al., 1998; 
Sugikawa et al., 1999). However, further studies demonstrated the off-target effects of 
ellipticine, namely on topoisomerases (Froelich-Ammon et al., 1995). The same happened 
with WR1065, the active metabolite of amifostine, whose cytotoxicity involves other 
mechanisms besides the restoration of the wt conformation to mutant p53 V272M (North et 
al., 2002). The styrylquinazoline CP-31398 and its derivative STIMA-1 are two additional 
unspecific reactivators of mutant p53. CP-31398 was originally reported to activate wt p53 
and mutant p53 V173A and R249S with in vivo antitumor effect (Foster et al, 1999). Despite 
this, more recent studies demonstrated a p53-independent tumor growth-inhibitory effect 
for CP-31398, likely due to its ability to intercalate with DNA without direct binding to wt or 
mutant R249S (Rippin et al., 2002; Tanner and Barberis, 2004). Additionally, unfavorable 
pharmacokinetics and toxicity profiles were reported in rats and dogs for CP-31398 
(Johnson et al., 2011).  
PRIMA-1 (p53 reactivation and induction of massive apoptosis) is one of the most 
studied reactivators of mutant p53. Besides the first described reactivation of R175H and 
R273H (Bykov et al., 2002b), its growth-inhibitory effect in cells expressing other mutant 
p53 forms have been reported (Bykov et al., 2002a). PRIMA-1 and its more active 
metabolite, PRIMA-1MET (APR-246), have shown high in vivo antitumor activity with no 
apparent toxicity (Bykov et al., 2002b; Bykov et al., 2005b). Regarding the molecular 
mechanism of action, it was shown that the metabolites of PRIMA-1/PRIMAMET have a 
chemical active double bond that covalently react with thiol groups in mutant p53 (Lambert 
et al., 2009). Recently, the human phase I clinical trial of APR-246 was completed (Table 
1.3; Lehmann et al., 2012). APR-246 was well tolerated with a favorable pharmacokinetic 
profile. Moreover, the side effects observed were reversible and less severe than the 
conventional chemotherapy without any apparent bone marrow toxicity (Lehmann et al., 
2012). 
The maleimide-derived molecule MIRA-1 (mutant p53-dependent induction of rapid 
apoptosis), and its derivative MIRA-3, seem to restore the apoptotic cell death in tumor cells 
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through reactivation of mutant p53 R175H and R273H (Bykov et al., 2005a). However, a 
recent study showed that MIRA-1 was highly toxic in normal cells and exhibited p53-
independent cytotoxicity, mediated by activation of caspase-9, in tumor cells (Bou-Hanna 
et al., 2015).  
The SCH529074 is other small molecule described as reactivator of mutant p53 
(Demma et al., 2010). However, it also binds to the DNA binding domain of p53, blocking 
the MDM2-regulated ubiquitination of wt p53 (Demma et al., 2010).  
PhiKan083 is a carbazole derivative that binds and stabilizes the conformational 
mutant p53 Y220C (Boeckler et al., 2008). However, this compound does not have in vitro 
antitumor activity. Later, its derivative PK7088 showed to be a reactivator of mutant p53 
Y220C with in vitro antitumor activity. Despite this, the potency of PK7088 against tumor 
cells remains very low (Liu et al., 2013).  
The thiosemicarbazone NSC319726 was found to specifically reactivate mutant p53 
R175H with potent mutant p53 R175H-dependent in vivo antitumor activity (Yu et al., 2012). 
Nevertheless, its mechanism of action is currently unknown despite some clues related with 
zinc chelating and ROS inducing properties (Yu et al., 2012).  
Recently, it was identified chetomin (CTM) as a mutant p53 R175H reactivator through 
the p53-Hsp40 regulatory axis, causing a potential conformational change to a wt-like p53 
(Hiraki et al., 2015). This compound selectively inhibited the in vitro and in vivo growth of 
mutant p53 R175H-expressing cancer cells (Hiraki et al., 2015). 
Finally, p53R3, a quinazoline, showed to restore the DNA binding ability to mutant 
p53 R175H and R273H. Furthermore, p53R3 enhances the mRNA expression of numerous 
p53 target genes in a p53-dependent manner, in glioma cells bearing mutant or wt p53 
(Weinmann et al., 2008). 
 
 
 Combination therapy 
The combination therapy, to achieve increased cancer cell death, has been 
considered one of the most promising strategies to minimize the emergence of drug 
resistance and to achieve maximal therapeutic outcomes with minimal side effects in cancer 
therapy (Hoe et al., 2014).  
As previously referred, promising opportunities to be explored include the combination 
of targeted therapies with conventional chemotherapeutic drugs, or alternatively of two 
targeted therapies that may act on the same or on different cell signaling pathways (Zhang 
et al., 2014a). Particularly, potent synergistic effects have been observed with the 
association of reactivators of p53 activity with drugs targeting distinct signaling pathways. 
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For example, a marked stimulation of cell death has been reported with the combination of 
Nutlin-3 (MDM2 inhibitor) with inhibitors of ATM or MET, as ku-55933 (for ATM) and 
crizotinib (for MET) (Sullivan et al., 2012). Additionally, the combination of drugs that act on 
the same pathway with different target proteins can amplify the activation of this pathway 
and its final effects. For example, the combination of mutant p53-targeting molecules, such 
as PK7088, with drugs that act on the p53-MDM2 interaction, as Nutlin-3, has also shown 
promising outcomes, due to the prevention of p53 rapid degradation by MDM2 after p53 
reactivation (Liu et al., 2013). Similarly, the association of MDM2 inhibitors with conventional 
chemotherapeutic drugs that induce apoptosis through a functional p53-dependent 
pathway, namely doxorubicin or cytarabine, significantly increased the antitumor activity, in 
tumors with a compromised p53 pathway by overexpression of MDM2 (Zheng et al., 2010; 
Koster et al., 2011). The efficacy of this type of associations has been evaluated in clinical 
trials (Table 1.3). Consistently, the reactivator of mutant p53 APR-246 has also shown 
synergistic effects in combination with cisplatin and danorubicin, in mutant p53-expressing 
tumors (Bykov et al., 2005b; Ali et al., 2011). The combination of APR-246 with carboplatin 
and doxorubicin will be also evaluated in clinical trials (Table 1.3). 
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Table 1.3. Small molecule activators of p53 currently under clinical trials [Adapted from (Hoe 
et al., 2014)]. 
Compound 
Mechanism of 
action 
Study phase 
ClinicalTrials.gov 
identifiers 
RG7112 
(RO5045337) 
p53-MDM2 inhibition 
Phase I trial in advanced solid 
tumors, hematological neoplasms, 
liposarcomas (all completed), AML 
and myelogenous leukemia (active) 
NCT00559533 
NCT01164033 
NCT00623870 
NCT01143740 
NCT01677780 
RG7112 with 
cytarabine 
p53-MDM2 inhibition Phase I in AML (completed) NCT01635296 
RG7112 with 
doxorubicin 
p53-MDM2 inhibition 
Phase I in soft tissue sarcoma 
(completed) 
NCT01605526 
RG7388 
(RO5503781) 
p53-MDM2 inhibition 
Phase I in advanced solid and 
hematological malignancies 
(completed) 
NCT01462175 
RG7388 with 
cytarabine 
p53-MDM2 inhibition 
Phase I in AML, leukemia and 
neoplasms (recruiting) 
NCT01773408 
NCT02545283 
MI-773 
(SAR405838) 
p53-MDM2 inhibition 
Phase I in malignant neoplasms 
(recruiting) 
NCT01636479 
DS-3032 p53-MDM2 inhibition 
Phase I in advanced solid tumor 
and lymphoma (recruiting) 
NCT01877382 
DS-3032b p53-MDM2 inhibition 
Phase I in hematological 
malignancies (recruiting) 
NCT02319369 
CGM097 p53-MDM2 inhibition Phase I in advanced solid tumors NCT01760525 
MK8242 p53-MDM2 inhibition Phase I in advanced solid tumors NCT01451437 
HDM201 p53-MDM2 inhibition 
Phase I in liposarcoma, advanced 
solid and hematological (recruiting) 
NCT02343172 
NCT02143635 
RG7775 
(RO6839921) 
p53-MDM2 inhibition 
Phase I in AML and malignant 
neoplasms (recruiting) 
NCT02098967 
PRIMA-MET 
(APR-246) 
Reactivation of 
mutant p53 
Phase I in hematological and 
prostatic neoplasms (completed) 
NCT00900641 
PRIMA-MET 
with 
Carboplatin and 
PLD 
Reactivation of 
mutant p53 
Phase Ib/II in platinum sensitive 
recurrent high-grade serous ovarian 
cancer with mutated p53 (recruiting) 
NCT02098343 
AML – Acute myeloid leukaemia PLD - Pegylated liposomal doxorubicin hydrochloride 
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 Cyclotherapy 
The cyclotherapy is a very interesting therapeutic strategy, in which drugs are used 
to selectively protect normal tissues from cytotoxic drugs. Although this concept was first 
described in 1992 (Lane, 1992), just recently it has been more explored.  
 In the p53-based cyclotherapy, the selective induction of reversible cell cycle arrest 
by low doses of a wt p53 activator may protect normal cells from drugs targeting actively 
proliferating cells, while tumor cells, with a dysfunctional p53 pathway, are not protected 
and remain susceptible to chemotherapy (Rao et al., 2013). Even in tumors with an intact 
p53 pathway, the p53 stabilization leads preferentially to apoptosis or senescence, while in 
normal cells the p53 stabilization usually causes cycle arrest (Rao et al., 2013). With this 
strategy, the therapeutic window of conventional chemotherapeutic agents may be 
improved, with the reduction of side effects of chemotherapy, and without loss of efficacy 
(Rao et al., 2013). Actually, several in vitro studies demonstrated the protective effect of low 
doses of Nutlin in normal cells exposed to chemotherapeutic agents (Carvajal et al., 2005; 
Kranz and Dobbelstein, 2006; Cheok et al., 2010). Despite this, just one in vivo study 
supports this therapeutic strategy by showing that Nutlin-3 pretreatment protects mice from 
neutropenia induced by the Polo-Like-Kinase-1 (PLK-1) inhibitor BI2536 (Sur et al., 2009).
  
 
 
1.4. Screening strategies to search for small molecule activators of p53 
Even though all the pharmacological efforts developed around the p53-based 
therapies, new reactivators of the p53 function with improved pharmacological properties 
are required. However, several aspects related with drug development and screening 
strategies available have limited such research. Despite this, several screening approaches 
have been developed to search for p53-MDMs interaction inhibitors, namely based on 
computational aided drug design, biophysical assays and cell-based assays [reviewed in 
(Wang and Hu 2012; Wang et al., 2012; Zhao et al., 2013)]. However, few screening assays 
have been developed to search for mutant p53 reactivators.  
The contribution of these assays for the identification of new small molecule 
reactivators of p53 activity will be addressed. Due to the complexity of drug development 
targeting p53, the combination of some of these strategies has greatly contributed to the 
advances observed in this area.  
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 Cell-free assays 
 
 Computational aided drug design 
The development of bioinformatics led to the emerging of two major approaches in 
Medicinal Chemistry, the straightforward in silico compound-selection (virtual screening) 
and the structure-based de novo design. These tools have been widely used in the design 
of MDMs inhibitors, considering the three essential a.a. involved in the interaction between 
p53 and MDMs (Figure 1.14). Although PHE19 and TRP23 interact in a similar way to 
MDM2 and MDMX, LEU26 does not (Zhang et al., 2014a). It was also suggested a fourth 
important residue, LEU22, which appears to have an important role in the overall 
interactions between p53 and MDMs (Fu et al., 2012). Moreover, the contribution of the 
MDM2 residues LEU54, HIS96 and ILE99 for the interaction is different from the equivalent 
MDMX residues MET53, PRO95 and LEU98, which may justify the differential binding 
affinities of p53 to MDM2/MDMX (Zhang et al., 2014). 
 
   
Figure 1.14. Complex of the MDM2 (blue) and MDMX (green) structures with the three residues 
from p53 (orange) that are involved in p53-MDMs interactions. 
  
 
The structure-based de novo design technique has been used for designing novel 
small molecule ligands for macromolecular binding pockets. This approach is applied in 
complementarity with three dimensional (3D) binding site properties of the target protein, 
such as electrostatics, shape, size, lipophilicity, aromaticity, among others. The spiro-
oxindoles MI-63 and MI-219 were discovered using a structure-based de novo design (Ding 
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et al., 2006; Shangary et al., 2008). This design started with the search for chemical 
moieties that could mimic the interaction of TRP23 (the most critical amino acid for the 
interaction). In fact, the oxindole showed to greatly mimic the side chain of TRP23 for 
interaction with MDM2. Besides the confirmation of this fact, computational modeling 
studies revealed that the spiropyrrolidine ring provides a rigid scaffold from which two 
hydrophobic groups can be projected to mimic the side chain of PHE19 and LEU26. 
Furthermore, a structure-based optimization that involves the additional interaction of 
LEU22 led to MI-63 and thereafter to MI-219 with good oral bioavailability in mice due to 
improved water solubility (Ding et al., 2006; Shangary et al., 2008). Further modifications 
were made in this family of compounds, and new small molecules with higher affinity to 
MDM2 and improved pharmacokinetic profile were obtained, as MI-773, which are waiting 
to enter in phase I clinical trials (Zak et al., 2013). The structure-based de novo design 
strategy was also used to find a new class of potent p53-MDM2 inhibitors with a piperidinone 
scaffold (Rew et al., 2012; Lucas et al., 2012). Using computer modeling, SAR (structure–
activity relationship) studies and crystal structure, the affinity of known MDM2 inhibitors to 
MDM2 was improved through conformational control of both the piperidinone ring and the 
appended N-alkyl substituent, emerging the AM-8553 that, besides the high affinity to 
MDM2, presentes excellent pharmacokinetic properties (Lucas et al., 2012). 
Sulfonamide I (NSC279287) was the first example to be identified by virtual screening 
using the NCBI database and a computational pharmacophore model of MDM2 (Galatin 
and Abraham, 2004). Using molecular modeling programs to generate predictive QSAR 
regression equations for p53-MDM2 inhibition, based on the template of the interaction 
between p53-based peptide inhibitors and MDM2, the development of the pharmacophore 
model to mimic the portions of p53 necessary to MDM2 binding was possible (Galatin and 
Abraham, 2004). The mechanism of action of NSC279287 was confirmed using an ELISA-
based p53-MDM2 binding assay and a p53 reporter gene assay using MDM2-
overexpressing osteosarcoma cells (Galatin and Abraham, 2004). With a library of 150,000 
compounds of the NCI (National Cancer Institute) database, and an approach combining 
pharmacophore and structure-based screening, 354 potential MDM2 inhibitors were 
identified (Lu et al., 2006). The pharmacophore model consisted of three elements that 
mimicked the three key hydrophobic binding residues in p53 together with three associated 
distance constraints. Computational docking was performed to dock each hit to the p53-
binding site in MDM2, and their binding affinities were ranked. As result, the quinolinole 
NSC66811 was identified as MDM2 inhibitor, what was thereafter confirmed using a 
fluorescence-based binding assay (Lu et al., 2006). Other example was the use of the virtual 
screening to find the reactivator of mutant p53, the compound PhiKan083 (Boeckler et al., 
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2008). After mutant p53 Y220C protein crystallization, 2,066,906 compounds were 
screened for their binding affinities to mutant p53 Y220C core domain of crystal structure. 
The 80 selected compounds were then tested for their abilities to induce chemical shift 
changes using NMR spectroscopy. The results obtained revealed that PhiKan083 was able 
to bind to mutant p53 Y220C (Boeckler et al., 2008). 
 
 
 Biophysical and biochemical assays 
In general, these assays are simple and reliable, and can be used for the high 
throughput screening (HTS) of large small molecule libraries. Despite this, a major 
drawback is the fact that the target proteins are tested in a non-cellular context (Colas, 
2008). In order to identify small molecule inhibitors of the p53 interaction with MDM2 and 
MDMX, a variety of biophysical assays have been established and efficiently used, namely 
Surface Plasmon Resonance (SPR), Enzyme-Linked Immunosorbant Assay (ELISA), 
Homogenous Time-Resolved Fluorescence (HTRF) binding assay (also called TR-FRET), 
ThermoFluor Microcalorimetry, Isothermal Titration Calorimetry (ITC), Fluorescence 
Polarization (FP) binding assay, among others.  
Nutlin-3a was discovered by screening of a library of compounds using the SPR 
(Vassilev et al., 2004). The SPR assay was performed on a Biacore Series S Sensor chip 
CM5 derived from immobilization of a PentaHis antibody to capture the His-tagged p53 
protein. The assay was conducted with MDM2 fragments that, when in contact with an 
inhibitor of the p53-MDM2 interaction, do not bind to p53 immobilized in the chip. The 
resonance signal is dependent on the amount of MDM2 that is able to conjugate with p53 
(Vassilev et al., 2004).  
The ELISA is a well-known methodology to study protein-protein interactions, as well 
as to analyze the effect of compounds on such interactions. For instance, to measure the 
p53-MDM2 protein interaction, one of the proteins is attached to a plate surface, and the 
amount of the second protein that is able to bind to the attached protein is measured through 
addition of a specific antibody linked to an enzyme that will bind to the second protein.  
When a specific substrate is added, the enzyme produces a measurable readout that is 
proportional to the amount of bound protein (Arkin et al., 2012). The ELISA assay allowed 
the discovery of Sulfonamide 1 (NSC279287; Galatin and Abraham, 2004), terphenyl 
compounds 2 and 6 (Chen et al., 2005), and chalcones B and B-1 (Stoll et al., 2001) as 
inhibitors of the p53-MDM2 interaction.  
The HTRF binding assay was also performed to search for inhibitors of the p53 
interaction with MDM2 and MDMX. This technique is based on the transference of energy 
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between two fluorophores, a donor and an acceptor, when in close proximity. Thus, 
molecular interactions between p53 and MDMs can be assessed by coupling each partner 
with a fluorescent label and by detecting the level of energy transfer (Arkin et al., 2012). 
With this screening strategy, chromenotriazolopyrimidine 1 (Allen et al., 2009) and RG7388 
(Ding et al., 2013) were identified as p53-MDM2 interaction inhibitors. 
The ITC assay is a well-established method to characterize protein-protein 
interactions, as well as the binding of a small molecule to a target protein. This is a label-
free technique, where all the components are in solution. ITC measures the binding energy 
and provides information concerning thermodynamic parameters (affinity, enthalpy/entropy 
and stoichiometry) of a binding interaction. The signal measured is the heat generated or 
absorbed by a binding interaction (Arkin et al., 2012). Using the ITC assay, combined with 
HTRF, the small molecule RO5963 was identified as dual inhibitor of the p53-MDMs 
interactions (Graves et al., 2012). 
Also based in calorimetry, the ThermoFluor Microcalorimetry technology is an affinity 
HTS assay that uses fluorescent dyes to monitor protein unfolding as a function of 
temperature for the identification of compounds that bind to MDM2. The amount of 
compound bound to MDM2 is measured by the increase in thermal stability. The thermal 
stability is quantified as a change in midpoint transition temperature in the presence of the 
compound at a single concentration (Shangary and Wang, 2009). Using this approach, the 
benzodiazepinediones TDP521252 and TDP665759 were identified as inhibitors of the p53-
MDM2 interaction (Koblish et al., 2006). 
The FP binding assay is another method through which protein-protein interactions 
and the binding of a small molecule to a protein can be monitored (Figure 1.15). This is a 
sensitive nonradioactive screening assay based on the use of a consensus peptide labeled 
to a fluorophore. In the absence of a small molecule interaction inhibitor, the formation of a 
peptide-protein complex increases the FP value. On the other hand, in the presence of an 
inhibitor, the fluorescently labeled peptide is displaced, leading to a decrease of the FP 
value due to its increased rotational mobility (Lea and Simeonov, 2011). Using this assay, 
bisarylsulfonamide compounds (Wang et al., 2004) and the therphenyl derivative 14 (Yin et 
al., 2005) were identified as p53-MDM2 interaction inhibitors. Additionally, WK298 
(Popowicz et al., 2010) and SJ-172550 (Reed et al., 2010) were identified as inhibitors of 
the p53-MDMX interaction using the same assay.  
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Figure 1.15. Fluorescence polarization assay. After exposure to a polarized excitation light, a 
rapidly rotating p53 peptide fluorophore gives low FP signal (depolarized light). The association of a 
relatively large molecule, such as MDM2, with the p53 peptide fluorophore slows down the motion of 
the fluorophore, leading to increased FP signal (polarized light). 
 
 
Many other biophysical and biochemical assays have been developed and adapted, 
in the last years, to search for new p53-MDMs interaction inhibitors. However, those 
referred above have conducted to the discovery of the most relevant protein-protein 
interaction inhibitors described to date.  
 
 
 Cell-based assays  
Cellular assays are characterized by a higher complexity and variability. However, in 
contrast to biophysical assays, the cell-based assays provide relevant data about the 
activity of compounds in a more physiological cellular environment, particularly of their cell 
permeability and cytotoxicity (Korn and Krausz, 2007). Based on that, human and yeast 
cells have been used by several research groups to develop screening assays for the 
search of new small molecule inhibitors of the p53-MDMs interactions and reactivators of 
mutant p53. 
 
 
 Human cell-based assays 
In cancer research, these assays are usually carried out with tumor cells for the study 
of the cytotoxic effect of small molecules, as well as of their impact on p53 activity. The 
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resonance energy transfer (RET) assays, including fluorescence (FRET) and 
bioluminescence (BRET), have been highly used to study protein-protein interactions in a 
cellular environment (Mazars and Fahraeus, 2010; Couturier and Deprez, 2012). For FRET, 
a robust and affordable system for HTS is not available yet, whereas BRET has been widely 
applied in HTS, namely in the search for p53-MDM2 interaction inhibitors (Yurlova et al., 
2014). This assay, known for its reproducibility, is based on the fusing of Renilla Luciferase 
donor (Rluc) and Yellow Fluorescent acceptor Protein (YFP) to p53 or MDM2. Rluc oxidizes 
its substrate Coelenterazine h, resulting in the emission of energy (Mazars and Fahraeus, 
2010). If a suitable energy acceptor is under the proximity, and is favorably oriented, this 
energy can be transferred, with the subsequent emission of energy at a longer wavelength 
by the excited acceptor molecule (Mazars and Fahraeus, 2010). The BRET assay was 
validated using Nutlin-3a as control, and showed to be an efficient method for the fast 
analysis of inhibitors of the p53-MDM2 interaction (Mazars and Fahraeus, 2010). However, 
small changes in the positioning of the donor and acceptor can result in signal decline, 
which does not necessarily reflect a splitting of the p53-MDM2 interaction (Yurlova et al., 
2014). Contrary to this approach, one elegant way to detect protein-protein interactions in 
mammalian cells is based on protein complementation, which reconstitutes a functional 
enzymatic or fluorescent reporter from the interaction of two proteins. One example is the 
cellular model to evaluate the capacity of small molecules to disrupt the p53-MDM2 
interaction, based on a bimolecular fluorescence complementation assay (Figure 1.16; 
Amaral et al., 2013). This assay involves the fusion of two non-fluorescent fragments of a 
reporter protein to p53 and MDM2 proteins. In the case of interaction, the reporter fragments 
come together, fold into an almost-native conformation, and thereby reconstitute the 
functional fluorophore (Amaral et al., 2013). After validation with the positive control Nutlin-
3, this efficient assay was used to test a commercially available chemical library of 33 
protein phosphatase inhibitors, with the subsequent identification of potential small 
molecule inhibitors of the p53-MDM2 interaction (Amaral et al., 2013). 
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Figure 1.16. Bimolecular fluorescence complementation (BiFC) assay. The p53 and MDM2 
proteins are fused to non-fluorescent fragments (V1 and V2) of a fluorescent reporter protein. When 
protein-protein interaction occurs, V1 and V2 get close enough to reconstruct the functional 
fluorophore (Venus). [Adapted from (Amaral et al., 2013)]. 
 
In 2005, the reverse mammalian protein-protein interaction trap (MAPPIT) assay was 
reported for the p53-MDM2 interaction (Eyckerman et al., 2005). This assay is a bait-and-
prey system with an inhibitory motif attached to the prey protein, which allows a positive 
readout upon interference with the designated protein–protein interaction (Eyckerman et 
al., 2005). However, the detection is dependent on the signal transduction of cytokine 
receptor; therefore anything that interferes with this signaling pathway would also affect the 
readout of the assay. In this way, a mammalian two-hybrid system, based on a direct 
activation of a reporter gene, can be a reliable alternative to the MAPPIT assay. Li and 
colleagues (2011) developed a mammalian two-hybrid system, consisting in a full-length 
p53 or MDM2 inserted at the C-terminal of the DNA binding domain (BD) of GAL4 or at the 
transcriptional activation domain (AD) of NFkB. In this assay, the p53-MDM2 interaction will 
bring the BD and AD in proximity with the subsequent activation of the downstream Firefly 
luciferase reporter gene (Li et al., 2011c). After validation with the positive control Nutlin, 
the authors discovered that SL-01, a Z-L-Phe chloromethyl ketone, was a p53-MDM2 
interaction inhibitor (Li et al., 2011c). Since in these assays, the reconstitution of the protein-
protein interaction is often irreversible, this type of method is not appropriate to screen for 
compounds that disrupt an interaction once it is formed. Nevertheless, the fully reversible 
microscopy assisted fluorescent two-hybrid (F2H) assay does not present this limitation 
(Yurlova et al., 2014). This assay was developed to search for inhibitors of p53-MDMs 
interactions (Yurlova et al., 2014). The F2H is based on the anchorage of the green-
fluorescent bait protein (p53) at a defined spot in the nucleus, formed by the lac-operator 
array on the genomic DNA (Yurlova et al., 2014). The interaction with the RFP-tagged 
human MDM2/MDMX can be evaluated by enrichment of red fluorescence at the location 
of the green spot. The disruption of the p53-MDMs interactions is determined based on the 
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fading of the red spots from the anchored green spots (Yurlova et al., 2014). With this assay, 
five small molecules with potent activity as p53-MDM2 inhibitors were identified (Yurlova et 
al., 2014). Other method with a quite similar principle is the imaging-based positional 
biosensor high-content screening (HCS) assay (Dudgeon et al., 2010a,b). With this 
technique three structurally-related methylbenzo-naphthyridin-5-amine hit compounds were 
identified (Dudgeon et al., 2010a). 
Using the p53-response promoter method, 46,260 compounds were screened in 
order to find a reactivator of mutant p53 R273H (Kravchenko et al., 2008). This method is 
based on the transfection of tumor cells (in this particular case, of the epidermal carcinoma 
cell line A431 expressing mutant p53 R273H) with a reporter construct carrying a cassette 
for expression of β-galactosidase under the control of a minimal cytomegalovirus promoter 
coupled to multiple p53-binding elements (Kravchenko et al., 2008). The signal obtained in 
the presence of o-nitrophenyl β-d-galactoside (ONPG) will be proportional to p53 
transcriptional activity. Using this approach, the small-molecule RETRA (reactivation of 
transcriptional reporter activity) was identified. RETRA induced expression of p73, and its 
release from the complex with mutant p53, as well as p73-dependent apoptosis in A431 
cells, and in vivo significant reduction of tumor formation (Kravchenko et al., 2008). 
A method that is widely used to search for reactivators of mutant p53 is based on the 
analysis of the ability of small molecules to induce a p53-dependent growth inhibition in 
mutant p53-expressing tumor cells. Actually, the analysis of the cytotoxic effect of a 
NCI/DTP (National Cancer Institute/Development Therapeutics Program) chemical library 
on several human tumor cell lines expressing mutant p53 R273H or R175H, led to the 
identification of a reactivator of these two mutant p53, PRIMA-1 (Bykov et al., 2002b). Using 
the same approach, APR246, MIRA-1 and STIMA-1 were also identified as reactivators of 
mutant p53R273H and R175H (Bykov et al., 2005a,b; Zachea et al., 2008). Finally, an in 
silico screen based on data from the NCI/DTP anticancer drug screen, reported the IC50 
(half maximal inhibitory concentration) of about 50,000 compounds against 60 tumor-
derived cell lines (Yu et al., 2012). From this screening, three thiosemicarbazones, that 
selectivelly inhibited mutant p53-expressing cell lines compared to wt p53-expressing cells, 
were selected, and NSC319726 was identified as reactivator of mutant p53 R175H (Yu et 
al., 2012). Interestingly, contrary to previous screens that used engineered isogenic cell 
lines, Yu and collaborators (2012) used heterogeneous panels of cell lines. However, in 
general, since this method is only based on growth inhibition, many compounds selected 
using this methodology may not act directly through p53 activation. 
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 Yeast-based assays 
In the last years, yeast-based assays, consisting in engineered yeast cells 
overexpressing human disease-related proteins, have greatly contributed to the elucidation 
of the biology and pharmacology of these proteins (Pereira et al., 2012a,b; Guaragnella et 
al., 2014).  Besides this, yeast-based HTS assays have been largely explored in targeted 
screening due to several advantages, when compared to cell-free assays and human cell-
based assays. In particular, comparing with cell-free assays, the purification of the target 
protein is not required, what makes this approach less expensive, and the analysis of some 
relevant drug-like properties, such as permeability, instability and cytotoxicity became 
possible. Moreover, due to its easy manipulation and reduced doubling time, yeast allows 
simple and rapid screenings well-adaptable to HTS methodologies. In addition, since this 
organism provides an “empty room”, where the activity of human proteins can be analyzed 
with fewer interferences of proteins of the same family or pathway, screening assays 
directed to specific human proteins can be performed with high efficiency (Pereira et al., 
2012a,b). Actually, these cells have proved to be extremely useful as a first-line targeted 
screening approach for a previous selection of compounds to be tested in more complex 
cell systems (Pereira et al., 2012a,b). 
The p53 tumor suppressor, without orthologues in yeast, is an example of a human 
protein that has been widely studied in this microorganism in the last few years.  
 
1.4.2.2.1. Yeast transactivation assays 
In 1990, it was shown that p53 was also a transcription factor in yeast (Fields and 
Jang, 1990). This enabled the development of powerful simplified cell-based assays for 
functional analyses of p53, particularly of the impact of mutations and interacting proteins 
(such as MDMs) on its activity. The FASAY (Functional Analysis of Separated Alleles in 
Yeast) assay was one of the first techniques to be developed in yeast to evaluate the status 
of p53 transcriptional activity (Ishioka et al., 1993). This technique consists in the expression 
of a p53 cDNA obtained from tumor samples in a yeast strain with a HIS3 reporter gene 
downstream of a human p53 response element (RE). The p53 status is evaluated using a 
culture medium without histidine: functional p53 enables growth by inducing HIS3 
expression, while yeast clones expressing mutant p53 will not grow. However, the best-
known FASAY version used ADE2, instead of HIS3, as a reporter gene. In this case, the 
reporter yeast strain (defective in adenine synthesis) is grown in low-adenine medium, 
where it produces white colonies upon ADE2 expression (wt p53), or red colonies in its 
absence (mutant p53; Flaman et al., 1995). These assays have given place to the luciferase 
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transactivation assay, in which the p53 transcriptional activity is evaluated by quantification 
of the luciferase activity. These assays were obtained by replacing the ADE2 ORF by a 
luciferase reporter gene in the same chromosomal locus, and were initially used to confirm 
the results from the ADE2 reporter gene assay in the analysis of the REs transactivation by 
different p53 mutants (Resnick et al., 2003). In 2011, a dual-luciferase transactivation assay 
was adapted for HTS of a matrix of factors that can influence the p53 activity, including 
small molecules, mutations and interacting proteins as MDM2 (Andreotti et al., 2011). By 
testing Nutlin-3a and RITA, this system was validated to search for inhibitors of the p53-
MDM2 interaction (Andreotti et al., 2011). Recently, this assay was extended to p63 and 
p73 proteins of the p53 family, which exhibit intrinsic differences in transactivation 
specificities (Figure 1.17A; Ciribilli et al., 2013; Monti et al., 2014).  
In a recent study from our group, ACT1 was identified as a yeast endogenous target 
gene of human p53 (Leão et al., 2013b). In that work, a correlation between the p53 activity 
and the endogenous actin protein expression levels was established. This opened the way 
to simplified yeast transactivation assays, without the requirement of artificial reporter 
genes, to study the impact of small molecules on the activity of p53 family proteins. In fact, 
it was shown that inhibitors of p53-MDMs interactions abolished the MDMs-inhibitory effect 
with the re-establishement of the increased actin expression levels induced by p53 (Figure 
1.17B). This was observed, for example, with Nutlin-3a for the p53-MDM2 interaction (Leão 
et al., 2015a), and with SJ-172550 for the p53-MDMX interaction (Leão et al., 2015a).  
One of the most renowned applications of the yeast transcriptional assays has been 
on the study of mutant p53. Actually, these yeast assays have allowed the evaluation of 
LOF and DNE of mutant p53 (Petitjean et al., 2007a). In fact, the contribution of the yeast 
transcriptional assays to the study of the molecular epidemiology of mutant p53, including 
frequency, type, and site of mutations associated with carcinogenesis, as well as of their 
impact on the function of p53 family proteins in human tumor cells, have become this 
technique a powerful clinical tool. Indeed, with it, possible factors that contribute to tumor 
development may be identified, and the best cancer therapy can be selected taking into 
account the type and site of mutant p53 (Fronza et al., 2000; Smardová et al., 2005). 
 
 
1.4.2.2.2. Yeast growth-inhibitory assays 
It was observed that the expression of human wt p53 in Saccharomyces cerevisiae 
induces a marked growth inhibition associated with cell cycle arrest (Nigro et al., 1992) or 
death (Amor et al., 2008). Additionally, it was demonstrated that, also in yeast, the human 
MDM2 was able to inhibit the p53 transcriptional activity and to promote the p53 
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ubiquitination and subsequent degradation in yeast (Di Ventura et al., 2008). With several 
evidences sustaining the similarities of the biology of p53 between mammalian and yeast 
cells, yeast became a powerful tool for genetic, molecular and functional studies of p53.  
The marked cytotoxic effect of human p53 in yeast, which is proportional to its activity 
and it is easily quantified by measurements of yeast cell growth, led to the development of 
simple yeast growth-inhibitory assays for the targeted screening of modulators of p53 
activity (Pereira et al., 2012a,b; Guaragnella et al., 2014). Particularly, using yeast cells co-
expressing p53 and MDMs, it was demonstrated that, as in human cells, both MDM2 and 
MDMX inhibit the p53-induced yeast growth inhibition (Leão et al., 2013b,c; Figure 1.17B). 
This system was thereafter validated to search for inhibitors of the p53 interaction with 
MDM2 and MDMX, by testing the known inhibitors of these interactions Nutlin-3a and SJ-
172550, respectively (Vassilev et al., 2004; Reed et al., 2010). The use of these yeast-
based assays conducted to the discovery of pyranoxanthone 1, as the first p53-MDM2 
interaction inhibitor with a xanthone scaffold (Leão et al., 2013c). Additionally, α-mangostin 
and gambogic acid were described, for the first time, as potential inhibitors of the p53-MDM2 
interaction (Leão et al., 2013a). More recently, these assays were extended to other 
members of the p53 family (Leão et al., 2015a). In fact, the observation that both MDM2 
and MDMX inhibit the yeast growth-inhibitory effect of p63 and p73 enabled the 
development of yeast phenotypic assays to study the impact of human MDMs on these p53 
family proteins. Interestingly, using Nutlin-3a, reported to also inhibit the p73-MDM2 
interaction in human tumor cells (Lau et al., 2008), the effectiveness of the yeast growth-
inhibitory assay to search for small molecule p73-MDM2 interaction inhibitors was 
demonstrated (Leão et al., 2015a). Notably, in the same work, a similar yeast system 
developed to search for p73-MDMX interaction inhibitors revealed that SJ-172550 may also 
disrupt this interaction. However, no further studies have been performed in human tumor 
cells in order to confirm this result.     
 
 
1.4.2.2.3. Yeast two-hybrid assays 
The yeast two-hybrid (Y2H) was the first molecular genetic tool developed to study 
protein-protein interactions in a cellular context (Fields and Song, 1989). Through HTS of 
large cDNA libraries, it has allowed the identification of protein interactors (prey) of a protein 
of interest (bait) (Figure 1.17C). Since its discovery, the Y2H has been a very useful tool, 
namely in the discovery of new protein interactions of p53. For example, with the Y2H, the 
p53 fragment responsible for oligomerization (OD) was identified, and its involvement in 
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mutant p53 oligomerization with wt p53 was revealed (Iwabuchi et al., 1993). This finding 
provided a molecular explanation for mutant p53 DNE.  
Using this assay, the four amino acid residues of MDM2 essential for the interaction 
with p53 (GLY58, ASP68, VAL75, CYS77) were determined (Freedman et al., 1997). The 
Y2H has also contributed to detect mutant p53 in tumor samples based on its inability to 
bind to 53BP1, an interactor partner and enhancer of p53 transcriptional activity also 
identified by Y2H (Schwartz et al., 1998). Additional interactions between p53 and other 
proteins were firstly described or confirmed using this approach. 
In 1996, Vidal and colleagues developed a reverse Y2H assay for drug screening. In 
this case, cells grow when the interaction between proteins does not occur due to the 
presence of disrupters of the respective protein-protein interaction (Vidal et al., 1996). In 
the same year, it was also developed the yeast three-hybrid assay for small molecule target 
identification (Licitra and Liu, 1996). This approach is based on small molecule-protein 
interactions by dimerization of two receptor proteins via a linking heterodimeric ligand 
(Licitra and Liu, 1996). The reverse Y2H and the yeast three-hybrid assays reveal to be 
promising assays to find inhibitors of p53-MDMs interactions.  
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Figure 1.17. Yeast-based assays developed to study the impact of protein interacting partners 
and small molecules on the function of p53. These assays use yeast cells co-expressing a human 
p53 and a protein interacting partner (e.g. MDM2, MDMX, mutant p53). (A) Yeast transactivation 
assay. The impact of interacting protein partners and small-molecules on p53 transcriptional activity 
is evaluated using a reporter gene (e.g. ADE2, Luciferase) under the regulation of a human p53-
family response element (RE). (B) Yeast growth-inhibitory assay. Expression of a p53 induces yeast 
growth inhibition associated with an increase of actin expression. The impact of interacting protein 
partners and small-molecules on p53 function is evaluated by quantification of yeast cell growth and 
actin protein expression levels. (C) Yeast two-hybrid assay. A protein (bait; e.g. p53) is fused to 
the GAL4-DNA binding domain (DBD) and the interacting protein partner (prey; e.g. MDM2) is fused 
to the GAL4-transactivation domain (AD). If the bait and prey establish a physical interaction, the 
function of GAL4 is restored, allowing it to bind to a specific sequence, leading to the transcription of 
a reporter gene (e.g. HIS3, ADE2, LacZ); this effect is abolished by small-molecule inhibitors of the 
bait-prey interaction. 
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1.5. Scope of this thesis 
Compelling evidence has therefore demonstrated that inactivation of the p53 pathway 
underlies tumor development and maintenance. Actually, the majority of human cancers 
have been associated with compromised p53 functions, either by mutation or by inhibition 
through interaction with negative regulators such as MDM proteins. This strongly supports 
the notion that an activation of p53 is a highly effective strategy in cancer treatment.  
With the present thesis, we aimed to find new pharmacological opportunities against 
cancer by targeting p53. Particularly, we intended to discover: 
i) Inhibitors of the p53 interaction with MDMs (Chapter 3); 
ii) Reactivators of mutant p53 (Chapter 4).  
To achieve such goals, yeast-based screening assays, previously developed by our 
group or implemented for the first time under the scope of this thesis, were used to test 
several libraries of compounds synthesized by collaborative Medicinal Chemistry groups to 
target p53. The chemical libraries selected, in this work, were composed by compounds 
with scaffolds previously reported to be promising in the search for modulators of p53 
activity, namely flavonoids (Stoll et al., 2001) and small molecules containing indole and/or 
isoindolinone moieties (Ding et al., 2006; Pientracosta et al., 2006). The drug discovery 
strategy used in this thesis also encompassed the validation of the molecular mechanism 
of action and antitumor activity of the compounds selected in yeast in more complex cellular 
systems, particularly in human tumor cell lines and in animal models.  
The major contributions of this work to anticancer drug research by targeting p53 are 
presented in the final discussion of this thesis (Chapter 5).  
 
 
 
 
 
 
 
 
CHAPTER 2 
 
 
 
 
 
 
 
  
Material and Methods 
 
62 
 
63 
 
2.1. Compounds  
PRIMA-1, doxorubicin, SJ-172550 and Pifithrin- (PTF-) were purchased from 
Sigma-Aldrich (Sintra, Portugal), Phikan083 from Tocris (VWR, Carnaxide, Portugal); 
etoposide from Calbiochem (VWR, Carnaxide, Portugal) and Nutlin-3a was from Alexis 
Biochemicals (Grupo Taper, Sintra, Portugal). All tested compounds were dissolved in 
dimethyl sulfoxide (DMSO; Sigma-Aldrich, Sintra, Portugal). Synthesis of compounds 1a-c, 
2a-b, 3a-b and 4a-b (Section 1), OXAZ-1 (Section 2) and SLMP53-1 (Section 3) is described 
in Appendix. Compounds OXAZ-2 to -6 were synthesized according to the described 
procedures (Amat et al., 2007a,b; Pereira et al., 2014).  
 
2.2. Plasmids 
The following yeast expression vectors were used: pLS89-(TRP1) encoding human 
wt p53 under the GAL1-10 inducible promoter (kindly provided by Dr. Richard Iggo; Swiss 
Institute for Experimental Cancer Research, Switzerland); pGADT7-(LEU2) encoding 
human MDM2 under the ADH1 constitutive promoter (generous provided by Dr. Xue-Min 
Zhang; National Center of Biomedical Analysis, China); and pTS76-(LEU2) encoding 
human mutant p53R280K or p53Y220C under the ADH1 constitutive promoter (kindly 
provided by Dr. Gilberto Fronza; IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, 
Italy). 
 
2.3. Yeast transformation 
The plasmids used in the yeast transformation process were firstly amplified in 
Escherichia coli DH5α from Lucigen (Frilabo, Porto, Portugal), and thereafter extracted 
using the GenEluteTM HP Plasmid Miniprep Kit (Sigma-Aldrich, Sintra, Portugal). After 
extraction, yeast strains were transformed using the LiAc/SS Carrier DNA/PEG method as 
described (Gietz and Schiestl, 2007). For selection of transformed yeast, cells were 
routinely grown in selective minimal medium with 2% (w/w) glucose (Sigma-Aldrich, Sintra, 
Portugal), 0.7% (w/w) yeast nitrogen base without a.a. from Difco (Quilaban, Sintra, 
Portugal), and all the a.a. required for yeast growth (50 μg/mL), except leucine/tryptophan 
(for single expression systems) or leucine and tryptophan (for co-expression systems), and 
incubated at 30ºC, under continuous orbital shaking (200 r.p.m.). 
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2.4. Yeast-based screening assay 
For expression of human proteins, cells (routinely grown in minimal selective medium) 
were diluted to 0.05 OD600 in induction selective medium containing 2% (w/w) galactose, 
1% (w/w) raffinose, 0.7% (w/w) yeast nitrogen base without a.a. from Difco (Quilaban, 
Sintra, Portugal), and a mixture of all the a.a. required for yeast growth (50 μg/mL) except 
leucine/tryptophan (for single expression systems) or leucine and tryptophan (for co-
expression systems). Cells transformed with the empty vector(s) were used as control 
yeast. Yeast cells were incubated at 30ºC under continuous orbital shaking (200 r.p.m.), in 
the presence of 0.1 – 50 μM of compounds or 0.1% DMSO only, for approximately 30 h (for 
single expression systems) and 42 h (for co-expression systems) (time required by control 
yeast, incubated with DMSO only, to achieve 0.4 OD600). In the experiments with pifthrin-
PFT-, yeast cells expressing wt/mutant p53 were incubated with 5 μM PFT- alone or 
combined with 10 μM SLMP53-1, or DMSO only for approximately 30 h. Yeast growth was 
analyzed by counting the number of colony-forming units (CFU), after 2 days incubation at 
30ºC, on Sabouraud Dextrose Agar from Liofilchem (Frilabo, Porto, Portugal). 
 
2.5. Yeast cell cycle analysis 
Yeast cell cycle progression was analyzed basically as described (Leão et al., 2013c). 
Briefly, 1107 cells were fixed in 70% (v/v) ethanol, incubated with 250 µg/mL RNase A 
(Sigma-Aldrich, Sintra, Portugal) and 1 mg/mL Proteinase K (Sigma-Aldrich, Sintra, 
Portugal) for 3 h, followed by addition of 10 µM Sytox Green Nucleic Acid from Invitrogen 
(Alfagene, Carcavelos, Portugal) and flow cytometry analysis. 
 
2.6. Human cell lines growth conditions 
The human cell lines used are described in Table 2.1. All tumor cell lines were routinely 
cultured in RPMI-1640 medium with ultraglutamine from Lonza (VWR, Carnaxide, Portugal) 
supplemented with 10% fetal bovine serum (FBS) from Gibco (Alfagene, Carcavelos, 
Portugal). MCF10A cell line was cultured in DMEM F12 supplemented with MEGM 
SingleQuot Kit Suppl. & Growth Factors from Lonza (VWR, Carnaxide, Portugal). All cell 
lines were maintained in a humidified incubator at 37°C with 5% CO2. 
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Table 2.1. Human cell lines used in this work.  
Cell line Tissue/Disease p53 status Supplier 
HCT116 p53+/+ 
Human colon 
adenocarcinoma 
wt ATCC (kindly provided by Dr. B. Vogelstein, 
The Johns Hopkins Kimmel Cancer Center, 
Baltimore, MD, USA) HCT116 p53-/- null (knock out) 
MCF-7 
Human breast 
adenocarcinoma 
wt 
Dr. Alberto Inga, CIBIO, University of Trento, 
Italy 
SJSA-1 Human osteosarcoma wt 
ATCC (kindly provided by Dr. Célia Gomes, 
IBILI, Faculdade de Medicina, Universidade de 
Coimbra, Portugal) 
MDA-MB-231 
Human breast 
adenocarcinoma 
Mutant 
p53R280K 
ATCC 
MDA-MB-468 
Human breast 
adenocarcinoma 
Mutant 
p53R273H 
Huh-7 
Human 
hepatocarcinoma 
Mutant 
p53Y220C 
MCF10-A 
Human breast 
epitelial/ 
non-tumorigenic 
wt 
 
 
2.7. Sulforhodamine B (SRB) assay 
Human cell lines were incubated in 96-well plates, at a final density of 5.0 × 103 
cells/well (for HCT116, MCF-7, MDA-MB-468, SJSA-1 and HuH-7 cell lines) or 1.0 × 104 
cells/well (for MDA-MB-231 and MCF10A cell lines), for 24 h. Cells were thereafter treated 
with serial dilutions (1.85 to 150 μM) of compounds for 48 h. The effect of compounds on in 
vitro growth was analyzed using the SRB assay. Briefly, following fixation with 10% 
trichloroacetic acid, plates were stained with 0.4% SRB (Sigma-Aldrich, Sintra, Portugal) 
and washed with 1% acetic acid. The bound dye was then solubilized in 10 mM Tris Base 
and the absorbance was measured at 510 nm in a microplate reader (Biotek Instruments 
Inc., Synergy MX, USA). The maximum concentration of solvent used in these assay 
(0.25% DMSO) was included as control. The concentration of compounds that causes 50% 
growth inhibition (GI50) was thereafter determined.  
In the synergistic assays, HCT116 p53+/+, HCT116 p53-/- and MDA-MB-231 cell lines 
were treated with the GI10 concentration of OXAZ-1, SLMP53-1 or DMSO only, and 
increasing concentrations of doxorubicin (9.38 – 750 nM) or etoposide (0.38 – 6.00 M). 
The effect of combined treatments on cell growth was analyzed after 48 h incubation, using 
the SRB assay. To further quantify the synergistic effect of the combined treatment, the 
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following equation was used, basically as reported (Jin, 1980), Q = Ea+b / (Ea + Eb ˗ Ea × 
Eb), where Q is the combination index of the combined treatment, Ea + b represents the 
cell proliferative inhibition rate of combined drugs, Ea and Eb are signs of the cell 
proliferative inhibition rate of each drug; Q < 0.85, Q > 1.15 and 0.85 < Q < 1.15 indicate 
antagonism, synergy, and additive effect, respectively. 
 
2.8. Analysis of cell cycle and apoptosis in human cell lines 
Cell lines were incubated in 6-well plates, at a final density of 1.5 × 105 cells/well (for 
HCT116, MCF-7 and SJSA-1 cell lines) or 2.3 × 105 cells/well (for MDA-MB-231 and 
MCF10A cell lines), for 24 h. Cells were thereafter treated with compounds or DMSO only 
for 16, 24 and 48 h. For cell cycle analysis, cells were fixed in ice-cold 70% ethanol and 
incubated at 37ºC with RNase A (Sigma-Aldrich, Sintra, Portugal) at a final concentration of 
20 g/mL for 15 min, and further incubated with 50 g/mL propidium iodide (PI; Sigma-
Aldrich, Sintra, Portugal) for 30 min, followed by flow cytometry analysis. Apoptosis 
determination was performed by flow cytometry using the Annexin V-FITC Apoptosis 
Detection Kit I from BD Biosciences (Enzifarma, Porto, Portugal), according to the 
manufacturer’s instructions; synergistic effects of combined treatments between the GI10 
concentration of OXAZ-1 or SLMP53-1 (or DMSO only) and doxorubicin or etoposide, were 
analyzed (determination of Q value) as described in the SRB assay. 
 
2.9. Western blot analysis 
To analyze the protein expression of human tumor cell lines, cells were plated in 6-
well plates at a final density of 1.5 × 105 cells/well (for HCT116, MCF-7 and SJSA-1 cell 
lines) or 2.3 × 105 cells/well (for MDA-MB-231 cell line) and incubated for 24 h. Cells were 
then treated with the GI50 (growth inhibition of 50%) concentration of compounds or DMSO 
only for 4, 8, 16, 24 and 48 h. Whole cell lysates were prepared by lysing the cells with RIPA 
buffer (Sigma-Aldrich, Sintra, Portugal) in the presence of EDTA-free protease inhibitor 
cocktail (Sigma-Aldrich, Sintra, Portugal). For mitochondrial and cytosolic fractions of 
human tumor cell lines, the Mitochondrial Fractionation Kit from Active Motif (Frilabo, Porto, 
Portugal) was used according to the manufacturer’s instructions.  
For the analysis of yeast protein expression, samples were lysed with CellyticTM Y Cell 
Lysis Reagent (Sigma-Aldrich, Sintra, Portugal) in the presence of EDTA-free protease 
inhibitor cocktail (Sigma-Aldrich, Sintra, Portugal). Protein extracts were quantified using 
the Coomassie staining, Bradford from Sigma-Aldrich (Sintra, Portugal).  
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Proteins (40 g) were electrophoresed using a 10% SDS–PAGE and transferred to a 
Whatman nitrocellulose membrane from Protan (VWR, Carnaxide, Portugal). Membranes 
were blocked with 5% milk and probed overnight with the primary antibody (Table 2.2) 
followed by 2 h incubation with a horseradish-peroxidase (HRP)-conjugated secondary 
antibody (Table 2.2.). For loading control, membranes were stripped (Abcam protocol) and 
reprobed with an anti-yeast phosphoglycerate kinase (Pgk1p) antibody for yeast, or with an 
anti-GAPDH antibody for tumor cell lines. For analysis of mitochondrial and cytosolic 
fractions, membranes were reprobed with the loading controls anti-COX IV and anti-GAPDH 
antibodies, respectively. The signal was detected using the ECL Amersham kit from GE 
Healthcare (VWR, Carnaxide, Portugal) and the Kodak GBX developer and fixer (Sigma-
Aldrich, Sintra, Portugal). Band intensities were quantified using the Bio-Profil Bio-1D++ 
software (Vilber-Lourmat, Marne La Vallée, France), and were normalized against the 
control sample (DMSO; set as 1). Western blots presented in this thesis are representative 
of three independent experiments. 
 
2.10. Co-immunoprecipitation (co-IP) assay 
The co-IP assay was performed using the Pierce Classic Magnetic IP and Co-IP Kit 
from Thermo scientific (Dagma, Carcavelos, Portugal), according to the manufacturer’s 
instructions. Briefly, HCT116 p53+/+ cells were plated at the final density of 5 × 105 cells/plate 
and incubated for 24 h. Cells were then treated with different concentrations of compounds 
or DMSO only for 16 h or 24 h. After cell lysis, 500 g of total protein was incubated with 
mouse monoclonal anti-p53 (DO-1) or with mouse immunoglobulin G (IgG, control) from 
Santa Cruz Biotechnology (Frilabo, Porto, Portugal), overnight at 4ºC. Immunocomplexes 
were immunoprecipitated using magnetic beads. Detection of p53, MDM2, MDMX and 
GAPDH (loading control) in whole cell lysate (input) and in immunoprecipitated fraction (IP) 
was performed by Western blot analysis as described in 2.9. 
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Table 2.2. Antibodies used in Western Blot and Immunohistochemistry. 
Antigen Final Dilution Supplier 
Primary antibodies 
p53 (DO-1) 
(mouse monoclonal) 
1:500 (yeast) 
1:5000 (human cells) 
Santa Cruz Biotechnology 
(Frilabo, Porto, Portugal) 
MDM2 (SMP14) 
(mouse monoclonal) 
1:100 
BAX (2D2) 
(mouse monoclonal) 
1:1000 
p21 (C-19) 
(rabbit polyclonal) 
1:1000 
Actin (C-11) 
(rabbit polyclonal) 
1:500 
PARP (C2-10) 
(mouse monoclonal) 
1:2000 
Cyt c (A8) 
(mouse monoclonal) 
1:200 
PUMA (B-6) 
(mouse monoclonal) 
1:100 
COX IV (F-8) 
(mouse monoclonal) 
1:500 
GAPDH (6C5) 
(mouse monoclonal) 
1:10000 
MDMX (A-300) 
(rabbit polyclonal) 
1:2000 Bethyl Laboratories 
Pgk1p (22C5D8) 
(mouse monoclonal) 
1:5000 Invitrogen (Alfagene, Carcavelos, Portugal) 
Ki-67 (SP6) 
(rabbit monoclonal) 
1:200 
(immunohistochemistry) 
Pierce Thermo Scientific (Taper, Sintra, 
Portugal) 
VEGF (VG1) 
(mouse monoclonal) 
1:200 
(immunohistochemistry) 
CD34 (QBEND/10) 
(mouse monoclonal) 
1:500 
(immunohistochemistry) 
BAX (6A7) 
(mouse monoclonal) 
1:200 
(immunohistochemistry) 
Secondary antibodies 
Anti-mouse horseradish-
peroxidase (HRP)-conjugated 
1:5000 
Santa Cruz Biotechnology 
(Frilabo, Porto, Portugal) 
Anti-rabbit horseradish-
peroxidase (HRP)-conjugated 
1:5000 
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2.11. Dual-luciferase reporter assay in human tumor cell lines 
Dual-luciferase reporter assay was performed basically as reported (Leão et al., 
2013c; Bisio et al., 2010). Briefly, about 5  104 cells/well of HCT116 tumor cell line were 
incubated in 24-well plates for 24 h. Cells were thereafter transfected at approximately 80% 
confluence using the Myrus LT-1 reagent (Tema Ricerca, Milan, Italy) according to the 
manufacturer’s instructions. Specifically, 350 ng of the reporter vectors containing either the 
p21 (pGL3-1138) or the MDM2 (pGL3-MDM2) promoter were used along with 50 ng of the 
control pRLSV40 plasmid included to normalize the transfection efficiency. Transfected 
cells were treated with the GI50 and 2GI50 concentration of SLMP53-1 (or DMSO only), for 
16 h. Cells were harvested and 10 L cell cultures was transferred to a white 384-well plate, 
followed by 10 L of 2x Passive Lysis Buffer (Promega, Milan, Italy), and incubation for 15 
min at room temperature with continuous orbital shaking (500 r.p.m.). Afterward, 10 L of 
Firefly Luciferase Bright Glo substrate (Promega, Milan, Italy) were added to the cell 
suspension and the light units were measured with a luminometer (Mithras LB940 plate 
reader-Berthold Technologies, Milan, Italy). To measure Renilla activity, 5 L Firefly 
Luciferase Substrate (Luciferase Assay Reagent, LARII, Promega, Milan, Italy) followed by 
5 L Stop&Glow buffer (Promega, Milan, Italy) were added, and the light units were 
measured again with a luminometer. In this assay, since the expression of luciferase occurs 
in a p53-dependent manner, the p53 transcriptional activity is reflected by the luciferase 
activity, which was quantified in the presence and absence of the tested compounds. 
 
2.12. RNA extraction and quantitative real-time polymerase chain reaction 
(RT-qPCR) 
Total RNA from tumor cell lines was extracted using the RNeasy Kit (Qiagen, Milan, 
Italy). About 1 µg RNA was used for cDNA synthesis using the M-MuLV reverse 
transcritptase and the Revert Aid cDNA Synthesis kit (Thermo Fisher, Italy) in 20 μL final 
volume, and following the manufacturer's instructions. qPCR assays were performed in a 
384-well plate format on a CFX Touch Real-Time PCR Detection System (Bio-rad, Italy), 
starting with 25 ng cDNA, as previously described (Lion et al., 2013). The 2x KAPA SYBR® 
FAST qPCR Kit (Kapa Biosystems, Rome, Italy) and specific primers, purchased from 
Eurofins (MWG, Italy), were employed. GAPDH, B2M and ACTB were used as reference 
genes. 
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2.13. TransAM assay 
About 1.5  106 cells/well of MDA-MB-231 cell line were incubated for 24 h and 
thereafter treated with 2GI50 and 3GI50 concentration of SLMP53-1 (or DMSO only) for 24 
h. Nuclear protein extracts were obtained using the Nuclear Extract Kit from Active Motif 
(Frilabo, Porto, Portugal), and the protein concentration was measured using NanoDrop 
1000 from Thermo scientific (Portugal). The p53 DNA binding ability was evaluated using 
the TransAM p53 Transcription Factor Assay Kit from Active Motif (Frilabo, Porto, Portugal), 
according to the manufacturer’s instructions. Briefly, equal amount of total nuclear protein 
was loaded into 96-well plate coated with an immobilized oligonucleotide containing a p53 
consensus binding site. The amount of bound p53 protein was quantified using an anti-p53 
antibody followed by a HRP-conjugated secondary antibody. The HRP signal was 
measured after addition of a manufacturer’s substrate, using the BioTek Synergy HT plate 
reader at 450 nm. A nuclear extract of wt p53-expressing MCF-7 cells treated with H2O2 
was used as kit positive control.  
 
2.14. Transfection of p53 siRNA 
MDA-MB-231 cells were transfected with 100 nM of small interfering RNAs (siRNAs) 
against p53 (SMARTpool p53) and negative nonspecific siRNAs (Non-targeting Pool) from 
Thermo Scientific/Dharmacon (Dagma, Carcavelos, Portugal), using Lipofectamine 2000 
(Invitrogen, Alfagene, Carcavelos, Portugal), and following the manufacturer’s instructions. 
After 24 h transfection, cells were treated with the GI50 concentration of SLMP53-1 (or 
DMSO only) for 24 h. 
 
2.15. Analysis of reactive oxygen species (ROS) generation 
Analysis of intracellular ROS generation was performed by flow cytometry. Briefly, 
about 1.5 × 105 cells/well (for HCT116 cell line) or 2.3 × 105 cells/well (for MDA-MB-231 cell 
line) were incubated in 6-well plates for 24 h. Cells were then treated with the GI50 
concentration of OXAZ-1, SLMP53-1 or DMSO only for 24 h (SLMP53-1) or 48 h (OXAZ-
1). Cells were harvested and stained with 5 M Cell-ROX Green Reagent from Life 
Technologies (Alfagene, Carcavelos, Portugal) for 30 min at 37ºC. 
 
2.16. Analysis of mitochondrial membrane potential (∆ψm) 
For analysis of ∆ψm, about 1.5 × 105 cells/well (for HCT116 cell line) or 2.3 × 105 
cells/well (for MDA-MB-231 cell line) were incubated in 6-well plates for 24 h. Cells were 
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then treated with the GI50 concentration of OXAZ-1, SLMP53-1 or DMSO only for 8 h (for 
HCT116 cell line) or 16 h (for MDA-MB-231 cell line). Cells were harvested and incubated 
with 1 nM DiOC6(3) (Alfagene, Carcavelos, Portugal) for 30 min at 37ºC; followed by flow 
cytometry analysis. Cells treated with 50 M carbonilcyanide p-
triflouromethoxyphenylhydrazone (FCCP; Sigma-Aldrich, Sintra, Portugal), for 15 min at 
37ºC, were used as positive control. 
 
2.17. In vitro migration assays  
Cell migration was analyzed using the Wound Healing Scratch assay as described in 
(Labelle-Côté et al., 2011), and the QCM 24-Well Fluorimetric Chemotaxis Cell Migration 
Kit (8 µm), from Merck Millipore (VWR, Carnaxide, Portugal). In the Wound Healing Scratch 
assay, about 5 × 105 cells/well of HCT116 p53+/+ or MDA-MB-231 cell lines were grown to 
confluence in 6-well plates for 24 h. Using a sterile 200 μL tip, a fixed-width wound was 
created in the cell monolayer and the GI10 concentration of DIMP53-1, SLMP53-1 or DMSO 
only was added to medium. Cells were thereafter photographed, using the Moticam 5.0MP 
camera with Motic’s AE2000 inverted microscope (VWR, Carnaxide, Portugal) with 400x 
magnification, at different time-points of treatment until complete closure of the wound. In 
the QCM 24-Well Fluorimetric Chemotaxis Cell Migration Kit (8 μm), about 0.5 × 106 
cells/mL of HCT116 p53+/+ or MDA-MB-231 cell lines were prepared in serum free RPMI 
1640 and treated with the GI25 (for HCT116 p53+/+ cell line) or the GI50 (for MDA-MB-231 
cell line) concentration of DIMP53-1, SLMP53-1, or DMSO only, followed by incubation 
during 24 h (for HCT116 p53+/+ cell line) or 8 h (for MDA-MB-231 cell line). Cell suspensions 
were distributed into 24-well plates (300 μL/insert), followed by addition of 500 μL medium 
containing 10% FBS to the lower chamber. Cells that migrated through the 8 μm pore 
membranes were eluted, lysed and stained with a green-fluorescence dye that binds to 
nucleic acids. The number of migrated cells is proportional to the fluorescence signal 
measured using the BioTek Synergy HT plate reader at 480/520 nm (ex/em).  
 
2.18. Genotoxicity studies by micronucleus assay 
Genotoxicity was analyzed by cytokinesis-block micronucleus assay in lymphocytes 
as described (Fernandes et al., 2011). Fresh peripheral blood samples were collected from 
healthy volunteers into heparinized vacutainers. Blood samples, suspended in RPMI 
medium supplemented with 10% FBS, were treated with different concentrations of 
DIMP53-1, SLMP53-1, DMSO only or 1g/mL cyclophosphamide (known mutagenic agent; 
positive control; Sigma-Aldrich, Sintra, Portugal) for 44 h. Cells were thereafter treated with 
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3 g/mL cytochalasin B (cytokinesis preventive; Sigma-Aldrich, Sintra, Portugal) for 28 h. 
Lymphocytes were isolated by density gradient separation (Histopaque-1077 and -1119; 
Sigma-Aldrich, Sintra, Portugal), fixed in 3:1 methanol/glacial acetic acid, and stained with 
Wright stain (Sigma-Aldrich, Sintra, Portugal). For each sample, 1000 binucleated 
lymphocytes were blindly scored using a Nikon AlphaPhotoF2 YS2 light optical microscope 
(Portugal); the number of micronuclei per 1000 binucleated lymphocytes was recorded. 
 
2.19. In vivo antitumor and toxicity assays 
Animal experiments were conducted according to the European Council Directives on 
Animal Care and to the National Authorities. The BALB/c Nude mice and Wistar rats were 
purchased from Charles-River Laboratories and housed under pathogen free conditions in 
individual ventilated cages. For toxicity assays, Wistar rats were treated with 50 mg/kg of 
DIMP53-1, SLMP53-1, vehicle (DMSO) or saline solution (control) by intraperitoneal 
injection, twice a week during two weeks. After the four administrations, samples of blood 
and organs (kidneys, liver, heart, lungs, spleen) were collected for toxicological analysis. 
Each group was composed by five animals. Xenograft tumor assays were performed with 
HCT116 p53+/+, HCT116 p53-/- and MDA-MB-231 human tumor cell lines. Briefly, 1 × 106 
HCT116 cells (in PBS) or 5 × 106 MDA-MB-231 cells (in PBS/BD Matrigel Matrix High 
Concentration, 1:1; BD Biosciences, Enzifarma, Porto, Portugal) were inoculated 
subcutaneously in the dorsal flank of each mice. Tumor dimensions were assessed by 
caliper measurement and their volumes were calculated [tumor volume = (length  width2) 
/ 2]. Treatment was started when tumors reached volumes of approximately 100 mm3 (which 
occurred 14 days after the grafts). Mice were then treated twice a week with 50 mg/kg 
DIMP53-1 or SLMP53-1, or vehicle (control) by intraperitoneal injection during two weeks. 
Tumor volumes and body weights were monitored twice a week until the end of the 
treatment. Animals were sacrificed by cervical dislocation at the end of the study. After 
sacrifice, tumors were removed and photographed. Human endpoints were established 
namely euthanasia in case of tumors reached 1500mm3, or if the animals presented any 
signs of morbidity. The following number of animals was used: HCT116 p53+/+ and HCT116 
p53-/- xenografs (Control-6, Treatment-6), MDA-MB-231 xenografts (Control-6, Treatment-
6). 
2.20. Immunohistochemistry 
Tumor tissues were fixed in 10% formalin, embedded in paraffin, sectioned at 4 µm, 
and stained with hematoxylin and eosin (H&E) or antibodies, following standard 
methodologies. Briefly, after deparaffination and rehydration, antigen retrieval was 
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performed by boiling the sections for 20 min in 10 mM citrate buffer (pH 6.0) for all antibody’s 
staining, with the exception of anti-VEGF, for which the tissue was treated with 10 mM EDTA 
buffer (pH 8.0). The slices were then held for 20 min at room temperature. After dewaxing 
and blocking the endogenous peroxidases with UltraVision Hydrogen Peroxide Block, 
sections were treated with UltraVision Protein Block solution, both from Lab Vision Thermo 
Scientific (Taper, Sintra, Portugal). Incubation with primary anti-Ki-67, anti-VEGF, anti-
CD34 and anti-BAX (Table 2.2) was performed for 2 h, at room temperature, with the 
exception of anti-BAX that was incubated overnight at 4°C. Immunostaining was carried out 
using the UltraVision Quanto Detection System HRP DAB kit, from Lab Vision Thermo 
Scientific (Taper, Sintra, Portugal), according to the manufacturer’s instructions. Tissue 
sections were counterstained with Gill’s heamatoxylin from Thermo Scientific (Taper, Sintra, 
Portugal), dehydrated, clarified and mounted. The primary antibody was replaced by 10% 
non-immune serum for negative controls. Finally, images were obtained using the Motic’s 
AE2000 inverted microscope (400× magnification) with the Moticam 5.0MP camera.  
Microvessel densities (MVD) were determined by counting all CD34-positive vessels 
(Weidner et al., 1991; Maeda et al., 2007). The hot spots were selected under a microscope 
(100×), and individual counts were made under a 400× magnification (0.155 mm2 per field). 
The average counts from five fields were recorded. Any single highlighted endothelial cell, 
or endothelial cell cluster clearly separated from adjacent microvessels, and distinct clusters 
of brown-staining endothelial cells were counted as separate microvessels. 
 
2.21. TUNEL assay 
TUNEL assay was performed using the In Situ Cell Death Detection Kit Fluorescein 
from Roche (Sigma-Aldrich, Sintra, Portugal), according to the manufacturer’s instructions. 
Briefly, after deparaffination and rehydration, tissues sections were treated for 20 min in 10 
mM citrate buffer (pH 6.0), and incubated with TUNEL Reaction Mixture for 60 min at 37ºC 
in the dark. Tissues were counterstained with 0.1 μg/mL DAPI. Images were obtained using 
an Eclipse E400 fluorescence microscope (Nikon), 400x magnification, with a Digital Sight 
camera system (Nikon DS-5Mc), carrying built-in software for image acquisition (Nikon 
ACT-2U). 
 
2.22. Flow cytometric data acquisition and analysis 
For the flow cytometry analysis, the AccuriTM C6 flow cytometer from BD Biosciences 
(Enzifarma, Porto, Portugal) and the CellQuest software from BD Biosciences (Enzifarma, 
Porto, Portugal) were used. For the identification and quantification of cell cycle phases, the 
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FlowJo software or the ModFit LT software (Verity Software HouseInc., Topsham, USA) 
were used. 
 
2.23. Statistical analysis 
Data were analyzed statistically using the GraphPad software. Differences between 
means were tested for significance using the Student’s t-test (*p < 0.05; **p < 0.01; ***p < 
0.001). 
 
2.24. Computational chemistry 
The structures of the synthesized compounds 1a–c, 2a–b, 3a–b and 4a–b, Nutlin-3a 
and 1,4-benzodiazepine-2,5-dione (BZD) were built with MOE. All the structures were 
energetically minimized using the MMFF94x force field with a RMS gradient of 0.1 and 
inserted in a test database. The crystallographic structure of MDM2 protein bound to the 
MI-63 analog inhibitor was downloaded from the Protein Data Bank (PDB code: 3LBL), 
imported in MOE and the co-crystallized waters were removed. After superposition of the 
A, C and E chains, it was verified that the two chains with a closer match were chains C 
and E. However, since the indole nitrogen of MI-63 analog is a hydrogenbond donor to 
LEU54, it was found that the one closer to the optimal distance of 2.8 Å, between donor and 
acceptor atoms, was the MI-63 analog interacting with chain C. Therefore, only the C chain 
was kept and the residues were protonated to match their state at physiological pH using 
the protonate3D module of MOE. The binding pocket was defined by using alpha spheres 
(sphere that contacts 4 atoms on its boundary and contains no internal atoms) within 5 Å of 
the MI-63 analog crystallographic pose. All the docking experiments were performed using 
a rigid protein docking protocol with a triangle matcher placement with a London dG scoring 
and a MMFF94x force field refinement. The best scored conformation per structure was 
selected and results were ranked through their binding affinities. These studies were carried 
out by Santos group from iMed UL. 
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inhibition of the p53-MDM2 interaction 
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Queiroz G, Bisio A, Inga A, Pereira C, Santos MMM, Saraiva L. 
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As referred in Chapter 1, the restoration of p53 activity by inhibition of the p53-MDM2 
interaction represents an appealing anticancer strategy for tumors with wt p53. Although 
several small molecules have emerged as inhibitors of the p53-MDM2 interaction, only few 
have reached clinical trials due to their low selectivity, high toxicity and poor 
pharmacokinetic profiles (Lauria et al., 2011; Wang et al., 2012; Wang and Hu, 2012; Zhao 
et al., 2013a). Efforts are therefore in progress to identify new scaffolds of p53-MDM2 
interaction inhibitors with improved pharmacological properties.  
In the present work, the activity of a synthesized small library of phenylalaninol-
derived oxazolopyrrolidone lactams (Schemes 3.1.1 and 3.2.2) as potential p53-MDM2 
interaction inhibitors was evaluated. The synthesis of this family was based in the principle 
that oxazolo moiety with aromatic side chains attached would mimic the rigid heterocyclic 
scaffold present in most p53-MDM2 interaction inhibitors. 
 
 
 
Scheme 3.1.1. Synthesis of compounds 1a–c and 2a–b. Reagents and conditions: (i) toluene, 
reflux, 66–92%. 
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Scheme 3.1.2. Synthesis of compounds 3a–b and 4a–b. Reagents and conditions: (i) toluene, 
reflux, 57–84%. 
 
 
 Identification of compounds 1b and 3a as potential p53-MDM2 
interaction inhibitors using a yeast-based assay 
In this work, a previously developed yeast-based assay (Leão et al., 2013c) was used 
for the analysis of the activity of the synthesized small library of phenylalaninol-derived 
oxazolopyrrolidone lactams as inhibitors of the p53-MDM2 interaction. The effectiveness of 
this yeast assay was recently demonstrated by the discovery of a new inhibitor of the p53-
MDM2 interaction with a xanthone scaffold (Leão et al., 2013c). In this assay, the expression 
of human wt p53 induces growth inhibition and S-phase cell cycle arrest, which is abolished 
by co-expression with human MDM2 (Leão et al., 2013a,c). Inhibitors of the p53-MDM2 
interaction, such as Nutlin-3a (positive control), reduce the impact of MDM2 on p53 activity, 
thus restoring the p53-induced yeast growth inhibition and cell cycle arrest (Figure 3.1.1A 
and B). Notably, these small molecules do not interfere with the activity of p53 when 
expressed alone (Leão et al., 2013a,c). Using this approach, the effect of 1–50 μM of 
compounds was evaluated using, as endpoint, the MDM2-dependent reduction of p53-
induced yeast growth inhibition. 
Five oxazolopyrrolidone lactams derived from S-phenylalaninol were firstly tested. 
From the concentration-response curves obtained for the tested compounds, the 
concentration of 10 μM was selected as the lowest concentration at which a higher reduction 
of the MDM2 effect was obtained (Figure 3.1.1A for compounds 1b and 3a), without 
interfering with the growth of control yeast (empty vectors). 
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Figure 3.1.1. Identification of compounds 1b and 3a as potential inhibitors of the p53-MDM2 
interaction using the yeast-based assay. (A) Percentage of reversion of the MDM2 negative effect 
on p53-induced growth inhibition caused by compounds 1b and 3a and Nutlin-3a (positive control); 
the growth of yeast cells co-expressing p53 and MDM2 treated with 1–50 μM of compounds or DMSO 
only, for 42 h, was analysed by CFU counts; results are plotted as relative to the growth inhibition 
achieved with yeast cells expressing p53 alone treated with DMSO only (set to 100%); presented 
data are mean ± S.E.M. of five independent experiments. (B) Effect of compounds 1b and 3a on the 
inhibition of p53-induced yeast cell cycle arrest by MDM2. Yeast cells were incubated with 10 μM 
compounds 1b and 3a, 10 μM Nutlin-3a or DMSO only, for 42 h. Cell cycle phases were quantified 
by flow cytometry; presented data are mean ± S.E.M. of two independent experiments. (C) Effect of 
compounds 1b and 3a on the growth of yeast cells expressing p53 alone and control yeast (vector); 
growth curves were obtained by CFU counts for yeast cells expressing p53 alone and control yeast 
treated with 1–50 μM of compounds 1b and 3a or DMSO only, for 42 h; presented data are 
mean ± S.E.M. of five independent experiments. In (A) and (B), values significantly different from 
DMSO only are indicated (*p < 0.05; **p < 0.001). 
 
 
Among the tested compounds, compound 1b significantly reverted the inhibitory effect 
of MDM2 on p53-induced yeast growth inhibition at a wide range of concentrations (Figure 
3.1.1A), exhibiting a similar effect to Nutlin-3a (Table 3.1.1). Accordingly, like Nutlin-3a, 
compound 1b significantly reduced the inhibitory effect of MDM2 on p53-induced S-phase 
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cell cycle arrest (Figure 3.1.1B). Besides, compound 1b did not interfere with the activity of 
p53, when expressed alone, and with the growth of control yeast (vector) (Figure 3.1.1C). 
With the results obtained in yeast, we could assume that a phenyl group is preferred 
to a methyl group at position R1 (compounds 1b and 2b versus compounds 1a and 2a) 
(Table 3.1.1). Also, compounds 1 containing an isoindolinone moiety are more active than 
compounds 2 with a pyrrolidone moiety (Table 3.1.1). 
  
 
Table 3.1.1. Effect of compounds 1a-c and 2a-b on the reversion of p53-induced yeast growth 
inhibition by MDM2. 
 
Compounds R1 R2 Reversion of MDM2 effect (%)a 
1a Me H 53.6 ± 3.0 
1b Ph H 82.5 ± 6.4 
1c H OMe 69.9 ± 3.5 
2a Me — 38.7 ± 3.2 
2b Ph — 47.6 ± 6.1 
DMSO — —   2.3 ± 5.6 
Nutlin-3a — — 73.2 ± 3.0 
 
a Yeast cells co-expressing p53 and MDM2 were incubated in selective medium with 10 μM 
compound or DMSO only, for 42 h. Nutlin-3a was used as positive control. The growth inhibition 
obtained with yeast cells expressing only p53 treated with DMSO was considered as 100%. Data are 
mean ± S.E.M. of five independent experiments. 
 
 
Due to the relevance of chirality on the biological activity, it was pivotal to assess the 
potential value of the enantiomers of the most active compounds. Four oxazolopyrrolidones 
derived from R-phenylalaninol were chosen to be analyzed on the p53-MDM2 interaction. 
In general, all compounds were more active than the S-phenylalaninol counterparts. In 
addition, as observed with compound 1b, the compound 3a significantly reverted the 
inhibitory effect of MDM2 on p53-induced yeast growth inhibition at a wide range of 
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concentrations tested (Figure 3.1.1A), exhibiting a similar effect to Nutlin-3a (Table 3.1.2). 
Accordingly, the oxazoloisoindolinone 3a significantly reduced the inhibitory effect of MDM2 
on p53-induced S-phase cell cycle arrest (Figure 3.1.1B), without interfering with the activity 
of p53, when expressed alone, and with the growth of control yeast (vector) (Figure 3.1.1C). 
In order to check the selectivity of compounds 1b and 3a for MDM2, the effect of these 
two compounds on MDMX was also checked, using a previously developed yeast assay to 
search for inhibitors of the p53–MDMX interaction (Leão et al., 2013b). Contrary to the well-
known inhibitor of the p53–MDMX interaction SJ-172550 (Leão et al., 2013b), compounds 
1b and 3a did not behave as potential inhibitors of this interaction, since they did not 
interfere with the negative effect of MDMX on p53 in yeast (data not shown).  
 
 
Table 3.1.2. Effect of compounds 3a-b and 4a-b on the reversion of p53-induced yeast growth 
inhibition by MDM2. 
 
Compounds R1 R2 
Reversion of MDM2 
effect (%)a 
3a Ph H 88.1 ± 1.9 
3b H OMe 66.8 ± 5.0 
4a Me — 66.5 ± 4.7 
4b Ph — 75.1 ± 4.0 
 
a Yeast cells co-expressing p53 and MDM2 were incubated in selective medium with 10 μM 
compound or DMSO only, for 42 h. Nutlin-3a was used as positive control. The growth inhibition 
obtained with yeast cells expressing only p53 treated with DMSO was considered as 100%. Data are 
mean ± S.E.M. of five independent experiments. 
 
 Oxazoloisoindolinone 3a in vitro antitumor activity involves selective 
activation of the p53–pathway through inhibition of the p53-MDM2 
interaction 
The tumor cell growth inhibitory potential of compounds 1b and 3a, and the 
contribution of the p53-pathway to their activities were thereafter ascertained using human 
colon adenocarcinoma HCT116 cell lines with wt p53 (HCT116 p53+/+) and its isogenic 
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derivative, in which p53 has been knocked out (HCT116 p53−/−). The GI50 values obtained 
for compound 1b in p53+/+ (8.8 μM) and p53−/− (11.4 μM) HCT116 cells indicated a potent 
growth inhibitory effect against these tumor cells (Figure 3.1.2). In spite of this, contrary to 
Nutlin-3a, no differences in the activity of compound 1b were observed between p53+/+ and 
p53−/− HCT116 cells. Together these results indicated that compound 1b was a nonselective 
activator of the p53-pathway in human tumor cells.  
Although a similar GI50 value to that of compound 1b was obtained with compound 3a 
(9.7 μM) in HCT116 p53+/+ cells, a significant increase in the selectivity of compound 3a to 
the p53-pathway was observed (Figure 3.1.2). In fact, as observed with Nutlin-3a, a 
significant reduction of the potency of compound 3a was observed in HCT116 p53−/− cells. 
 
 
Figure 3.1.2. Compound 3a exhibits in vitro antitumor 
activity through selective activation of a p53-dependent 
pathway in human tumor cells. The GI50 concentration was 
determined for compounds 1b, 3a and Nutlin-3a, in human 
colon adenocarcinoma HCT116 cells with (HCT116 p53+/+) 
and without (HCT116 p53−/−) p53, after 48 h incubation, using 
the SRB assay. Presented data are mean ± S.E.M. of four 
independent experiments; values significantly different from 
HCT116 p53+/+ cells are indicated (**p < 0.01). 
 
 
 
The molecular mechanism of action of compound 3a as inhibitor of the p53-MDM2 
interaction was thereafter investigated in HCT116 tumor cells. In HCT116 p53+/+ cells, the 
growth inhibitory effect of compound 3a, at GI50 and twice the GI50 (2xGI50) concentration, 
was associated with the induction of G0/G1-phase cell cycle arrest (Figure 3.1.3A). 
Accordingly, 9.7 μM oxazoloisoindolinone 3a up-regulated the p21 protein expression levels 
in p53+/+, but not in p53−/−, HCT116 cells (Figure 3.1.3B).  
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Figure 3.1.3. Compound 3a induces cell cycle arrest in human tumor cells. (A) Effect of 
compound 3a on cell cycle progression of HCT116 p53+/+ cells was determined after 48 h treatment 
with 9.7 μM compound 3a and 3.2 μM Nutlin-3a  or with 2 × GI50. Cell cycle phases were analyzed 
by flow cytometry using PI and quantified using ModFit LT software. Presented data are 
mean ± S.E.M. of two independent experiments; values significantly different from DMSO are 
indicated (*p < 0.05; **p < 0.01). (B) Compound 3a increases the p21 protein levels in p53+/+, but not 
in p53−/−, HCT116 cells. Western blot analysis was performed after 4 h treatment with 9.7 μM 
compound 3a or DMSO only. The quantification of band intensity was performed using GAPDH as 
loading control. 
 
 
Additionally, it was observed that the growth inhibitory effect of compound 3a in 
HCT116 p53+/+ cells was also associated with the induction of late apoptosis both at 
GI50 and 2xGI50 concentration (Figure 3.1.4A). The activation of a p53-dependent apoptotic 
pathway by 9.7 μM compound 3a was further supported by the occurrence of PARP 
cleavage (Figure 3.1.4B), and by the up-regulation of BAX and PUMA (Figure 3.1.5A) in 
p53-expressing, but not in p53-null, HCT116 cells. 
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Figure 3.1.4. Compound 3a induces early and late apoptosis in HCT116 p53+/+ cells. (A) 
Apoptosis was determined after 48 h treatment with 9.7 μM compound 3a and 3.2 μM Nutlin-3a or 
with 2 × GI50, and was analyzed by flow cytometry using FITC-Annexin V and PI; quantification of 
cells in apoptosis are mean ± S.E.M. of two independent experiments; values significantly different 
from DMSO are indicated (*p < 0.05; **p < 0.01). (B) Compound 3a leads to PARP cleavage in p53+/+, 
but not in p53−/−, HCT116 cells. Western blot analysis was performed after 24 h treatment with 9.7 μM 
compound 3a or DMSO only. The quantification of band intensity was performed using GAPDH as 
loading control. 
 
 
It was also observed that 9.7 μM compound 3a up-regulated the expression levels of 
MDM2 and increased the p53 baseline levels in p53+/+, but not in p53−/−, HCT116 cells 
(Figure 3.1.5A). This stabilization of p53 protein levels indicated an inhibition by compound 
3a of the p53 degradation caused by its interaction with MDM2.  
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Figure 3.1.5. Compound 3a increases the expression levels of p53 target genes and disrupted 
the p53-MDM2 interaction in HCT116 p53+/+ cells. (A) Western blot analysis was performed after 
8 h (for p53) and 24 h (for BAX, MDM2 and PUMA) treatments with 9.7 μM compound 3a or DMSO 
only. The quantification of band intensity was performed using GAPDH as loading control. (B) 
HCT116 p53+/+ cells were treated with 10 and 20 μM compound 3a or DMSO only for 16 h, followed 
by IP with p53 antibody or mouse immunoglobulin G (IgG) antibody and immunoblot with MDM2 and 
p53 antibodies; whole cell lysate (input). GAPDH was used as loading control. 
 
 
Moreover, the ability of compound 3a to block the p53-MDM2 interaction in HCT116 
p53+/+ cells was checked by co-IP. The results obtained confirmed that 10 and 20 μM 
compound 3a blocked the p53-MDM2 interaction (Figure 3.1.5B). In fact, these experiments 
showed that little or no MDM2 protein co-immunoprecipitated with p53 in HCT116 
p53+/+ cells treated with compound 3a. 
 
 
 Predicted binding model supports the binding of compound 3a to MDM2 
Molecular docking studies with the tested phenylalaninol-derived oxazolopyrrolidone 
lactams were performed on the MDM2 hydrophobic cleft using the Molecular Operating 
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Environment (MOE) software and the crystallographic structure with PDB code 3LBL 
(www.pdb.org) (Berman et al., 2000) allowing to rank the compounds by binding affinities 
summarized in Table 3.1.3. Only the best scoring conformation per molecule was 
considered in the discussion. 
 
 
Table 3.1.3. Binding affinities found by molecular docking for the tested compounds. 
Compounds ΔG kcal/mol 
3a -21.61 
1b -20.80 
4a -18.34 
1c -18.11 
4b -16.89 
2b -16.80 
1a -16.77 
2a -15.74 
3b -14.82 
Nutlin-3a -26.50 
2-Cl-BZD -21.91 
 
 
The co-crystallized ligand MI-63 analog was re-docked as a way to validate the 
molecular docking method. The root mean square deviation (RMSD) between the predicted 
and co-crystallized pose of MI-63 analog was 1.11 Å (predicted binding energy: 
−29.37 kcal/mol) which indicates that the software is able to accurately reproduce the 
binding pose of the co-crystallized ligand. A second validation of the docking method was 
performed by confirming that the interactions observed for the docked Nutlin-3a and BZD 
structures were in agreement with the interactions found for these two compounds in other 
crystallographic structures (PDB code: 4J3E, for Nutlin-3a; PDB code: 1T4E, for BZD). The 
values obtained for inhibitors which are known to establish the well characterized 
interactions with the MDM2 protein were found to be between −26.50 (Nutlin-3a) and −21.91 
(BZD) kcal/mol. Among the tested phenylalaninol-derived oxazolopyrrolidone lactams, 
compounds 3a and 1b presented values of −21.61 and −20.80 kcal/mol respectively, thus 
having the best binding affinities within this new group of p53-MDM2 interaction inhibitors 
(Table 3.1.3). It is important to stress that these compounds were also the ones having the 
highest activities in the yeast screening assay and that a good correlation was found 
between the binding affinities estimated by docking for this class of compounds and the 
percentage of inhibition. The binding interactions established between compound 3a and 
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MDM2 protein were visually inspected and the conformation with the highest score is 
displayed in Figure 3.1.6. It was found that for the most active compound, 3a, the binding 
interactions are in agreement with one of the possible binding modes already described for 
isoindolinones derivatives, found through NMR studies (Riedinger et al., 2008). The 
aromatic ring of the isoindolinone core establishes hydrophobic contacts with residue ILE61. 
The phenyl group at position C9b is projected towards the deep hydrophobic pocket of 
MDM2 and the methylene-phenyl moiety establishes hydrogen-π interactions with residue 
LEU54. The 1YCR structure containing p53 interacting with MDM2 was aligned and 
superposed with the 3LBL structure using the MDM2 residues defining the pocket. The 
alignment and the positioning of residues responsible for the most important interactions 
are depicted in Figure 3.1.6. The picture makes clear the mimetic nature of compound 3a, 
where the location occupied by PHE19 is now occupied by the aromatic ring of isoindolinone 
moiety, the TRP23 by the phenyl group at position 9b and LEU26 by the methylphenyl 
group. 
In protein–protein interactions, there are some concerns about possible 
conformational changes produced on the binding site upon binding to proteins or ligands 
that will impose the usage of other research techniques besides docking. 
The binding site defined by the area where all organic molecules mimicking the p53 
interaction is not very deep like a pocket, but resembles a cleft/groove and is hydrophobic 
in nature. However, all the organic molecules have a ring or fused rings located deeply in 
the pocket where PHE19 of p53 interact. In opposition to the other two pockets (defined by 
TRP23 and LEU26 of p53), this one goes deep in the protein structure and seems to work 
as an anchor point guiding the positioning of the binding molecules. 
For instance, superposing structures 1YCR (p53 co-crystallized) with 1T4E 
(benzodiazepine co-crystallized) shows a relatively low RMSD for the alpha carbons (0.9 Å). 
The a.a. of the three pockets defined by p53 have very similar rotameric states for the 
residues, defining the three referred pockets except for TYR67, HIS73 and MET62. The 
latter is the only residue in a different rotameric state not belonging to a coil region found 
between TYR67 and HIS73. MET62 is the only residue in a different rotameric state not 
belonging to the coil region. All these residues have no specific interactions with the co-
crystallized molecules, except a generic hydrophobic match. Moreover, the synthesized 
molecules reported in the manuscript also have no direct interactions with this residue and 
the closest atoms are characteristically at a distance of at least 4 Å. Therefore, the possibility 
of using molecular docking to predict the binding modes of the newly synthesized molecules 
seems adequate. 
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Figure 3.1.6. Docking pose of compound 3a within the MDM2 hydrophobic cleft limits depicted 
with a surface (in green, hydrophobic; in pink, hydrophilic areas). Receptor carbon residues are 
displayed in yellow and LEU54 and ILE61 are highlighted. Part of the p53 backbone (helix in red, 
turn in blue, loop in white) and residues PHE19, TRP23 and LEU26 are represented with carbons in 
light blue.  
 
 Discussion 
In this work, nine phenylalaninol-derived oxazolopyrrolidone lactams were 
synthesized and their capacity to inhibit the p53-MDM2 interaction was investigated. The 
screening of the compounds using a yeast cell model led to the identification of two potential 
inhibitors of the p53-MDM2 interaction, compounds 1b and 3a. The results obtained in 
human tumor cells demonstrated that compound 1b is a nonselective activator of the p53-
pathway in human tumor cells.  
Contrary to compound 1b, the in vitro tumor growth inhibitory activity of compound 3a 
revealed to be dependent on p53-pathway. In conformity to what was obtained in yeast, 
oxazoloisoindolinone 3a mimicked the activity of known small molecule inhibitors of the p53-
MDM2 interaction in human tumor cells, leading to the successful activation of p53 and 
downstream cell signaling. In fact, in tumor cells, the oxazoloisoindolinone 3a exhibited the 
most relevant hallmarks of a typical inhibitor of the p53-MDM2 interaction. Particularly, it 
decreased the proliferation of wt p53-carrying tumor cells, presenting a significantly lower 
potency in tumor cells without p53. Additionally, in wt p53-carrying tumor cells, it induced 
cell cycle arrest and apoptosis, led to p53 stabilization and increased the expression levels 
91 
 
of proteins encoded by p53 target genes. Most importantly, oxazoloisoindolinone 3a was 
able to inhibit the p53-MDM2 interaction in tumor cells. Finally, molecular docking studies 
supported the binding of oxazoloisoindolinone 3a to MDM2 and provided insights about its 
binding mode, what may allow a more guided structure optimization of compound 3a.  
Altogether, in this work, synthesis combined with computational docking studies and 
biological screening assays led to the identification of oxazoloisoindolinone 3a, which 
belongs to a new class of potent and selective small molecule activators of the p53-pathway 
with promising antitumor activity. Additionally, oxazoloisoindolinone 3a may be the basis for 
the structure-based design of p53-MDM2 interaction inhibitors with improved 
pharmacological properties compared to those currently available. 
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A tryptophanol-derived oxazolopiperidone lactam is 
cytotoxic against tumors via inhibition of p53 interaction 
with murine double minute proteins 
 
Soares J, Raimundo L, Pereira NAL, dos Santos DJVA, Pérez M, Queiroz G, Leão M, 
Santos MMM, Saraiva L. 
Pharmacol Res 2015 May-Jun; 95-96: 42-52. 
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As referred in Chapter 1, despite many results demonstrated the greatest efficiency 
of dual inhibition of MDM2 and MDMX on p53 activation, to date, just few small molecule 
dual inhibitors of p53-MDMs interactions have been identified. Therefore, in this work, new 
inhibitors of p53-MDMs interactions were searched from a small library of enantiopure 
tryptophanol-derived oxazolopiperidinone lactams. The selection of this family of 
compounds was based in the conjugation of an oxazolo ring with a piperidinone ring, two 
scaffolds that are described to act as p53-MDM2 interaction inhibitors (Sun et al., 2014).  
 
 
 Identification of OXAZ-1 as potential dual inhibitor of p53-MDMs 
interactions, using a yeast-based screening assay 
In this work, six (S)-tryptophanol-derived oxazolopiperidinone lactams (Figure 3.2.1) 
were tested for their ability to inhibit the p53 interaction with MDM2 and MDMX, using 
previously developed yeast-based screening assays (Leão et al., 2013b,c). 
 
 
Figure 3.2.1. Chemical structure of tryptophanol-derived oxazolopiperidone lactams 
evaluated in yeast. 
 
 
As referred in Chapter 3.1, in the yeast assays MDMs reduce the human p53-induced 
growth inhibition, an effect reverted by p53-MDMs interaction inhibitors (Leão et al., 
2013b,c). The efficiency of these yeast assays to search for inhibitors of these interactions 
was validated by testing Nutlin-3a and SJ-172550, respectively. As in mammalian cells 
(Graves et al., 2012), also in yeast Nutlin-3a did not interfere with the MDMX-inhibitory 
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activity, confirming its activity on MDM2 only (Table 3.2.1; Figure 3.2.2A), while SJ-172550 
did not interfere with the MDM2-inhibitory activity, confirming its activity on MDMX only 
(Table 3.2.1; Figure 3.2.2A).  
 
 
Table 3.2.1. EC50 values obtained for the compounds tested in yeast. 
 
 
 
 
 
 
 
 
 
 
Yeast cells co-expressing p53 and MDM2/MDMX were incubated with 0.1–50 μM compounds or 
DMSO only, for 42 h. The EC50 (concentration that caused 50% of the reversion effect) values were 
determined from concentration-response curves of the reversion of the MDM2/MDMX-inhibitory 
effect obtained for 0.1–50 μM compounds (see Figure 3.2.2A for OXAZ-1 and positive controls). Data 
are mean ± S.E.M. of six independent experiments. 
 
 
Using this approach, the effect of 0.1–50 μM compounds was evaluated. From the 
concentration-response curves of the reversion of MDM2-inhibitory effect obtained for each 
compound, it was shown that, with the exception of OXAZ-5, all the other tested compounds 
presented similar effects to Nutlin-3a with reversion of the MDM2-inhibitory effect (Table 
3.2.1). However, only OXAZ-1 was able to revert the MDMX-inhibitory effect, exhibiting a 
higher potency than SJ-172550 (Table 3.2.1). Interestingly, contrary to Nutlin-3a and SJ-
172550, OXAZ-1 reverted the inhibitory effect of both MDMs (Table 3.2.1; Figure 3.2.2A). 
Additionally, OXAZ-1 did not interfere with the growth of control yeast and yeast expressing 
p53, MDM2 or MDMX alone (Figure 3.2.2B). 
 
 
Compounds 
EC50 (M) 
p53-MDM2 p53-MDMX 
Nutlin-3a 
SJ-172550 
OXAZ-1 
OXAZ-2 
OXAZ-3 
OXAZ-4 
OXAZ-5 
OXAZ-6 
1.6 ± 3.6 
> 50 
1.0 ± 2.4 
2.3 ± 3.7 
2.0 ± 3.3 
2.1 ± 2.4 
> 50 
3.0 ± 3.3 
> 50 
12.4 ± 4.3 
2.4 ± 3.7 
> 50 
> 50 
> 50 
> 50 
> 50 
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Figure 3.2.2. Identification of OXAZ-1 as potential dual inhibitor of p53-MDMs interactions, 
using a yeast-based screening assay. (A) Effect of 0.1–50 μM OXAZ-1, Nutlin-3a and SJ-172550 
on the reversion of p53-induced yeast growth inhibition by MDM2 and MDMX, after 42 h incubation. 
The growth of yeast cells co-expressing p53 and MDM2/MDMX was evaluated by CFU counts; 
results were plotted setting as 100% the growth achieved with yeast cells expressing p53 alone 
incubated with DMSO only; data are mean ± S.E.M. of six independent experiments; values 
significantly different from DMSO only are indicated (*p < 0.05, **p < 0.01, ***p < 0.001). (B) Effect 
of 0.1–50 μM OXAZ-1 on the growth of yeast expressing p53, MDMX, MDM2 or transformed with 
the empty vector after 42 h incubation. Yeast cell growth was evaluated by CFU counts; results were 
plotted setting as 100% the growth achieved with DMSO only; data are mean ± S.E.M. of five 
independent experiments; values are not significantly different from DMSO only (p > 0.05). (C) Effect 
of 10 μM OXAZ-1 on the actin protein levels of yeast cells co-expressing p53 and MDM2/MDMX after 
42 h incubation. Immunoblots represent one of three independent experiments; Pgk1p was used as 
loading control. 
 
 
In a recent work, it was shown that expression of human p53 in yeast increased the 
expression levels of ACT1 (described as a yeast p53 target gene; Leão et al., 2013b), an 
effect abolished by MDM2 and MDMX, and re-established by Nutlin-3a and SJ-172550, 
respectively (Leão et al., 2013b). Here, it was shown that, like Nutlin-3a (for MDM2) and 
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SJ-172550 (for MDMX), OXAZ-1 (at 10 μM for MDM2 and 20 μM for MDMX) increased the 
actin protein levels in yeast cells co-expressing p53 and MDM2/MDMX (Figure 3.2.2C). 
These results reinforced a reversion of the MDMs-inhibitory effect by OXAZ-1. 
 
 OXAZ-1 has a p53-dependent tumor growth-inhibitory effect mediated by 
disruption of p53-MDMs interactions and induction of a mitochondria-
mediated apoptotic pathway 
The tumor cell growth-inhibitory potential of OXAZ-1 and the contribution of the p53 
pathway to its activity were thereafter ascertained using the human colon adenocarcinoma 
HCT116 cell lines with wt p53 (HCT116 p53+/+) and its p53-null isogenic derivative (HCT116 
p53−/−). The GI50 values obtained for OXAZ-1, after 48 h treatment, in p53+/+ and 
p53−/− HCT116 cells, revealed a p53-dependent growth-inhibitory effect by OXAZ-1 (Figure 
3.2.3A). In fact, a significant reduction of the potency of OXAZ-1 was observed when the 
p53 pathway was knocked out in HCT116 p53−/− cells.  
In HCT116 p53+/+ cells, the growth-inhibitory effect of OXAZ-1, at the 
GI50 concentration (25 μM), was associated with G0/G1-phase cell cycle arrest (Figure 
3.2.3B) and late apoptosis (Figure 3.2.3C). The activation of a p53-dependent apoptotic 
pathway by 25 μM OXAZ-1 was further supported by the inability of this compound to induce 
apoptosis (Figure 3.2.3C) and PARP cleavage (Figure 3.2.3D), in p53-null HCT116 cells. 
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Figure 3.2.3. OXAZ-1 induces growth inhibition associated with cell cycle arrest and p53-
dependent apoptosis, in human colon adenocarcinoma HCT116 tumor cells. (A) The 
GI50 concentration of OXAZ-1 was determined in p53+/+ and p53-/- HCT116 cells, after 48 h treatment, 
using the SRB assay. Data are mean ± S.E.M. of four independent experiments; values significantly 
different from HCT116 p53+/+ cells are indicated (**p < 0.01). (B) Effect of 25 μM OXAZ-1 on cell was 
analyzed by flow cytometry using PI staining, after 24 h treatment; data are mean ± S.E.M. of two 
independent experiments; values significantly different from DMSO are indicated (**p < 0.01). (C) 
Effect of 25 μM OXAZ-1 on apoptosis was analyzed by flow cytometry using FITC-Annexin V and PI, 
after 24 h treatment; data are mean ± S.E.M. of two independent experiments; values significantly 
different from DMSO are indicated (***p < 0.001). (D) Effect of 25 μM OXAZ-1 on PARP cleavage, 
after 24 h treatments. Immunoblots represent one of three independent experiments; GAPDH was 
used as loading control. 
 
By western blot analysis, it was also observed that 25 μM OXAZ-1 led to p53 
stabilization and increased the levels of proteins encoded by major p53 transcription targets, 
such as MDM2, MDMX, p21, PUMA and BAX, in p53+/+, but not in p53−/−, HCT116 cells 
(Figure 3.2.4A). 
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Figure 3.2.4. OXAZ-1 leads to p53 stabilization and to the up-regulation of p53 target genes 
by blocking the p53 interaction with MDM2 and MDMX, in HCT116 p53+/+ cells. (A) Effect of 
25 μM OXAZ-1 on the protein levels of p53, MDM2, MDMX, p21, PUMA and BAX in p53+/+ and p53-
/- HCT116 cells after 24 h treatment. Immunoblots represent one of three independent experiments; 
GAPDH was used as loading control. (B) Cells were treated with 25, 50 and 75 μM OXAZ-1 or DMSO 
only for 16 h, followed by immunoprecipitation with p53 or mouse immunoglobulin G (IgG) antibodies, 
and western blot with MDM2, MDMX and p53 antibodies; whole cell lysate (Input); immunoblots 
represent one of three independent experiments; GAPDH was used as loading control. 
 
 
The ability of OXAZ-1 to block the p53 interaction with MDM2 and MDMX was further 
demonstrated by co-IP, in HCT116 p53+/+ cells (Figure 3.2.4B). In fact, at 50 and 75 μM 
(corresponding to 2×GI50 and 3×GI50 concentrations, respectively), little or no MDM2 was 
co-immunoprecipitated with p53, and a visible decrease of the amount of MDMX co-
immunoprecipitated with p53 was observed (Figure 3.2.4B). Similar results were reported 
for RO-5963, for which the disruption of the p53 interaction with MDM2 and MDMX was 
observed at 4×GI50 concentration (Graves et al., 2012). 
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Figure 3.2.5. OXAZ-1 induces a p53-dependent mitochondria-mediated apoptotic pathway in 
HCT116 p53+/+ cells. (A) Effect of 25 μM OXAZ-1 on ROS production, in p53+/+ and p53-/- HCT116 
cells after 48 h treatment, and on Δψm dissipation in HCT116 p53+/+ cells after 8 h treatment. For 
assessment of ROS production and Δψm, cells were stained with CellROX and DIOC6(3), 
respectively, and analyzed by flow cytometry; histograms represent one of two independent 
experiments; M2 cursor indicates the subpopulation analyzed; represented values correspond to the 
increase in the percentage of CellROX-positive cells and of cells with Δψm dissipation obtained after 
treatment with OXAZ-1 or DMSO only, and are mean ± S.E.M. of two independent experiments; in 
Δψm analysis, FCCP was used as positive control. (B) Effect of 25 μM OXAZ-1 on BAX translocation 
from cytosol to mitochondria after 24 h treatment. GAPDH and COX IV were used as loading control 
of cytosolic and mitochondrial fractions, respectively. (C) Effect of 25 μM OXAZ-1 cyt c release into 
the cytosol after 24 h treatment. GAPDH was used as loading control. In (B) and (C), immunoblots 
represent one of three independent experiments. 
 
Additionally, it was also observed that 25 μM OXAZ-1 led to a marked increase of 
ROS production in p53+/+, but not in p53−/−, HCT116 tumor cells and to Δψm dissipation in 
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HCT116 p53+/+ cells (Figure 3.2.5A). Moreover, besides the increase of BAX production 
(Figure 3.2.4A), 25 μM OXAZ-1 triggered its translocation from cytosol to mitochondria 
(Figure 3.2.5B), and the release of cyt c from mitochondria to cytosol (Figure 3.2.5C). 
Altogether, these results showed that OXAZ-1 was a potent inducer of a p53-dependent 
mitochondria-mediated apoptotic pathway in human tumor cells. 
 
 
 MDMX-overexpression tumor cells are sensitive to OXAZ-1 
Tumor cells overexpressing MDMX have been described as fairly insensitive to 
MDM2-only inhibitors (e.g., Nutlin-3a) due to their inability to inhibit the p53–MDMX 
interaction (Graves et al., 2012; Patton et al., 2006; Wade et al., 2006). Based on this, the 
effect of OXAZ-1 was tested in human breast adenocarcinoma MCF-7 cells, a well-known 
MDMX-overexpressing tumor cell line (Graves et al., 2012). As expected, a similar growth 
inhibitory effect to that obtained in HCT116 p53+/+ cells was achieved in MCF-7 cell lines by 
OXAZ-1 (GI50 value of 23.5 ± 2.5 μM, n = 4). Additionally, as in HCT116 p53+/+ cells, also in 
MCF-7 cells, the OXAZ-1-induced growth inhibition was associated with G0/G1-phase cell 
cycle arrest (Figure 3.2.6A) and late apoptosis (Figure 3.2.6B) with PARP cleavage (Figure 
3.2.6C). Moreover, also in MCF-7 cells, 23.5 μM OXAZ-1 led to the stabilization of p53 
protein levels and to the up-regulation of p53 transcription targets involved in cell cycle (p21) 
and apoptosis (BAX) (Figure 3.2.6D). Altogether, these results showed that also in MDMX-
overexpression tumor cells OXAZ-1 was able to activate the p53 pathway mostly inhibited 
by MDMX. 
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Figure 3.2.6. OXAZ-1 induces growth inhibition associated with cell cycle arrest and 
apoptosis in MDMX-overexpressing human breast adenocarcinoma MCF-7 tumor cells 
through activation of the p53 pathway. (A) Effect of 47 μM (2xGI50) OXAZ-1 on cell cycle, after 
24 h treatment. Cell cycle phases were analyzed by flow cytometry using PI staining; data are 
mean ± S.E.M. of two independent experiments; values significantly different from DMSO are 
indicated (**p < 0.01). (B) Effect of 47 μM OXAZ-1 on apoptosis, after 24 h treatment. Apoptosis was 
analyzed by flow cytometry using FITC-Annexin V and PI; data are mean ± S.E.M. of two 
independent experiments; values significantly different from DMSO are indicated (*p < 0.05). (C, D) 
Effect of 23.5 μM OXAZ-1 on PARP cleavage (C), and on p53, p21 and BAX protein levels (D), after 
24 h treatments. Immunoblots represent one of three independent experiments; GAPDH was used 
as loading control. 
 
 
 OXAZ-1 sensitizes tumor cells to conventional chemotherapeutic drugs 
in a p53-dependent manner 
It was also investigated if OXAZ-1 increased the sensitivity of tumor cells to the effects 
of conventional chemotherapeutic drugs, such as doxorubicin and etoposide. For that, the 
tumor growth inhibitory effect of a very low concentration of OXAZ-1 (GI10 of 9 μM; for which 
no significant effects on tumor cell growth were observed), combined with increasing 
concentrations of doxorubicin and etoposide, was investigated in HCT116 cells. The results 
obtained revealed pronounced synergistic effects between OXAZ-1 and the tested 
conventional chemotherapeutic drugs in p53+/+, but not in p53-/-, HCT116 cells (Figure 
3.2.7A–C). In fact, in HCT116 p53+/+ cells, the Q values obtained, at the three tested 
concentrations of doxorubicin and etoposide, were higher than 1.15 (1.43 < Q < 2.22 for 
doxorubicin; 1.64 < Q < 2.22 for etoposide; Figure 3.2.7A). Interestingly, the best result 
obtained corresponded to the lowest concentrations tested of doxorubicin and etoposide. 
Accordingly, synergistic effects between OXAZ-1 and the lowest concentrations tested of 
doxorubicin (9.38 nM) and etoposide (0.38 μM) were obtained in the analysis of total 
apoptosis by Annexin V in HCT116 p53+/+ cells (Figure 3.2.7B). Contrary, OXAZ-1 did not 
significantly interfere with the tumor growth inhibitory effect of doxorubicin and etoposide 
for the three tested concentrations of these chemotherapeutic drugs in p53-null HCT116 
cells (Figure 3.2.7C). Altogether, the results obtained showed a p53-dependent synergistic 
effect of OXAZ-1 with conventional chemotherapeutic drugs. 
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Figure 3.2.7. OXAZ-1 sensitizes HCT116 p53+/+ tumor cells to the effects of doxorubicin and 
etoposide. (A) HCT116 p53+/+ tumor cells were treated with increasing concentrations of doxorubicin 
(9.38–37.5 nM) or etoposide (0.38–3.00 μM) and 9 μM (GI10 concentration) of OXAZ-1 or DMSO 
only (control). Effect of compounds on tumor cell growth was analyzed after 48 h incubation, using 
the SRB assay; the percentage of cell growth achieved with OXAZ-1 only was 90.6%; data are 
mean ± S.E.M. of four independent experiments. (B) Effect of combined treatment on apoptosis was 
determined after 48 h treatment with a fixed concentration of doxorubicin (9.38 nM) or etoposide 
(0.38 μM) and the GI10 concentration of OXAZ-1 or DMSO only (control). The percentage of apoptotic 
cells achieved with OXAZ-1 only was 1.5%; apoptosis was analyzed by flow cytometry using FITC-
Annexin V and PI; data are mean ± S.E.M. of three independent experiments. (C) HCT116 
p53−/− tumor cells were treated with increasing concentrations of doxorubicin (18.75–150 nM) or 
etoposide (0.75–6.00 μM) and 9 μM OXAZ-1 or DMSO only (control). Effect of compounds on tumor 
cell growth was analyzed after 48 h incubation, using the SRB assay; the percentage of cell growth 
achieved with OXAZ-1 only was approximately 100%; data are mean ± S.E.M. of four independent 
experiments. In A and B, the Q values are indicated for combined treatments of OXAZ-1/doxorubicin 
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and OXAZ-1/etoposide; Q < 0.85, Q > 1.15 and 0.85 < Q < 1.15 indicate antagonism, synergy and 
additive effects, respectively; dotted line represents Q = 1.15. 
 
 
 Discussion 
In this work, a yeast-based screening assay was used to search for inhibitors of the 
p53 interaction with MDM2 and MDMX. From the analysis of a small library of enantiopure 
tryptophanol-derived oxazolopiperidone lactams, the (S)-tryptophanol derivative OXAZ-1 
was identified as potential dual inhibitor of the p53-MDMs interaction. The study of this 
compound in human tumor cell lines supported the results from yeast, showing that OXAZ-
1 was able to block the MDM2 and MDMX interaction with p53. Beyond that, it was shown 
that the in vitro tumor growth inhibitory effect of OXAZ-1 was highly dependent on p53 and 
exhibited typical hallmarks of an inhibitor of the p53 interaction with MDM proteins (Wade 
et al., 2013). Particularly, it led to p53 stabilization, what is consistent with an inhibition of 
the MDM2-mediated p53 degradation by OXAZ-1, and up-regulated p53 transcriptional 
targets. Additionally, like RO-5963 (Graves et al., 2012), OXAZ-1 efficiently reduced the 
proliferation of wt p53-carrying tumor cells with high levels of MDMX (MCF-7 cells). In fact, 
also in MDMX-overexpression tumor cells, OXAZ-1 induced cell cycle arrest and apoptosis 
through activation of the p53 transcriptional activity. OXAZ-1 therefore overcame the 
commonly reported (Graves et al., 2012; Patton et al., 2006; Wade et al., 2006) resistance 
of MDMX-overexpression tumors to MDM2-only inhibitors. 
Cancer cell mitochondria are structurally and functionally different from normal cells. 
Additionally, tumor cells are more susceptible to mitochondrial perturbations than normal 
cells. Based on this, mitochondrially-targeted agents have emerged as a promising 
approach to selectively eradicate chemotherapy-refractory cancer cells (Fulda et al., 2010). 
In fact, the activation of cell death programs by pharmacological agents that induce or 
facilitate mitochondrial membrane permeabilization (MMP) has emerged as an attractive 
strategy for cancer treatment (Fulda et al., 2010). MMP can be triggered by agents that 
increase cytosolic calcium or stimulate ROS generation. Moreover, MMP can be favored by 
pro-apoptotic proteins of the Bcl-2 family, such as BAX. In fact, during apoptosis, BAX is 
translocated from the cytosol to mitochondria where it triggers MMP (Fulda et al., 2010; 
Chipult et al., 2004). MMP results in the immediate Δψm dissipation, with the consequent 
release of pro-apoptotic factors into the cytosol, such as cyt c (Fulda et al., 2010). The 
results obtained in the present work showed that OXAZ-1 also targets mitochondria of tumor 
cells. Actually, OXAZ-1 potently triggered a mitochondrion-centered p53-dependent 
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apoptotic cell death characterized by ROS generation, BAX translocation to mitochondria, 
Δψm dissipation, and mitochondrial cyt c release. 
The pharmacological activation of the p53 pathway can be exploited in combination 
therapy with non-targeted genotoxic agents to protect from side effects of 
chemotherapy (Wang et al., 2014), or to promote cell death via p53-dependent 
mechanisms (Hoe et al., 2014). In fact, examples were already reported showing the 
efficacy of such combinations in anticancer treatment. This is the case of Nutlin-3a, which 
has shown excellent results when combined with non-targeted genotoxic agents (Wade et 
al., 2013; Hoe et al., 2014). In this work, very low concentrations of OXAZ-1 exhibited 
pronounced p53-dependent synergistic effects with chemotherapeutic drugs such as 
etoposide and doxorubicin, strengthening the potential antitumor activity of OXAZ-1. 
Actually, the prospect of combining conventional chemotherapeutic agents with OXAZ-1 in 
cancer therapy represents a promising strategy to minimize the emergence of resistance 
and to achieve maximal therapeutic responses with minimal side effects. 
Although further work is still required to completely clarify the molecular targets of (S)-
tryptophanol derivative OXAZ-1, particularly its interaction with MDM2 and MDMX, relevant 
insights on its mode of action are already provided in this study (Figure 3.2.8). This work 
opens the way to a new class of selective activators of the p53 pathway through dual 
inhibition of the p53 interaction with MDM proteins, based on a tryptophanol-derived 
oxazolopiperidone lactam scaffold, with promising antitumor properties either alone or in 
combined therapies.  
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Figure 3.2.8. Proposed molecular mechanism of action of (S)-tryptophanol derivative OXAZ-1 
in human tumor cells. As a dual inhibitor of the p53 interaction with MDM2 and MDMX, OXAZ-1 
leads to p53 stabilization and to the activation of p53 transcriptional activity, increasing the levels of 
the p53 target proteins MDMX, MDM2, p21, BAX and PUMA. The increase of p21 leads to a G0/G1 
cell cycle arrest. The increase of BAX and PUMA leads to the activation of a mitochondrial apoptotic 
pathway, involving BAX translocation to mitochondria, ROS generation, Δψm dissipation, and 
cyt c from mitochondria, with the subsequent  activation of a caspase pathway with PARP cleavage; 
*p53 target genes. 
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In an attempt to find potent dual inhibitors of p53-MDMs interactions with in vivo 
antitumor activity, a hit-to-lead optimization was performed, in Santo’s lab, based on our 
previous results with reactivators of p53 activity. This led to a library of tryptophanol derived-
oxazoloisoindolinone derivatives screened in this work for their ability to inhibit the p53 
interaction with MDMs.  
 
 
 Identification of DIMP53-1 as potential dual inhibitor of p53-MDMs 
interactions, using yeast-based screening assays 
The ability of a library of tryptophanol derived-oxazoloisoindolinones to inhibit the p53-
MDMs interactions was tested using the previously described yeast-based screening 
assays (Leão et al., 2013b,c). With this approach, the effect of 0.1 - 50 M of tryptophanol 
derived-oxazoloisoindolinones was evaluated on p53-MDMs interactions (data not shown), 
and DIMP53-1 (Figure 3.3.1) was selected as a potential dual inhibitor of these protein-
protein interactions (Figure 3.3.2A). Actually, the obtained EC50 values revealed that 
DIMP53-1 potently inhibited both p53-MDMs (Figure 3.3.2B). Interestingly, the highest 
potency was observed on p53-MDMX interaction, where DIMP53-1 showed to be more 
potent than the positive control (Figure 3.3.2B). Additionally, DIMP53-1 did not interfere with 
the growth of control yeast and yeast expressing p53, MDM2 or MDMX alone (Figure 
3.3.2C), revealing a selective effect of DIMP53-1 on human protein-protein interactions. 
 
 
 
 
 
 
 
 
Figure 3.3.1. Chemical structure of DIMP53-1. 
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Figure 3.3.2. Identification of DIMP53-1 as potential dual inhibitor of p53-MDMs interactions. 
(A) Effect of 0.1–50 µM DIMP53-1, Nutlin-3a and SJ-172550 on the reversion of p53-induced yeast 
growth inhibition by MDM2 and MDMX, after 42 h incubation; results were plotted setting as 100% 
the growth achieved with yeast cells expressing p53 alone incubated with DMSO only; data are mean 
± S.E.M. of six independent experiments; values significantly different from DMSO only are indicated 
(***p < 0.001). (B) EC50 values of DIMP53-1, Nutlin-3a and SJ-172550 obtained from 0.1 – 50 μM 
concentration–response curves of the reversion of MDM2/MDMX-inhibitory effects. (C) Effect of 0.1 
– 50 µM DIMP53-1 on the growth of yeast expressing p53, MDMX or MDM2 alone, and of yeast 
transformed with the empty vector after 42 h incubation; results were plotted setting as 100% the 
growth achieved with DMSO only; data are mean ± S.E.M. of five independent experiments; values 
are not significantly different from DMSO only (p > 0.05). 
 
 DIMP53-1 has a p53-dependent tumor growth inhibitory effect mediated 
by dual inhibition of p53-MDMs interactions  
To confirm the molecular mechanism of action of DIMP53-1 as dual inhibitor of p53-
MDMs interactions, the effect of this compound was ascertained in human p53+/+ and p53-
/- HCT116 colon adenocarcinoma cells. The obtained GI50 values showed a significant 
reduction (from 7.0 to 17.3 μM) of the DIMP53-1 tumor growth inhibitory effect, when the 
p53 pathway was knocked out in HCT116 p53-/- cells (Figure 3.3.3A).  
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Figure 3.3.3. DIMP53-1 growth inhibitory effect is associated with cell cycle arrest, apoptosis 
and up-regulation of p53 target genes by blocking the p53 interaction with MDMs in HCT116 
p53+/+ cells. (A) GI50 values of DIMP53-1 in p53+/+ and p53-/- HCT116 cells, after 48 h treatment; 
data are mean ± S.E.M. of four independent experiments; values significantly different from HCT116 
p53+/+ cells are indicated (**p < 0.01). (B) Cell cycle arrest and (C) apoptosis were determined at 7 
μM  and  14 μM (2×GI50, 2×DIMP53-1) of DIMP53-1 after 24 h treatment in p53+/+ and p53-/- HCT116 
cells; data are mean ± S.E.M. of three independent experiments; values significantly different from 
DMSO are indicated (*p < 0.05; **p < 0.01; ***p < 0.001). (D) Western blot analysis was performed 
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after 24 h (MDM2) and 48 h (p53, MDMX, BAX, PUMA, p21) treatment with 7 μM  DIMP53-1 or 
DMSO only in p53+/+ and p53-/- HCT116 cells. (E) PARP cleavage was analyzed by Western blot 
after 24 h treatment with 7 μM  DIMP53-1 or DMSO only in p53+/+ and p53-/- HCT116 cells. (F) Co-
immunoprecipitation was performed with anti-p53 (IP: p53) or anti-immunoglobulin G (IgG) 
antibodies, followed by immunoblotting with anti-MDM2, anti-MDMX and anti-p53 antibodies in 
HCT116 p53+/+ cells treated with 7 and 14 μM DIMP53-1 or DMSO only for 24 h; whole cell lysate 
(Input). In (D), (E) and (F) immunoblots are representative of three independent experiments; 
GAPDH was used as loading control. 
 
 
Additionally, this compound was tested in two breast cancer cell lines (MDA-MB-231 
and MDA-MB-468 cells), both expressing mutant p53 forms. Accordingly, the obtained GI50 
values were much higher when compared to wt p53-expressing tumor cells (84.3 ± 7.8 μM 
for MDA-MB-231 cells; 37.5 ± 3.5 μM for MDA-MB-468 cells, n = 4). Together, these results 
revealed a wt p53-dependent tumor growth inhibitory effect by DIMP53-1. It was also 
verified that the growth inhibitory effect of DIMP53-1 in HCT116 p53+/+ cells, at 7 and 14 μM 
(2xGI50), was associated with G0/G1-phase cell cycle arrest (Figure 3.3.3B), apoptosis 
(Figure 3.3.3C), and PARP cleavage (Figure 3.3.3E), which were not observed in p53-null 
HCT116 cells. Additionally, by western blot analysis, it was shown that DIMP53-1 led to p53 
stabilization, and to the up-regulation of major p53 transcriptional targets, as revealed by 
the increased protein levels of MDM2, MDMX, BAX, PUMA and p21 in p53+/+, but not in 
p53-/-, HCT116 cells (Figure 3.3.3D). 
The ability of DIMP53-1 to block the p53 interaction with MDM2 and MDMX was 
thereafter demonstrated by co-IP assay, in HCT116 p53+/+ cells. In fact, at 7 and 14 μM, a 
visible decrease in the amount of MDM2 and MDMX co-immunoprecipitated with p53 was 
observed (Figure 3.3.3F). Altogether, these results revealed that DIMP53-1 is an activator 
of the p53 pathway through dual inhibition of the p53-MDMs interactions in human tumor 
cells. 
The effect of DIMP53-1 was further investigated in two other human wt p53-
expressing tumor cells overexpressing MDM2 (osteosarcoma SJSA-1 cells) and MDMX 
(breast adenocarcinoma MCF-7 cells). Despite slightly less potent than in HCT116 p53+/+ 
cells, a considerable growth inhibitory effect was obtained with DIMP53-1 in both tumor 
cells (Figure 3.3.4A). As in HCT116 p53+/+ cells, this growth inhibitory effect conducted by 
DIMP53-1 was associated with cell cycle arrest (at G0/G1- and S-phases in SJSA-1; at 
G0/G1-phase in MCF-7 cells; Figure 3.3.4B) and apoptosis (Figure 3.3.4C) at GI50 (11.8 ± 
0.7 μM for SJSA-1; 13.3 ± 0.5 μM for MCF-7) and 2xGI50 concentrations, and with PARP 
cleavage at the GI50 concentration (Figure 3.3.4D). Moreover, in both SJSA-1 and MCF-7 
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tumor cells, the GI50 concentration of DIMP53-1 led to p53 stabilization (Figure 3.3.4D), and 
to the up-regulation of several p53 transcriptional targets, as demonstrated by the increased 
protein levels of MDM2, MDMX, BAX and p21 (Figure 3.3.4D). Overall, this set of results 
demonstrated that DIMP53-1 also activated p53 in tumor cells with a wt p53 pathway mostly 
inhibited by MDM2 or MDMX. 
 
 
 
Figure 3.3.4. DIMP53-1 growth inhibitory effect is associated with cell cycle arrest, apoptosis 
and up-regulation of p53 target genes in MDM2- (SJSA-1) and MDMX- (MCF-7) overexpressing 
tumor cells. (A) GI50 concentration of DIMP53-1 in SJSA-1 and MCF-7 cells, after 48 h treatment; 
data are mean ± S.E.M. of four independent experiments. (B) Cell cycle arrest and (C) apoptosis 
were determined at GI50 (11.8 ± 0.7 μM for SJSA-1; 13.3 ± 0.5 μM for MCF-7) and 2×GI50 
concentrations of DIMP53-1, after 24 h treatment; data are mean ± S.E.M. of three independent 
experiments; values significantly different from DMSO are indicated (*p < 0.05; **p < 0.01; ***p < 
0.001). (D) Western blot analysis was performed after 24 h (cleaved PARP, MDMX and p21) and 48 
h (p53, MDM2, BAX) treatment with GI50 concentration of DIMP53-1 or DMSO only. In (D) and (E) 
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immunoblots are representative of three independent experiments; GAPDH was used as loading 
control. 
 
 DIMP53-1 prevents in vitro tumor cell migration 
The impact of DIMP53-1 on the invasive ability of HCT116 p53+/+ cells was 
investigated by migration assays. In the Wound Healing Scratch assay, 3 M (GI10) 
DIMP53-1 inhibited the HCT116 p53+/+ cell migration, and the subsequent wound closure, 
when compared to cells treated with DMSO only (Figure 3.3.5A). These results were further 
confirmed using the Chemotaxis Cell Migration assay, in which 3 M DIMP53-1 led to a 
pronounced reduction of HCT116 p53+/+ cell migration, compared to DMSO only, upon 24 
h treatment (Figure 3.3.5B). Together, these results demonstrated that DIMP53-1 was able 
to inhibit the migration of human colon adenocarcinoma cells. 
 
 
 
Figure 3.3.5. DIMP53-1 prevents the migration of HCT116 p53+/+ cells. (A) HCT116 p53+/+ 
confluent cells treated with 3 µM DIMP53-1 (or DMSO only) were observed at different time-points 
in the Wound Healing assay. (B) Effects of 3 µM (GI10) DIMP53-1 on the migration of HCT116 p53+/+ 
cells for 24 h, analyzed by the chemotaxis assay; the migratory cells were quantified by fluorescence 
signal, set as 1 cells treated with DMSO only; data are mean ± S.E.M. of three independent 
experiments. 
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 DIMP53-1 has no in vitro toxicity in human non-tumorigenic cells 
The cytotoxicity and genotoxicity of DIMP53-1 were investigated in human non-
tumorigenic cells. For that, the growth inhibitory effect of DIMP53-1 in non-tumorigenic 
human breast epithelial MCF10A cells was assessed by SRB assay. The obtained GI50 
concentration of DIMP53-1 in MCF10A was higher than 50 M (maximum concentration 
tested), what indicated a selective cytotoxicity of DIMP53-1 to tumor cells. Additionally, the 
genotoxicity of DIMP53-1 was tested by assessing its ability to induce micronucleus (MN) 
in cultured peripheral lymphocytes of normal individuals. When compared to samples 
treated with DMSO only, 7, 14 and 21 μM DIMP53-1 did not increase the number of MN in 
lymphocytes (Figure 3.3.6). These results showed that DIMP53-1 had no apparent in vitro 
genotoxicity. 
 
 
Figure 3.3.6. DIMP53-1 has no in vitro genotoxicity. Genotoxicity of 7, 14 and 21 M DIMP53-1 
by cytokinesis-block micronucleus (MN) assay after 72 h treatment in human lymphocyte cells. Cells 
treated with 5 g/mL cyclophosphamide were used as positive control (C+); data are mean ± S.E.M. 
of three independent experiments; values significantly different from DMSO only are indicated (**p < 
0.01). 
 
 
 DIMP53-1 has in vivo antitumor activity without apparent toxicity 
The in vivo antitumor potential of DIMP53-1 was evaluated using human tumor 
xenograft mice models of p53+/+ and p53-/- HCT116 tumor cells. Four intraperitoneal 
administrations (twice a week) of 50 mg/kg DIMP53-1 inhibited the growth of HCT116 p53+/+ 
tumors (Figure 3.3.7A) compared to control (vehicle). Conversely, using the same 
conditions, DIMP53-1 did not interfere with the growth of HCT116 p53-/- tumor xenografts, 
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what further reinforced its p53-dependent antitumor activity (Figure 3.3.7A). Furthermore, 
no significant loss of body weight or morbidity signs were observed in DIMP53-1-treated 
mice compared to control (Figure 3.3.7B). 
 
 
 
Figure 3.3.7. DIMP53-1 has a p53-dependent antitumor activity in vivo. (A) BALB/c nude mice 
carrying HCT116 p53+/+ or HCT116 p53-/- xenografts treated with 50 mg/kg DIMP53-1 or vehicle 
(control); values significantly different from control mice are indicated (*p < 0.05, **p < 0.01, ***p < 
0.001). (B) BALB/c nude mice body weight during DIMP53-1 treatment; values are not significantly 
different from control (p > 0.05). 
 
 
In order to evaluate some primary toxicity signs, DIMP53-1 was tested in Wistar rats. 
Following the same administration procedure to that conducted in tumor xenograft mice 
models, organs relative weight (trophism), as well as biochemical and hematological data 
were analyzed for the three rat groups (saline, vehicle and DIMP53-1; Table 3.3.1). No 
differences between the three groups on relative weight of liver, kidneys, heart and spleen 
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were observed. Concerning biochemical data, only a slight decrease of urea in the vehicle 
group compared to saline group, and a slight increase of uric acid in the DIMP53-1 group 
compared to control groups (saline and vehicle groups) was observed. These results 
indicated no apparent liver or kidney toxicity by DIMP53-1. Regarding hematological data, 
just a small increase on the reticulocytes number was observed in vehicle group compared 
to saline group, with no alterations between DIMP53-1 and the other two control groups. 
Overall, no apparent toxic side effects were observed for DIMP53-1 on the tissues most 
commonly affected by conventional chemotherapeutics. 
 
 
Table 3.3.1. Safety profile for the three mice groups under study at the final time point. 
 Saline Vehicle Treated 
Body weight and relative tissue weight (trophism) 
BW (g) 340.30 ± 13.45 361.80 ± 0.01 353.25 ± 3.99 
Heart/BW (g/kg) 3.03  ± 0.03 3.01 ± 0.09 3.19 ± 0.12 
Liver/BW (g/kg) 38.71 ± 2,36 38.52 ± 0.89 40.72 ± 1.14 
Kidney/BW (g/kg) 7.08 ± 0.40 6.81 ± 0.27 6.96 ± 0.32 
Spleen (g/kg) 2.10 ± 0.20 2.15 ± 0.12 2.07 ± 0.20 
Biochemical data  
Blood Glucose(mg/dL) 188.0 ± 7.51 207.20 ± 7.00 242.25 ± 25.68 
Urea (mg/dL) 20.67 ± 0.77 18.34 ± 0.24* 19.10 ± 0.62 
Uric acid (mg/dL) 1.07 ± 0.07 0.82 ± 0.10 4.10 ± 0.50* 
Creatinine (mg/dL) 0.30 ± 0.00 0.30 ± 0.01 0.36 ± 0.03 
Total Proteins (g/dL) 5.50 ± 0.00 5.35 ± 0.17 6.38 ± 0.40 
Albumin (g/dL) 3.03 ± 0.03 2.90 ± 0.05 3.13 ± 0.03 
ALT (U/L) 36.00 ± 2.89 30.75 ± 3.30 35.00 ± 1.87 
AST (U/L) 95.33 ± 25.36 56.25 ± 4.60 115.75 ± 20.89  
Total Chol (mg/dL) 44.33 ± 1.76 52.40 ± 3.54 54.00 ± 3.37 
Triglycerides (mg/dL) 107.00 ± 16.29 161.40 ± 17.55 229.50 ± 26.70 
Hematological data 
RBC count (x106/µL) 7.10 ± 0.15 7.41 ± 0.28 8.23 ± 0.24 
HGB (g/dL) 13.97 ± 0.18 13.95 ± 0.46 14.68 ± 0.28 
HCT (%) 40.50 ± 0.82 42.28 ± 2.03 47.85 ± 1.87 
WBC counts (x103/µL) 1.93 ± 0.68 2.15 ± 0.88 1.05 ± 0.26 
PLT counts (x103/µL) 811.00 ± 29.61 793.80 ± 28.35 726.75 ± 47.43 
RET counts (%) 2.80 ± 0.12 3.56 ± 0.23* 3.59 ± 0.31 
 
The results are expressed as mean ± S.E.M. of four independent experiments; *p < 0.05 versus 
Saline group; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BW, body weight; 
CK, Creatine Kinase; HCT, hematocrit; HGB,  Hemoglobin concentration; PCT, plateletcrit; PLT, 
platelet; RBC, red blood cell count; RET, reticulocytes; WBC, white blood cell. 
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Figure 3.3.8. DIMP53-1 increases apoptosis and reduces the proliferative activity and tumor 
angiogenesis of human HCT116 p53+/+ tumor xenografts. (A) Representative images of Ki-67, 
BAX, DNA fragmentation (TUNEL), CD34 and VEGF detection in human HCT116 p53+/+ and 
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HCT116 p53-/- xenograft tumor tissues inoculated in BALB/c nude mice treated with 50 mg/kg 
DIMP53-1 or vehicle (Scale bar = 5 m; Magnification 400x). (B) Microvessel density (MVD; 
expressed as number of vessels/mm2 relative to control) of  human HCT116 p53+/+ and HCT116 p53-
/- xenograft tumor tissues inoculated in BALB/c nude mice treated with 50 mg/kg DIMP53-1 or vehicle; 
values significantly different from control mice are indicated (*p < 0.05). 
 
 
The subsequent analysis of tumor tissues was performed to check in vivo antitumor 
events promoted by DIMP53-1. For that, proliferation, apoptotic and angiogenic markers 
were assessed in HCT116 p53+/+ tumors by immunohistochemistry and TUNEL staining 
(Figure 3.3.8A). DIMP53-1-treated HCT116 p53+/+ tumors showed low Ki-67-positive 
staining (indicative of a reduced proliferative status) compared to tumors treated with 
vehicle only (Figure 3.3.8A). The induction of apoptosis in DIMP53-1-treated tumor tissues 
was evidenced by the increase of BAX expression levels and of TUNEL-positive staining 
(indicative of nuclei DNA fragmentation), compared to tumors treated with vehicle only 
(Figure 3.3.8A). To study the angiogenic profile of tumor tissues, the vascular endothelial 
growth factor (VEGF; an angiogenesis inducing factor) and CD34 (a marker to detect newly 
formed vessels) were checked, and the Microvessel Density (MVD) was determined. The 
obtained results revealed low levels of VEGF, CD34 and MVD in DIMP53-1-treated HT116 
p53+/+ tumor tissues compared to tumors treated with vehicle only (Figures 3.3.8A and B). 
Particularly, an approximately five-fold reduction of MVD in DIMP53-1-treated tumors 
compared to control tumors was observed (Figure 3.3.8B). These results indicated an 
inhibition of angiogenesis by DIMP53-1. Conversely, no apparent differences in these 
markers were observed between DIMP53-1-treated and untreated HCT116 p53-/- tumors 
(Figures 3.3.8A and B). Actually, these tumors were characterized by high levels of Ki-67, 
CD34, VEGF and MVD, and by low levels of BAX and DNA fragmentation (Figure 3.3.8A 
and B). 
 
 
 Discussion 
Several anticancer strategies have been devised to rectify a dysfunctional p53 
pathway, particularly due to the overexpression of MDM2 and MDMX. The simultaneous 
inhibition of the p53 interaction with both MDMs has gained increasing attention as the most 
efficient anticancer therapeutic strategy, since it will conduct to a full p53 reactivation in wt 
p53-expressing tumor cells (Li and Lozano, 2013). Despite this, the number of dual 
inhibitors of p53-MDMs interactions identified so far remains very limited. 
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In this work, a yeast-based assay was used to screen for inhibitors of p53-MDMs 
interactions from a library of tryptophanol derived-oxazoloisoindolinones. From this 
analysis, the compound DIMP53-1 emerged as a potential dual inhibitor of p53-MDMs 
interactions. The molecular mechanism of action of DIMP53-1 was validated both in vitro 
tumor cell lines and in vivo tumor xenograft models. In fact, using human-derived isogenic 
tumor cells with and without p53, it was verified that the tumor cell growth inhibitory effect 
of DIMP53-1 was dependent on p53. Consistently, the anti-proliferative effect of DIMP53-1 
was associated with the induction of p53-dependent cell cycle arrest and apoptosis, p53 
stabilization, which is an indicative of inhibition of the MDM2-mediated p53 degradation, 
and up-regulation of several p53 transcriptional targets. Finally, it was confirmed that 
DIMP53-1 was able to block the p53-MDMs interactions in tumor cells. This in vitro 
antitumor potential of DIMP53-1 was further confirmed in wt p53-expressing tumor cells 
overexpressing either MDM2 or MDMX. Actually, DIMP53-1 overcame the frequently 
reported resistance of MDMX-overexpressing tumor cells to MDM2-only inhibitors as Nutlin-
3a (Graves et al., 2012; Li and Lozano, 2013).  
The loss of p53 function is closely related to the development of metastatic 
phenotypes (Powell et al., 2014), which is the most frequent cause of mortality (90%) in 
cancer patients (Spano et al., 2012). Actually, p53 can regulate the transcription of several 
genes involved in cell motility and adhesion, signal transduction, extracellular matrix and 
cytoskeleton organization, which are processes involved in cell migration and invasion 
(Powell et al., 2014; Roger et al., 2006). The p53 loss seems to contribute to the loosening 
of cell–cell junctions and to the disruption of epithelial cell integrity, contributing to the 
dissemination of cells from solid tumors. One example of a protein whose expression is 
directly regulated by p53 is KAI-1/CD82, a member of the tetraspanin or transmembrane 4 
superfamily, which suppresses cancer metastasis by inhibiting cell migration and invasion 
(Powell et al., 2014). Based on this, it is expected that the restoration of p53 function will 
lead to tumor regression and metastasis prevention. Consistently, the results obtained in 
this work revealed that low doses of DIMP53-1 prevented the migration of wt p53-
expressing tumor cells.  
In human tumor xenograft mice models, the p53-dependent antitumor activity of 
DIMP53-1 was further confirmed. In fact, DIMP53-1 suppressed the growth of wt p53-
expressing tumors, through inhibition of proliferation and induction of apoptosis, without 
interfering with the growth of p53-null tumor xenografts. Besides that, no apparent toxic side 
effects were observed for DIMP53-1 both in vitro and in vivo. Interestingly, in this work, the 
anti-angiogenic activity of DIMP53-1 was also demonstrated in wt p53-expressing tumor 
xenografts. Angiogenesis is a relevant hallmark of cancer since proliferation and metastatic 
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spread of cancer cells depend on an adequate supply of oxygen and nutrients (Baeriswyl 
and Christofori, 2009). The p53 activity is negatively correlated with this process through 
indirect inhibition of key proteins, such as VEGF. In fact, it was demonstrated that wt p53 
indirectly represses VEGF expression by interaction and inhibition of transcription factors 
such as SP1 and E2F (Pal et al., 2001; Qin et al., 2006). In this way, the p53 activation, 
namely by DIMP53-1, prevents angiogenesis.  
In conclusion, this work reports the identification of a selective activator of the p53 
pathway through dual inhibition of the p53-MDMs interactions. The impact of DIMP53-1 on 
main four hallmarks of cancer, namely through its anti-proliferative, pro-apoptotic, anti-
angiogenic and anti-metastatic potential, make this small molecule an appealing anticancer 
drug candidate. 
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To date, few small-molecule reactivators of mutant p53 have been identified. Aiming 
at the discovery of new reactivators, in this work a new cell-based screening strategy was 
developed and used to test a chemical library of tryptophanol-derived 
oxazoloisoindolinones. 
 
 
4.1. Development of a yeast-based screening assay to search for reactivators 
of mutant p53 
A yeast-based screening assay, consisting of Saccharomyces cerevisiae cells 
expressing human wt p53 or mutant p53 (R280K or Y220C; two of the most prevalent forms 
of human mutant p53; Petitjean et al., 2007b), was developed to search for mutant p53 
reactivators (Figure 4.1A and B). This assay was established based on the yeast growth 
inhibitory effect induced by wt p53, not observed with mutant forms of p53 (Leão et al., 
2013c; Figure 4.1C). Based on this phenotypic readout, mutant p53 reactivators would 
reestablish the wt p53-dependent growth inhibition. Since, to date, mutant p53R280K 
reactivators remain unknown, the mutant p53Y220C reactivator PhiKan083 (Boeckler et al., 
2008) was used as positive control to attest the efficacy of the yeast assay (Figure 4.1C). 
As expected, 50 M PhiKan083 restored the wt p53-induced yeast growth inhibition to 
mutant p53Y220C (in about 63%; Figure 4.1C). 
 
 
 
 
Figure 4.1. Yeast-based screening assay to search for reactivators of mutant p53 R280K and 
Y220C. (A) Schematic representation of the developed yeast-based screening assay. (B) 
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Immunoblots of human wt p53, mutant p53R280K and mutant p53Y220C expressed in yeast after 
30 h incubation in selective induction medium (representative of three independent experiments). 
(C) Contrary to wt p53, both mutant p53 R280K and Y220C do not present growth inhibition in the 
presence of DMSO. 50 µM PhiKan083 increase mutant p53Y220C-induced growth inhibition, after 
30 h; results were plotted setting as 1 the growth inhibitory effect of wt p53-expressing cells treated 
with DMSO only; data are mean ± S.E.M. of five independent experiments.  
 
 
4.2. Identification of SLMP53-1 as activator of wt p53 and reactivator of 
mutant p53R280K from a library of tryptophanol derived 
oxazoloisoindolinones using the yeast-based screening assay 
This yeast assay was thereafter used to evaluate the effect of synthesized 
enantiopure tryptophanol-derived oxazoloisoindolinones on wt and mutant p53 activity. 
These compounds were synthesized following our interest in enantiopure biologically active 
amino alcohol-derived compounds (Pereira et al., 2013; Pereira et al., 2014), and on our 
previous discovery compounds with in vitro p53-dependent antitumor activity (Chapter 3). 
With this new library, we intended to study the effect on p53 activity of the replacement of 
the phenyl moiety (present in our first set of compounds; Soares et al., 2015) by an indole 
moiety. Among the compounds tested, SLMP53-1 behaved as activator of wt p53 and 
reactivator of mutant p53R280K (Figure 4.2B and C). Actually, at 10 M (lowest 
concentration, from a range of 1 – 50 M, that caused a maximal effect; data not shown) 
SLMP53-1 increased the wt p53-induced yeast growth inhibition and restored the wt-like 
growth inhibitory effect to mutant p53R280K (in about 79%; Figure 4.2B), without interfering 
with the growth of control yeast (data not shown). Consistently, 10 M SLMP53-1 increased 
the S- and G2/M-phases cell cycle arrest in wt p53-expressing yeast, and reestablished the 
wt-like cell cycle arrest in mutant p53R280K-expressing yeast (Figure 4.2C). Interestingly, 
1 - 50 µM SLMP53-1 did not interfere with the growth of mutant p53Y220C-expressing yeast 
(Figure 4.2B).  
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Figure 4.2. SLMP53-1 activates wt p53 and restores the wt-like activity to mutant p53R280K in 
yeast. (A) Synthesis of SLMP53-1 and chemical structure of its enantiomer. (B) Increase of wt and 
mutant p53R280K-induced growth inhibition by 10 μM SLMP53-1, after 30 h; results were plotted 
setting as 1 the growth inhibitory effect of wt p53-expressing cells treated with DMSO only; data are 
mean ± S.E.M. of five independent experiments. (C) Increase of wt and mutant p53R280K-induced 
yeast cell cycle arrest by 10 μM SLMP53-1; data are mean ± S.E.M. of three independent 
experiments. In B and C, values significantly different from DMSO only are indicated: *p < 0.05, **p 
< 0.01.  
 
 
4.3. Growth inhibitory effect of SLMP53-1 on wt p53- and mutant p53R280K-
expressing tumor cells is mediated by p53-dependent cell cycle arrest 
and/or apoptosis 
The growth inhibitory potential of SLMP53-1, and the contribution of the p53 pathway 
to its activity, were ascertained in p53+/+ and p53-/- HCT116 tumor cells. A significant 
difference between the GI50 values obtained in p53+/+ (~16 M) and p53-/- (~34 M) HCT116 
cells indicated an involvement of p53 in the growth inhibitory effect of SLMP53-1 (Figure 
4.3A). Conversely, no significant differences were observed between the GI50 values of 
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PRIMA-1 in p53+/+ and p53-/- HCT116 cells (Figure 4.3A). In our experimental conditions, 
the GI50 value of PhiKan083 in HCT116 cells was higher than 150 M.  
 
 
 
 
Figure 4.3. SLMP53-1 growth inhibitory effect in human wt p53- and mutant p53R280K-
expressing tumor cells is mediated by p53-dependent cell cycle arrest and/or apoptosis. (A) 
GI50 value of SLMP53-1 in HCT116 cells, after 48 h treatment; values significantly different are 
indicated: **p<0.01. (B) Cell cycle, (C) Apoptosis and (D) PARP cleavage after 24 h with 16 µM 
SLMP53-1 in HCT116 cells. (E) GI50 value for SLMP53-1 in MDA-MB-231 (mutant p53R280K) and 
HuH-7 (mutant p53Y220C) cells, after 48 h treatment. (F) Cell cycle, (G) Apoptosis and (H) PARP 
cleavage after 24 h with 16 µM SLMP53-1 in MDA-MB-231 cells. In A-C and E-G, data are mean ± 
S.E.M. of three to four independent experiments. In B, C and G, values significantly different from 
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DMSO only are indicated: *p < 0.05, **p < 0.01. In F, values are not significantly different from DMSO 
only: p > 0.05. 
 
 
The SLMP53-1 growth inhibitory effect was associated with G0/G1-phase cell cycle 
arrest (Figure 4.3B), and apoptosis (Figure 4.3C) in p53+/+, but not in p53-/-, HCT116 cells. 
The enhancement of PARP cleavage by 16 M SLMP53-1 in p53+/+, but not in p53-/-, 
HCT116 cells further corroborated the activation of a p53-dependent apoptotic pathway 
(Figure 4.3D).  
Consistent with the yeast results, SLMP53-1 also inhibited the growth of mutant 
p53R280K-expressing MDA-MB-231 cells with a GI50 value similar to that obtained in 
HCT116 p53+/+ cells (~16 M; Figure 4.3E). Moreover, it presented a much lower growth 
inhibitory activity against mutant p53Y220C-expressing HuH-7 cells (Figure 4.3E). When 
compared to PRIMA-1, SLMP53-1 presented a higher potency in MDA-MB-231 cells, but 
was less potent against mutant p53Y220C-expressing HuH-7 cells (Figure 4.3E). In our 
experimental conditions, the GI50 values of PhiKan083 in MDA-MB-231 and HuH-7 cells 
were higher than 150 M.  
Interestingly, in MDA-MB-231 cells, despite not interfering with cell cycle progression 
(Figure 4.3F), 16 M SLMP53-1 stimulated cell death, as revealed by the increase of late 
apoptosis (Figure 4.3G), and PARP cleavage (Figure 4.3H). 
 
 
4.4. SLMP53-1 selectively activates p53 transcriptional activity and 
reestablishes mutant p53R280K DNA binding ability 
The effect of SLMP53-1 on wt p53 and mutant p53R280K activity was investigated by 
analysis of the expression levels of proteins encoded by p53 target genes in HCT116 p53+/+, 
HCT116 p53-/-, and MDA-MB-231 cells.  
In HCT116 p53+/+ cells, 16 M SLMP53-1 increased the p53, MDM2, p21, PUMA and 
BAX protein expression levels (Figure 4.4A). Instead, the levels of these proteins were not 
significantly changed in p53-null HCT116 cells treated with 16 M SLMP53-1, supporting 
the p53-dependent activity of this small molecule (Figure 4.4A). Additionally, 16 M 
SLMP53-1 increased the mRNA levels of CDKN1A (p21) and TNFRSF10B (KILLER) in 
HCT116 p53+/+ cells (Figure 4.4B). The selective activation of p53 transcriptional activity by 
SLMP53-1 was further reinforced by a dual-luciferase gene reporter assay using p53+/+ and 
p53-/- HCT116 cells transfected with p21- or MDM2-luciferase reporter vectors. At 16 and 
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32 M (2GI50), SLMP53-1 increased the expression of the two p53 reporters in HCT116 
p53+/+ cells, while no effect was observed in HCT116 p53-/- cells (Figure 4.4C). 
 
 
 
 
Figure 4.4. SLMP53-1 reactivates the transcriptional activity of wt p53 in HCT116 p53+/+ cells 
and of mutant p53R280K, through reestablishment of its DNA binding ability, in MDA-MB-231 
cells. (A) Protein levels of p53 target genes, and (B) gene expression of CDKN1A (p21) and 
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TNFRSF10B (KILLER), after 24 h with 16 µM SLMP53-1 in HCT116 cells. In B, fold expression 
changes are relative to DMSO and correspond to mean ± S.E.M. of three independent experiments. 
(C) p53 transcriptional activity after 16 h with 16 and 32 µM (2×GI50) SLMP53-1 in HCT116 cells 
assessed by dual-luciferase gene reporter assay. Data are plotted as mean relative light units (RLU) 
± S.E.M. of three independent experiments; values significantly different from DMSO only are 
indicated: *p < 0.05, ***p < 0.001. (D) Protein levels of p53 target genes after 24 h with 16 µM 
SLMP53-1 in MDA-MB-231 cells. (E) DNA binding affinity of mutant p53R280K after 24 h with 32 
and 48 µM (3×GI50) SLMP53-1 in MDA-MB-231 cells; the signal obtained with DMSO only was set 
as 1; data are mean ± S.E.M. of three independent experiments; values significantly different from 
DMSO only are indicateed: ***p < 0.001. (F) PARP cleavage and protein levels of PUMA and BAX 
after 24 h with 16 µM SLMP53-1 in mutant p53R280K-silenced MDA-MB-231 cells. In A, D and F, 
immunoblots are representative of three independent experiments.  
 
 
 In MDA-MB-231 cells, 16 M SLMP53-1 increased MDM2, PUMA and BAX protein 
levels, with no apparent increase of p53 protein levels (Figure 4.4D). The lack of mutant 
p53 protein stabilization was already reported for other mutant p53 reactivators, and has 
been attributed to a reestablishment of the MDM2-mediated p53 degradation (Yu et al., 
2012). Moreover, consistent with the lack of effect on cell cycle progression, 16 M 
SLMP53-1 did not affect p21 protein levels (Figure 4.4D).  
The restoration of mutant p53R280K DNA binding ability by SLMP53-1 was assessed 
by TransAM DNA binding assay, using MDA-MB-231 cells. The results revealed a dose-
dependent enhancement of the amount of p53 bound to DNA by SLMP53-1 relative to cells 
treated with DMSO only (Figure 4.4E).  
To further demonstrate that the SLMP53-1 effects were dependent on mutant 
p53R280K in MDA-MB-231 cells, mutant p53R280K was knocked-down by p53siRNA. In 
cells transfected with non-specific siRNA (siRNA-NS; control), 16 M SLMP53-1 increased 
the protein levels of PUMA, BAX and cleaved PARP, as observed in non-transfected cells 
(Figure 4.4F). As expected, these SLMP53-1 effects were efficiently abolished by mutant 
p53 silencing (Figure 4.4F).  
 
 
4.5. SLMP53-1 triggers a p53-dependent mitochondrial apoptotic pathway in 
wt p53- and mutant p53R280K-expressing tumor cells 
In HCT116 p53+/+ and MDA-MB-231 cells, 16 M SLMP53-1 led to ∆ψm dissipation 
and ROS generation (Figure 4.5A). Consistent with p53-dependence, these effects were 
not observed in 16 M SLMP53-1-treated HCT116 p53-/- cells (Figure 4.5A). Additionally, in 
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HCT116 p53+/+ (Figure 4.5B) and MDA-MB-231 (Figure 4.5C) cells, 16 M SLMP53-1 
triggered BAX, wt p53 (Figure 4.5B) and mutant p53R280K (Figure 4.5C) mitochondrial 
translocation, and led to cyt c release to cytosol (Figure 4.5B and C). Altogether, these 
results showed that SLMP53-1 induced a p53-dependent mitochondrial apoptotic pathway 
in both wt p53- and mutant p53R280K-expressing tumor cells.  
 
 
 
 
Figure 4.5. SLMP53-1 triggers a p53-mediated mitochondrial apoptotic pathway in HCT116 
p53+/+ and MDA-MB-231 cells. (A) Cells were treated with 16 µM SLMP53-1 for 8 h (HCT116 cells) 
or 16 h (MDA-MB-231 cells) in ∆ψm analysis, and for 24 h in ROS analysis. FCCP was used as 
positive control in ∆ψm; histograms are representative of three independent experiments; M2 cursor 
indicates the subpopulation analyzed. Graphical representation: increase in the percentage of cells 
with ∆ψm dissipation and ROS generation; values are mean ± S.E.M. of three independent 
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experiments. (B) and (C) Immunoblots of wt/mutant p53, BAX and cyt c, in cytosolic and 
mitochondrial fractions of HCT116 p53+/+ (B) and MDA-MB-231 (C) cells after 16 h with 16 µM 
SLMP53-1. In B and C, immunoblots are representative of three independent experiments.  
 
 
4.6. SLMP53-1 inhibits the migration of wt p53- and mutant p53R280K-
expressing tumor cells 
The results obtained in the Wound Healing Assay showed that the GI10 concentration 
(4 M) of SLMP53-1 reduced the migration of HCT116 p53+/+ and MDA-MB-231 tumor cells 
(Figure 4.6A and B). These results were corroborated by the chemotaxis cell migration 
assay, in which the GI25 concentration (7 M) of SLMP53-1 led to over 50% reduction of 
HCT116 p53+/+ cell migration compared to DMSO only (Figure 4.6C). A similar result was 
obtained with the constitutively more motile MDA-MB-231 cells treated with 16 M SLMP53-
1 (Figure 4.6C). These data showed that SLMP53-1 inhibited the in vitro migration of both 
wt p53- and mutant p53R280K-expressing tumor cells.  
 
 
4.7. SLMP53-1 sensitizes wt p53- and mutant p53R280K-expressing tumor 
cells to conventional chemotherapeutics in a p53-dependent manner 
We investigated whether SLMP53-1 increased the sensitivity of HCT116 p53+/+ and 
MDA-MB-231 tumor cells to conventional chemotherapeutics. For that, a low concentration 
of SLMP53-1, with no significant growth inhibitory effects (GI10 of 4 µM), was combined with 
increasing concentrations of doxorubicin and etoposide. In HCT116 p53+/+ cells, SLMP53-
1 showed synergistic effects with all tested concentrations of chemotherapeutics (Q>1.15), 
although the most pronounced effects were obtained with doxorubicin (Figure 4.7A). 
Conversely, no synergistic effects were observed between SLMP53-1 and the 
chemotherapeutics in HCT116 p53-/- cells (Figure 4.7B). As in HCT116 p53+/+ cells, 
synergistic effects between SLMP53-1 and all tested concentrations of doxorubicin and 
etoposide were also observed in MDA-MB-231 cells (Q>1.15; Figure 4.7C). Interestingly, 
pronounced synergistic effects between 4 µM SLMP53-1 and the lowest tested 
concentrations of doxorubicin (0.19 M) and etoposide (0.38 M) were also evident 
regarding total apoptosis in MDA-MB-231 cells (Q>1.15; Figure 4.7D). Altogether, these 
results showed p53-dependent synergistic effects of SLMP53-1 with conventional 
chemotherapeutics.  
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Figure 4.6. SLMP53-1 prevents the migration of HCT116 p53+/+ and MDA-MB-231 cells. (A) 
HCT116 p53+/+ and (B) MDA-MB-231 confluent cells treated with 4 µM SLMP53-1 (or DMSO only) 
were observed at different time-points in the Wound Healing Assay. (C) Effects of SLMP53-1 on the 
migration of HCT116 p53+/+ (7 M for 24 h) and MDA-MB-231 (16 M for 8 h) cells analyzed by the 
chemotaxis assay; the migratory cells were quantified by fluorescence signal, setting as 1 cells 
treated with DMSO only; data are mean ± S.E.M. of three independent experiments; values 
significantly different from DMSO only are indicated: ***p < 0.001.  
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Figure 4.7. SLMP53-1 sensitizes HCT116 p53+/+ and MDA-MB-231 cells to the effects of 
etoposide and doxorubicin. (A-C) Effects of combined treatment with 4 µM SLMP53-1 (or DMSO 
only) and increasing concentrations of doxorubicin (Doxo) or etoposide (Etop) on tumor cell growth, 
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after 48 h; data are mean ± S.E.M. of four independent experiments; the percentage of cell growth 
achieved with SLMP53-1 only was (A) 90.3% in HCT116 p53+/+, (B) 99.8% in HCT116 p53-/- and (C) 
90.5% in MDA-MB-231 cells. (D) Effects of combined treatment with 4 µM SLMP53-1 (or DMSO 
only) and 0.19 µM doxorubicin or 0.38 µM etoposide on apoptosis after 48 h in MDA-MB-231 cells. 
The percentage of apoptotic cells obtained with SLMP53-1 only was 0.2%; data are mean ± S.E.M. 
of three independent experiments. In A, C and D, the Q values are represented; dotted line 
represents Q=1.15.  
 
4.8. SLMP53-1 has no in vitro toxicity in non-tumorigenic cells  
The potential genotoxicity of SLMP53-1 was investigated using the cytokinesis-block 
micronucleus assay. At 16 M, SLMP53-1 did not increase the number of micronuclei in 
lymphocytes when compared to DMSO only (Figure 4.8A). Additionally, 16 M SLMP53-1 
induced only 5.6 ± 3.2% (n = 5) growth inhibition in non-tumorigenic MCF10A cells, showing 
that this concentration was not toxic to normal cells. Furthermore, unlike in tumor cells, in 
MCF10A cells, the growth inhibition induced by SLMP53-1 at the GI50 concentration (42.4 
± 2.9 M, n = 5) was associated with G0/G1-cell cycle arrest (Figure 4.8B), but not with 
apoptosis (Figure 4.8C). 
 
 
4.9. SLMP53-1 has potent in vivo antitumor activity with no evident toxicity 
To evaluate the in vivo antitumor potential of SLMP53-1, mice xenograft models 
carrying HCT116 p53+/+, HCT116 p53-/-, or MDA-MB-231 tumor cells were used. The results 
revealed that four intraperitoneal administrations (twice a week) of 50 mg/kg SLMP53-1 
were highly effective, blocking the growth of HCT116 p53+/+ tumors (Figure 4.8D) compared 
to control (vehicle). Most importantly, SLMP53-1 had no effect on HCT116 p53-/- tumor 
xenografts, corroborating its p53-dependent antitumor activity (Figure 4.8D). Potent 
antitumor activity was also established for MDA-MB-231 tumors, confirming the in vivo 
efficacy of SLMP53-1 against mutant p53R280K-expressing tumors (Figure 4.8D). No 
significant loss of body weight or morbidity signs were observed in treated mice compared 
to control, throughout the experimental period (Figure 4.8E). 
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Figure 4.8. SLMP53-1, with no apparent in vitro toxicity, has potent in vivo antitumor activity. 
(A) Genotoxicity of 16 µM SLMP53-1 by cytokinesis-block micronucleus (MN) assay after 72 h 
treatment in human lymphocyte cells. Cells treated with 1 g/mL cyclophosphamide were used as 
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positive control (C+); data are mean ± S.E.M. of three independent experiments. (B) Cell cycle after 
48 h with 42.4 µM SLMP53-1 in MCF10A cells; data are mean ± S.E.M. of three independent 
experiments. In A and B, values significantly different from DMSO only are indicated: ***p < 0.001. 
(C) Apoptosis after 48 h with 42.4 µM SLMP53-1 in MCF10A cells; data are mean ± S.E.M. of three 
independent experiments; no significant differences between SLMP53-1 and DMSO only: p > 0.05. 
(D) BALB/c nude mice carrying HCT116 p53+/+, HCT116 p53-/- or MDA-MB-231 xenografts treated 
with 50 mg/kg SLMP53-1 or vehicle (control); values significantly different from control mice are 
indicated: *p < 0.05, **p < 0.01, ***p < 0.001; representative pictures of control and SLMP53-1-treated 
tumors. (E) BALB/c mice body weight during SLMP53-1 treatment; no significant differences between 
control and SLMP53-1-treated mice: p > 0.05. 
  
 
 Considering the common chemotherapeutic side effects, some primary toxicity signs 
potentially triggered by SLMP53-1 were investigated in Wistar rats. For that, the organs 
relative weight (trophism), as well as biochemical and hematological data were analyzed 
for three rat groups (saline, vehicle and SLMP53-1; Table 4.1). No differences between the 
three groups on relative weight of liver, kidneys, heart and lungs were observed. Concerning 
biochemical data, only a slight decrease of urea in the vehicle group compared to saline 
group, and a slight decrease of uric acid and albumin in the SLMP53-1 group compared to 
vehicle group were observed. Hence, no evident liver or kidney toxicity was detected in the 
SLMP53-1-treated group. Finally, concerning hematological data, just a small increase on 
the reticulocytes number was observed in the vehicle group compared to saline group, with 
no alterations between the SLMP53-1 and vehicle groups. Altogether, no apparent toxic 
side effects were observed for SLMP53-1 on the tissues most commonly affected by 
conventional chemotherapeutics. 
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Table 4.1. Safety profile for the three mice groups under study at the final time point. 
 
Saline Vehicle Treated 
Body weight and relative tissue weight (trophism) 
BW (g) 340.30 ± 13.45 361.80 ± 0.01 348.30 ± 0.01 
Heart/BW (g/kg) 3.03  ± 0.03 3.01 ± 0.09 2.91 ± 0.07 
Liver/BW (g/kg) 38.71 ± 2,36 38.52 ± 0.89 35.74 ± 0.81 
Kidney/BW (g/kg) 7.08 ± 0.40 6.81 ± 0.27 6.55 ± 0.34 
Lung/BW (g/kg) 3.89 ± 0.07 3.81 ± 0.08 3.83 ± 0.11 
Biochemical data 
Blood Glucose (mg/dL) 188.0 ± 7.51 207.20 ± 7.00 186.80 ± 11.12 
Urea (mg/dL) 20.67 ± 0.77 18.34 ± 0.24* 18.48 ± 1.31 
Uric acid (mg/dL) 1.07 ± 0.07 0.82 ± 0.10 0.78 ± 0.05* 
Creatinine (mg/dL) 0.30 ± 0.00 0.30 ± 0.01 0.30 ± 0.01 
Total Proteins (g/dL) 5.50 ± 0.00 5.35 ± 0.17 5.08 ± 0.15 
Albumin (g/dL) 3.03 ± 0.03 2.90 ± 0.05 2.73 ± 0.09* 
ALT (U/L) 36.00 ± 2.89 30.75 ± 3.30 32.50 ± 4.87 
AST (U/L) 95.33 ± 25.36 56.25 ± 4.60 67.00 ± 11.05 
CK (U/L) 458.30 ± 148.60 229.50 ± 64.40 281.80 ± 101.90 
Total Chol (mg/dL) 44.33 ± 1.76 52.40 ± 3.54 60.25 ± 5.98 
Triglycerides (mg/dL) 107.00 ± 16.29 161.40 ± 17.55 169.80 ± 24.00 
Hematological data 
RBC count (x106/µL) 7.10 ± 0.15 7.41 ± 0.28 7.28 ± 0.27 
HGB (g/dL) 13.97 ± 0.18 13.95 ± 0.46 13.53 ± 0.25 
HCT (%) 40.50 ± 0.82 42.28 ± 2.03 39.63 ± 0.99 
WBC counts (x103/µL) 5.23 ± 0.52 5.95 ± 1.61 5.08 ± 0.434 
PLT counts (x103/µL) 811.00 ± 29.61 793.80 ± 28.35 852.50 ± 32.05 
PCT (%) 0.47 ± 0.03 0.46 ± 0.009 0.50 ± 0.02 
RET counts (%) 2.80 ± 0.12 3.56 ± 0.23* 3.28 ± 0.23 
The results are expressed as mean ± S.E.M. of four to six independent experiments. *p < 0.05 versus 
Control group; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BW, body weight; 
CK, Creatine Kinase; HCT, hematocrit; HGB,  Hemoglobin concentration; PCT, plateletcrit; PLT, 
platelet; RBC, red blood cell count; RET, reticulocytes; WBC, white blood cell. 
 
In order to assess the proliferation and apoptotic status of tumors, 
immunohistochemistry and TUNEL staining were performed with tumor tissues (Figure 4.9). 
Both HCT116 p53+/+ and MDA-MB-231 tumors, treated with SLMP53-1, showed low Ki-67-
positive staining (indicative of a low proliferative status), when compared to tumors treated 
with vehicle (Figure 4.9). Additionally, a marked increase of BAX expression levels in 
SLMP53-1-treated tumor tissues, compared to vehicle, was observed (Figure 4.9). A 
pronounced increase of TUNEL-positive staining (indicative of nuclei DNA fragmentation) 
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was also observed upon SLMP53-1 treatment (Figure 4.9). On the other hand, a uniform 
pattern, characterized by high levels of Ki-67 and low levels of BAX expression and DNA 
fragmentation, between HCT116 p53-/- tumors treated with SLMP53-1 and vehicle was 
obtained (Figure 4.9). 
 
 
 
Figure 4.9. SLMP53-1 decreases cell proliferation and enhances apoptosis in human tumor 
xenografts. Representative images of Ki-67, BAX and DNA fragmentation detection in human 
HCT116 p53+/+, HCT116 p53-/- and MDA-MB-231 tumor xenograft tissues inoculated in BALB/c nude 
mice treated with 50 mg/kg SLMP53-1 or vehicle (Scale bar = 50m; Magnification 400x).
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4.10. Discussion 
The p53 protein is a key player in apoptotic processes, what makes its reactivation 
an appealing therapeutic approach in cancer treatment. For that reason, efforts have been 
made in the last years to discover new small molecule reactivators of wt and mutant p53. 
The majority of these compounds have been found using the traditional screens, in which 
the first line screening is performed in tumor cell lines with different p53 status to access 
their biological activityand selectivity. Nevertheless, to test large libraries of compounds, 
this methodology requires many resources and time. To streamline the search for new 
reactivators of mutant p53, a yeast screening assay was developed, in this work. In fact, 
this simple and reliable cell-based drug targeted screening approach, can be easily 
adaptable to the HTS of large chemical libraries, based on simple cell growth 
measurements, in a cost-effective manner. In this work, besides the validation of the yeast 
model assay to search for reactivators of mutant p53R280K and Y220C (among the twenty 
most prevalent mutant p53s), using this approach a new reactivator of wt p53 and mutant 
p53R280K, the small molecule SLMP53-1, was discovered from a chemical library of 
enantiopure tryptophanol-derived oxazoloisoindolinones.  
 Considering the relevance of the absolute stereochemical configuration of 
biologically active compounds, the enantiomer of SLMP53-1 was also synthesized (Figure 
4.1A). Interestingly, this enantiomer was inactive in yeast and exhibited a much lower 
growth inhibitory effect against wt/mutant p53-expressing tumor cells compared to SLMP53-
1 (data not shown). These results highlight the relevance of the stereochemistry at positions 
C-3 and C-9b for the activity of SLMP53-1. Besides this, the activation of wt p53 and mutant 
p53R280K (a DNA contact mutant without major structural alterations), associated with the 
absence of effect of SLMP53-1 on structural mutant p53Y220C, lead us to hypothesize 
some preference of SLMP53-1 for the wt-like conformation of p53. Further studies are 
underway to analyze the activity of SLMP53-1 on other mutant p53s.  
Contrary to PRIMA-1, SLMP53-1 exhibited a p53-dependent tumor growth inhibitory 
activity. In fact, the induction of cell cycle arrest and apoptosis, and the enhancement of 
p53 transcriptional activity by SLMP53-1 in wt p53-expressing HCT116 tumor cells were 
completely abolished in p53-null HCT116 cells. Additionally, SLMP53-1 showed a much 
higher cytotoxicity against mutant p53R280K-expressing MDA-MB-231 cells than PRIMA-
1, which cytotoxicity against this tumor cell line has been reported (Russo et al., 2013). In 
these tumor cells, SLMP53-1 restored the wt-like sequence-specific DNA binding ability to 
mutant p53R280K, with subsequent up-regulation of p53 target genes. Curiously, in mutant 
p53R280K-expressing cells, the SLMP53-1-induced growth inhibition was only associated 
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with apoptosis, and not with cell cycle arrest. These results highlight key genetic differences 
between tumor cells associated with distinct p53 status (wt/mutant).  
The pathophysiological relevance of the mitochondrial p53 function in apoptotic cell 
death has been emphasized in several studies (Marchenko and Moll, 2007). In response to 
stress, a fraction of p53 translocates to mitochondria, where it binds to Bcl-2 family proteins 
inducing mitochondrial outer membrane permeabilization (MOMP), cyt c release, and 
subsequent apoptosis (Marchenko and Moll, 2007). The mitochondrial function of mutant 
p53 is still unclear. Interestingly, mutant p53 has been reported to localize constitutively at 
mitochondrial outer membrane due to its intrinsic cellular stabilization. Despite this, the 
mutant p53 apoptotic activity is compromised by its inability to bind to Bcl-2 and trigger 
MOMP (Marchenko and Moll, 2007; Wang et al., 2011a). In this work, SLMP53-1 triggered 
a mitochondrial p53 apoptotic pathway in wt p53-expressing tumor cells, involving ∆ψm 
dissipation, p53 and BAX mitochondrial translocation, as well as cyt c release. Similar 
events were triggered by SLMP53-1 in mutant p53R280K-expressing tumor cells, 
supporting the translocation of a functionally active mutant p53 to mitochondria. It is 
interesting to note that SLMP53-1 treatment induced a p53-dependent ROS generation, 
which may result from the stimulation of both pro-oxidant and mitochondrial p53 functions. 
Actually, SLMP53-1 enhances the expression of BAX and PUMA, which besides the 
connection with the p53 mitochondrial pathway are also strongly involved in its pro-oxidant 
function (Puzio-Kuter, 2011). Collectively, the results obtained indicate that SLMP53-1 is a 
“double hit” reactivator of p53-mediated apoptosis, stimulating both the transcription-
dependent and mitochondrial-mediated p53 functions.  
Considered the main cause of morbidity and mortality in cancer patients, tumor cell 
invasion and metastization are central issues in cancer treatment (Etienne-Manneville, 
2008; Muller et al., 2011). The pivotal role of p53 in the prevention of epithelial-
mesenchymal transition and migration is widely recognized (Muller et al., 2011). 
Accordingly, mutant p53 has been associated to prometastatic functions not only due to the 
loss of p53 function, but also to the GOF related to p63 inhibition, a well-known suppressor 
of tumorigenesis and metastasis (Muller et al., 2011). Low doses of SLMP53-1 potently 
inhibited the migration of wt/mutant p53-expressing cells, which sustains the reactivation of 
wt p53, as well as of mutant p53 through reestablishment of its wt function and possible 
inhibition of its GOF.  
Since the majority of conventional chemotherapeutics, as etoposide and doxorubicin, 
depend on a functional p53 pathway, combination with p53 reactivators is expected to 
enhance their efficacy. Indeed, low doses of SLMP53-1 showed p53-dependent synergistic 
effects with both chemotherapeutic agents in wt/mutant p53-expressing tumor cells. 
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Therefore, the combination of SLMP53-1 with conventional chemotherapeutics reveals 
great therapeutic potential, particularly against multidrug-resistant tumor cells, like triple-
negative breast cancers, minimizing drug side effects, while increasing tumor suppressor 
activity. 
The toxicity of standard chemotherapeutics remains a therapeutically limiting 
problem. Herein, SLMP53-1 was shown to be non-genotoxic. Additionally, despite activating 
wt p53, at the GI50 concentration obtained in tumor cells, SLMP53-1 was not cytotoxic 
against wt p53-expressing normal MCF10A cells. The minimal cytotoxic effects of p53 
reactivators on normal cells have been attributed to their lower susceptibility to apoptotic 
stimuli when compared to tumor cells with a constitutive activation of a DNA damage 
signaling pathway (Vassilev, 2004; Berns et al., 2004; Tovar et al., 2006). This leads normal 
cells to respond to p53 reactivators with cell cycle arrest (cytostatic effect), instead of cell 
death (cytotoxic effect) (Carvajal et al., 2005; Rao et al., 2013). Actually, this was observed 
in normal cells with SLMP53-1 at a three-fold higher GI50 concentration than that used in 
tumor cells. SLMP53-1 can thus be exploited in p53-based cyclotherapy, in which normal 
cells are protected from the cytotoxicity of chemotherapeutics by induction of cell cycle 
arrest.  
Assays in xenograft mice models reinforced the p53-dependent in vivo antitumor 
activity of SLMP53-1. In fact, SLMP53-1 potently suppressed the growth of wt p53- and 
mutant p53R280K-expressing tumors through inhibition of proliferation and induction of 
apoptosis, without interfering with the growth of p53-null tumors. Additionally, SLMP53-1 
had no apparent toxic side effects on tissues most commonly affected by chemotherapy, 
such as kidneys, liver and bone marrow. 
In conclusion, several evidences are herein provided supporting the anticancer 
therapeutic potential of SLMP53-1, both alone and combined with conventional 
chemotherapeutics. To our knowledge, this is the first report of a pharmacological 
reactivator of p53R280K, a mutant p53 form involved in highly metastatic and 
chemoresistant tumors (e.g. triple negative breast cancer cells MDA-MB-231). Besides its 
great potential as anticancer drug candidate, SLMP53-1 is a starting point for the 
development of new effective derivatives targeting mutant p53s.  
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Cancer is one of the major Public Health concerns of our world aging population 
(Ferlay et al., 2015). Besides, the therapeutic options for many cancer patients remain 
limited and disappointing, mainly due to chemoresistance and devastating side effects. On 
the other hand, the development of new targeted drugs has proved to be a time consuming 
and highly unreliable process.  
Due to its central role in tumorigenesis, p53 has been pointed out as one of the most 
relevant targets in cancer treatment. Actually, the activation of the p53 pathway either by 
inhibition of the p53 interaction with their negative regulators MDMs, or by reactivation of 
the wt-like function to mutant p53 have been highlighted as hopeful strategies in anticancer 
treatment (Zawacka-Pankau and Selivanova, 2015). However, despite all the efforts 
dedicated to find effective activators of p53, to date, few have enter into clinical trials and 
none has reached the clinic (Zawacka-Pankau and Selivanova, 2015). Additionally, the 
existence of few screening methods to find new mutant p53 reactivators contribute to the 
slow progress in this field. With this thesis, great advances have been achieved in this 
research area, not only with the validation of an efficient and reliable drug screening strategy 
targeting p53, but also with the discovery of new activators of the p53 pathway identified 
from the synthesized libraries (including small molecules containing indole and/or 
isoindolinone moieties) particularly:      
 
 
a) New inhibitors of p53-MDMs interactions 
 Despite the huge diversity of chemical families identified as inhibitors of the p53-
MDM2 interaction, only few molecules have advanced into clinical trials due to their low 
selectivity, high toxicity and poor pharmacokinetic profiles (Lauria et al., 2011; Wang et al., 
2012; Wang and Hu, 2012; Zhao et al., 2013a). For this reason, the identification of new 
scaffolds of inhibitors of the p53-MDM2 interaction with improved pharmacological 
properties remains a priority goal in p53-based anticancer therapy. Based on this, using a 
previously developed yeast-based screening assay (Leão et al., 2013c), in Chapter 3.1, an 
enantiopure phenylalaninol-derived oxazolopyrrolidone lactam (oxazoloisoindolinone 3a) 
was identified as new inhibitor of the p53-MDM2 interaction. The oxazoloisoindolinone 3a 
revealed potent in vitro p53-dependent tumor growth-inhibitory effect through stimulation of 
apoptosis and cell cycle arrest. Furthermore, insights on its binding mode to MDM2 have 
been provided by molecular docking studies (Figure 5.1). It must be noted that, also under 
the scope of this thesis, using the same screening approach, the molecular mechanism 
underlying the increased cytotoxicity against human tumor cells of O-prenyl derivative of 2′-
hydroxy-3,4,4′,5,6′-pentamethoxychalcone compared to its precursor was revealed. In fact, 
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the prenylation demonstrated to be a determinant factor for the enhancement of chalcones 
tumor cytotoxicity by improving their ability to disrupt the p53–MDM2 interaction (Leão et 
al., 2015b). 
The dual inhibition of the p53 interaction with MDM2 and MDMX has long been 
considered the most effective strategy for a full reactivation of wt p53 in tumors, particularly 
against MDMX-overexpressing tumor cells (e.g., retinoblastomas and melanomas) that are 
highly resistant to MDM2-only inhibitors (Graves et al., 2012; Wade et al., 2013). Despite 
this, to date, just three small molecule dual inhibitors of the p53-MDMs interactions have 
been reported. Focusing on this, the previously developed yeast-based screening assays 
to search for inhibitors of the p53 interaction with MDM2 or MDMX (Leão et al., 1013b,c) 
were used. This approach led us to the identification of our first dual inhibitor of p53-MDMs 
interactions, the compound OXAZ-1, from a chemical library of tryptophanol-derived 
oxazolopiperidone lactams (Chapter 3.2). Although less potent than oxazoloisoindolinone 
3a in tumor cells, the small molecule OXAZ-1 was able to inhibit the p53 interaction with 
both MDM2 and MDMX, and to strongly induce a p53-dependent mitochondrial apoptotic 
pathway. Additionally, OXAZ-1 sensitized tumor cells to the effect of conventional 
chemotherapeutics, what may open the way to a potential applicability in combined 
anticancer therapy (Figure 5.1). Despite this, the modest in vitro tumor growth-inhibitory 
activity of OXAZ-1 led us to pursue our search for more potent dual inhibitors of p53-MDMs 
interactions.  
Using the same yeast-based screening strategy (Leão et al., 1013b,c), in Chapter 3.3, 
a second dual inhibitor, the compound DIMP53-1, was identified from a chemical library of 
tryptophanol-derived oxazoloisoindolinones. Besides its higher in vitro growth-inhibitory 
effect, DIMP53-1 exhibited potent p53-dependent in vivo antitumor activity with no apparent 
toxic side effects. Most importantly, despite its anti-proliferative activity through induction of 
tumor apoptotic cell death, DIMP53-1 strongly inhibited cell migration and angiogenesis. 
Together, these findings show that DIMP53-1 is an appealing anticancer drug candidate 
(Figure 5.1). It should be noted, that DIMP53-1 is the first dual inhibitor with in vivo 
anticancer properties described to date. 
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Figure 5.1. Schematic representation of the antitumor properties of the new inhibitors of p53-
MDMs interactions discovered under this thesis: Oxazoloisoindolinone 3a (inhibitor of the 
p53-MDM2 interaction), OXAZ-1 and DIMP53-1 (dual inhibitors of p53-MDMs interactions). 
 
 
b) New reactivator of mutant p53  
Few small molecules have been recognized as true reactivators of the wt-like activity 
to mutant p53, and just APR-246 has reached clinical trials (Khoo et al., 2014; Zawacka-
Pankau and Selivanova, 2015; Girardini et al., 2014).  
To streamline the discovery process of new reactivators of mutant p53, a reliable and 
highly adaptable approach to HTS was developed under the scope of this thesis based on 
yeast cells expressing independent mutant p53 forms, such as R280K and Y220C. The 
efficacy of this approach to search for reactivators of mutant p53 was validated in this thesis 
with the identification of SLMP53-1, the first reactivator of mutant p53 R280K and activator 
of wt p53, from a chemical library of enantiopure tryptophanol-derived 
oxazoloisoindolinones (Chapter 4). SLMP53-1 revealed potent in vitro and in vivo p53-
dependent antitumor activity against wt/mutant p53-expressing tumors, without apparent 
toxic side effects (Figure 5.2). Additionally, it strongly stimulated a p53-mediated 
mitochondrial apoptotic pathway, inhibited cell migration and sensitized wt/mutant p53-
expressing tumor cells to conventional chemotherapeutics (Figure 5.2). Altogether, several 
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evidences are provided in this thesis supporting the great therapeutic potential of SLMP53-
1, either alone or in combined therapy, particularly against mutant p53 R280K-expressing 
tumors, such as triple negative breast cancer cells characterized by its poor prognosis due 
to be highly metastatic and chemoresistant to conventional chemotherapeutic drugs.       
 
 
 
Figure 5.2. Drug discovery strategy underlying the identification of the first reactivator of 
mutant p53 R280K: SLMP53-1 and its antitumor properties. Using a yeast screening assay, 
SLMP53-1 was identified as potential reactivator of wt and mutant p53 R280K. SLMP53-1 shows in 
vitro antitumor activity through stimulation of a mitochondrial-mediated apoptotic cell death, inhibits 
migration of highly metastatic tumor cells, has synergistic activity in combination with conventional 
chemotherapeutics, and shows potent in vivo p53-dependent antitumor activity. 
 
 
Final conclusions and future perspectives 
With the present thesis, a new yeast screening assay that will streamline the discovery 
of new reactivators of mutant p53 was developed. Additionally, by using yeast-based 
targeted screening assays, for a first selection of potential bioactive compounds to be tested 
in more complex cell systems, four new activators of the p53 pathway 
(Oxazoloisoindolinone 3a, OXAZ-1, DIMP53-1, and SLMP53-1) were discovered. In fact, 
with this thesis, the enormous contribution of yeast as screening tool to anticancer drug 
discovery is greatly reinforced. In particular, the extension of the yeast assay developed for 
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mutant p53 R280K and Y220C to other prevalent mutant p53 forms may open the way to 
the discovery of new potential reactivators. This would have a particular impact in 
personalized anticancer therapy of patients with mutant p53-expressing tumors. Actually, 
to date, only reactivators of few mutant p53 forms (R273H, R175H, Y220C, R248W, 
R249Q) have been reported. In this context, it would be interesting to test the ability of 
SLMP53-1 to reactivate other mutant p53 beyond R280K.   
Most importantly, with this work two promising anticancer drug candidates, DIMP53-
1 and SLMP53-1, were identified. Future pharmacokinetic studies of absorption, 
distribution, metabolism, and elimination (ADME), in association with a more detailed 
toxicological characterization, will evaluate their potential as pharmaceutical agents to 
possible progress to clinical trials.  
Likewise, a more detailed elucidation of the molecular mechanism of action of 
Oxazoloisoindolinone 3a, OXAZ-1, DIMP53-1, and SLMP53-1, by defining possible 
interactions with the target proteins, through biophysical binding assays and 
crystallographic analysis, would clarify their activity and would help their hit-to-lead 
optimization. Actually, Oxazoloisoindolinone 3a, OXAZ-1, DIMP53-1, and SLMP53-1 
represent promising starting points for the development of more effective derivatives.  
In addition, in future works, the anti-migration and anti-angiogenic properties of the 
anticancer drug candidates DIMP53-1 and SLMP53-1 could be further explored. This would 
better define the potential therapeutic applications of these compounds against certain 
types of cancer (namely high metastatic cancers). Moreover, the molecular mechanism 
responsible for the switch between survival and death under p53 activation could be also 
explored using DIMP53-1 and SLMP53-1 as pharmacological tools. In particular, it would 
be interesting to elucidate the different profiles (cell cycle arrest versus apoptosis) triggered 
by SLMP53-1 in tumor cells harbouring different p53 status (wt versus mutant p53).  
Besides the synergy observed between OXAZ-1 or SLMP53-1 with conventional 
chemotherapeutics, it would also be interesting to analyse the combination therapy between 
a dual interaction inhibitor (as DIMP53-1) and a wt/mutant p53 reactivator (as SLMP53-1) 
in order to achieve an overactivation of the p53 signalling pathway translated into synergistic 
antitumor effects. Furthermore, for all promising combinations, the synergistic interaction 
pathways need to be further elucidated. 
Finally, DIMP53-1 and SLMP53-1 could be explored in p53-cyclotherapy, 
representing other possible therapeutic applicability of these compounds as 
chemoprotectors, and therefore should be the focus of further studies. 
In conclusion, besides the incontestable impact of this work to the advance of p53 
pharmacology and targeted drug discovery, it gives rise to new hopes and therapeutic 
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opportunities in cancer treatment by providing potential anticancer drug candidates. 
Besides this, the present thesis provides attractive pharmacological tools to the p53 
research field, as well as starting scaffolds that may be the basis for future derivatives with 
improved pharmacological properties as anticancer therapeutic agents. 
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Section 1. General preparation of compounds 1a-c, 2a-b, 3a-b and 4a-b 
 
 
Chemicals were purchased from Sigma-Aldrich Chemical Co. Ltd., Spain and used 
without further purification. All compounds were characterized by NMR spectroscopy and 
mass spectrometry. NMR spectra was acquired on a Bruker 400 Ultrashield spectrometer 
at 400 MHz (1H NMR) and 100 MHz (13C NMR). Data were reported as follows: chemical 
shift (δ), multiplicity (s: singlet, d: doublet, dd: doublet of doublet; ddd: doublet doublet of 
doublets, t: triplet, td: triplet of doublets, m: multiplet, br: broad), coupling constants (J) in 
Hertz and integration. 1H and 13C chemical shifts are expressed in ppm using the solvent 
as internal reference. Elemental analysis for C, H and N elements were performed in a 
Flash 2000 Elemental Analyzer (ThermoScientific, UK) at Faculty of Pharmacy of Lisbon 
University. The purity of compounds submitted for biological testing was determined by 
elemental analysis to be ≥95%. Melting points were determined in a Bock-M Monoscope 
apparatus and are uncorrected. The specific rotation values were measured in a Perkin-
Elmer 241MC Polarimeter. The flash chromatography was performed using Merck Silica 
Gel (200-400 mesh). 
To a stirred solution of the appropriate aminoalcohol (0.1 g, 0.66 mmol) in toluene (10 
mL), it was added 1.1eq of the appropriate β-oxo-acid. The mixture was then refluxed under 
a dean-stark apparatus and an inert atmosphere. After cooling the reaction to room 
temperature the solvent was evaporated to dryness. The crude residue obtained was 
adsorbed onto silica and purified by flash chromatography with the adequate solvent 
system. 
 
1.1. (3S,9bR)-3-benzyl-9b-methyl-2,3-dihydrooxazolo[2,3-a]isoindol-5(9bH)-one 
(1a) 
A mixture of (S)-2-amino-3-phenyl-propan-1-ol (0.1 g, 0.66 mmol) and 2-acetyl-
benzoic acid (0.12 g, 0.73 mmol) in toluene (10 mL) was treated according to the general 
procedure for 16 h. Purification using EtOAc/n-Hex (2:3) afforded compound 1a (0.170 g, 
92%) as a colorless oil. [α] D20= +27.3 (c = 2.1, CH2Cl2). Elemental Anal. calcd. for 
C18H17NO2·0.75H2O: C 73.82, H 6.38, N 4.78, found: C 73.33, H 5.96, N 4.80. 1H and 13C 
NMR spectra were found to be identical to the ones described previously (Pereira et al., 
2013). 
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1.2. (3S,9bR)-3-benzyl-9b-phenyl-2,3-dihydrooxazolo[2,3-a]isoindol-5(9bH)-one 
(1b)  
A mixture of (S)-2-amino-3-phenyl-propan-1-ol (0.1 g, 0.66 mmol) and 2-benzoyl-
benzoic acid (0.16 g, 0.73 mmol) in toluene (10 mL) was treated according to the general 
procedure for 16 h. Purification using EtOAc/n-Hex (3:7), followed by recrystallization in 
Et2O/n-Hex, afforded compound 1b (0.193 g, 86%) as a white crystal solid. [α]D20= +144.6 
(c = 1.9, CH2Cl2). Elemental Anal. calcd. for C23H19NO2: C 80.91, H 5.62, N 4.10, found: C 
80.91, H 5.68, N 4.25. 1H and 13C NMR spectra were found to be identical to the ones 
described previously (Pereira et al., 2013). 
 
1.3.(3S,9bR)-3-benzyl-6,7-dimethoxy-2,3-dihydrooxazolo[2,3-a]isoindol-5(9bH)-
one (1c) 
A mixture of (S)-2-amino-3-phenyl-propan-1-ol (0.1 g, 0.66 mmol) and 6-formyl-2,3-
dimethoxy-benzoic acid (0.16 g, 0.73 mmol) in toluene (10 mL) was treated according to 
the general procedure for 16 h. Purification using EtOAc/n-Hex (1:3), followed by 
recrystallization in EtOAc/n-Hex, afforded compound 1c (0.141 g, 66%) as a white solid. mp 
124-127 ºC. [α]D20= +32.8 (c = 1.2, CH2Cl2).  1H NMR (400 MHz, CDCl3) δH (ppm) 7.34 – 
7.19 (m, 5H, H-ar), 7.15 (d, J = 8.1 Hz, 1H, H-ar), 7.04 (d, J = 8.1 Hz, 1H, H-ar), 5.61 (s, 
1H, CH), 4.49 – 4.37 (m, 1H, CH), 4.30 – 4.20 (m, 1H, CH2), 4.05 (s, 3H, CH3), 3.89 (dd, J 
= 8.6, 6.7 Hz, 1H, CH2), 3.85 (s, 3H, CH3), 3.12 (dd, J = 13.9, 5.5 Hz, 1H, CH2), 2.90 (dd, J 
= 13.8, 8.1 Hz, 1H, CH2). 13C NMR (101 MHz, CDCl3) δC (ppm) 171.95 (C=O), 154.29 (C-
q), 147.57 (C-q), 137.02 (C-q), 135.28 (C-q), 129.55 (C-ar), 128.72 (C-ar), 126.88 (C-ar), 
124.49 (C-q), 119.03 (C-ar), 116.84 (C-ar), 90.08 (CH), 74.78 (CH2), 62.52 (CH3), 56.73 
(CH3), 55.77 (CH), 39.88 (CH2). IR (KBr) 1698 (C=O) cm-1. Elemental Anal. calcd. for 
C19H19NO4·0.15 H2O: C 69.56, H 5.94, N 4.27, found: C 69.18, H 5.59, N 3.97. 
 
1.4. (3S,7aR)-3-benzyl-7a-methyltetrahydropyrrolo[2,1-b]oxazol-5(6H)-one (2a)  
A mixture of (S)-2-amino-3-phenyl-propan-1-ol (0.1 g, 0.66 mmol) and levulinic acid 
(0.08 mL, 0.73 mmol) in toluene (10 mL) was treated according to  the general procedure 
for 48 h. Purification using EtOAc/n-Hex (3:7) afforded compound 2a (0.111 g, 73%). 
Elemental Anal. calcd. for C14H17NO2·0.5H2O: C 69.97, H 7.57, N 5.83, found: C 69.63, H 
7.40, N 5.85. 1H and 13C NMR spectra were found to be identical to the ones described in 
literature (Allin et al., 2001). 
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1.5. (3S,7aS)-3-benzyl-7a-phenyltetrahydropyrrolo[2,1-b]oxazol-5(6H)-one (2b)  
A mixture of (S)-2-amino-3-phenyl-propan-1-ol (0.1 g, 0.66 mmol) and 3-benzoyl-
propionic acid (0.13 g, 0.73 mmol) in toluene (10 mL) was treated according to the general 
procedure for 48 h. Purification with EtOAc/n-Hex (3:7), followed by recrystallization in 
Et2O/n-Hex, afforded compound 2b (0.140 g, 72%) as a white solid. [α]D20= +4.7 (c = 1.9, 
CH2Cl2). Elemental Anal. calcd. for C19H19NO2: C 77.78, H 6.54, N 4.78, found: C 77.75, H 
6.68, N 4.98. 1H and 13C NMR spectra were found to be identical to the ones described 
previously (Pereira et al., 2013). 
 
1.6. (3R,9bS)-3-benzyl-9b-phenyl-2,3-dihydrooxazolo[2,3-a]isoindol-5(9bH)-one 
(3a)   
A mixture of (R)-2-amino-3-phenyl-propan-1-ol (0.1 g, 0.66 mmol) and 2-benzoyl-
benzoic acid (0.16 g, 0.73 mmol) in toluene (10 mL) was treated according to the general 
procedure for 16 h. Purification using EtOAc/n-Hex (1:9), followed by recrystallization in 
Et2O/n-Hex, afforded compound 3a (0.167 g, 74%) as a white crystal solid. [α]D20= -138.0 
(c = 2.2, CH2Cl2). Elemental Anal. calcd. for C23H19NO2: C 80.91, H 5.62, N 4.10, found: C 
81.05, H 5.69, N 4.26. 1H and 13C NMR spectra were found to be identical to the one 
obtained for compound 1b (Pereira et al., 2013). 
 
1.7.(3R,9bS)-3-benzyl-6,7-dimethoxy-2,3-dihydrooxazolo[2,3-a]isoindol-5(9bH)-
one (3b) 
 A mixture of (R)-2-amino-3-phenyl-propan-1-ol (0.1 g, 0.66 mmol) and 6-formyl-2,3-
dimethoxy-benzoic acid (0.16 g, 0.73 mmol) in toluene (10 mL) was treated according to 
the general procedure for 16 h. Purification using EtOAc/n-Hex (1:3), followed by 
recrystallization in EtOAc/n-Hex, afforded compound 3b (0.122 g, 57%) as a colorless 
crystal solid. [α]D20= -30.1 (c = 1.2, CH2Cl2). Elemental Anal. calcd.. for C19H19NO4.0.15H2O: 
C 69.56, H 5.94, N 4.27, found: C 69.18, H 5.59, N 3.97. The 1H NMR spectra was found to 
be identical to the one obtained for compound 1c. 
 
1.8. (3R,7aS)-3-benzyl-7a-methyltetrahydropyrrolo[2,1-b]oxazol-5(6H)-one (4a) 
A mixture of (R)-2-amino-3-phenyl-propan-1-ol (0.1 g, 0.66 mmol) and levulinic acid 
(0.08 mL, 0.73 mmol) in toluene (10 mL) was treated according to the general procedure 
for 16 h. Purification using EtOAc/n-Hex (1:2) afforded compound 4a (0.093 g, 61%) as a 
pale yellow solid. [α]D20= -52.7 (c = 0.9, CH2Cl2). Elemental Anal. calcd. for C14H17NO2·0.15 
H2O: C 69.56, H 5.94, N 4.27, found: C 69.18, H 5.59, N 3.97. The 1H NMR spectra was 
found to be identical to the one obtained for compound 2a. 
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1.9. (3R,7aR)-3-benzyl-7a-phenyltetrahydropyrrolo[2,1-b]oxazol-5(6H)-one (4b)  
A mixture of (R)-2-amino-3-phenyl-propan-1-ol (0.1 g, 0.66 mmol) and 3-benzoyl-
propionic acid (0.13 g, 0.73 mmol) in toluene (10 mL) was treated according to the general 
procedure for 48 h. Purification with EtOAc/n-Hex (3:7), followed by recrystallization in 
EtOAc/n-Hex, afforded compound 4b (0.165 g, 84%) as a white solid. [α]D20= -3.0º (c = 2.4, 
CH2Cl2). Elemental Anal. calcd. for C19H19NO2·0.15H2O: C 77.07, H 6.58, N 4.73, found: C 
77.09, H 6.42, N 4.82. The 1H NMR spectra was found to be identical to compound 2b. 
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1.10. 1H NMR and 13C NMR spectra of compound 3a 
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Section 2. Synthesis of OXAZ-1 
 
 
A solution of (S)-tryptophanol-derived oxazolopiperidone lactam OXAZ-5 (0.2 g, 0.548 
mmol) in CH2Cl2 (10 mL) was cooled to 0ºC. p-Toluenesulphonyl chloride (0.133 g, 0.701 
mmol) and tetra-butylammonium chloride (cat., 10% mmol) were added and the mixture 
was stirred for 10 min. Then, an aqueous solution of NaOH (30% m/v, 0.5 v CH2Cl2) was 
added and the reaction was allowed to stand at room temperature for 24 h. After this period, 
the reaction was diluted with CH2Cl2 (10 mL) and the phases were separated. The organic 
phase was washed with HCl (1 M, 10 mL) and dried over Na2SO4. After solvent evaporation 
the crude compound was purified by flash chromatography (EtOAc/n-hexane 1:1). The 
desired compound was obtained as a white crystal solid after recrystallization from 
dichoromethane.1H NMR (400 MHz, CDCl3) δ 7.96 (d, J  = 8.1 Hz, 1H), 7.72 (m, 3H), 7.36 
(s, 1H), 7.31 (t, J = 7.7 Hz, 1H),7.25 (m, 1H), 7.21 (m, 2H), 4.70 (dd, J = 9.9, 2.5 Hz, 1H), 
4.23 (m,1H), 3.95 (d, J = 9.4 Hz, 1H), 3.74 (t, J = 7.8 Hz, 1H), 3.70 (s, 3H), 3.58 (d, J = 14.1 
Hz, 1H), 2.68 (dd, J = 14.0, 9.8 Hz, 1H), 2.60 (dd, J = 17.6,4.6 Hz, 1H), 2.37 (m, 3H), 2.33 
(s, 3H), 2.28 (d, J = 12.0 Hz, 1H), 2.10 (dd, J = 17.6, 10.2 Hz, 1H), 1.21 (m, 1H). Elemental 
Anal. calcd. For C26H28N2O6S: C 62.89, H 5.68, N 5.64; found: C 62.98, H 5.84, N 6.00. The 
1H NMR spectra was found to be identical to the one described in (Pereira et al., 2014). 
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Section 3. Chemical synthesis of SLMP53-1 and its enantiomer 
 
 
All reagents and solvents were obtained from commercial suppliers and used without 
further purification. Melting point was determined using a Kofler camera Bock monoscope 
M. The infrared spectra were collected on a Shimadzu IRAffinity-1 FTIR infrared 
spectrophotometer. Only noteworthy IR absorptions (cm-1) are listed. Microanalyses were 
performed in a Thermo Scientific TM FLASH 2000 Series CHNS/O analyzer and are within 
±0.5% of theoretical values. Analysis Merck Silica Gel 60 F254 plates were used as 
analytical thin layer chromatography; flash chromatography was performed on Merck Silica 
Gel (200-400 mesh). Optical rotations were determined in a Perkin–Elmer 241 MC 
polarimeter at rt. 1H and 13C NMR spectra were recorded on a 400 MHz. Carbon nuclear 
magnetic resonance spectra were recorded at 100 MHz. 1H and 13C NMR chemical shifts 
are reported in δ (ppm) referenced to the solvent used and the proton coupling constants J 
in hertz (Hz) (Chapter 4.1). Spectra were assigned using appropriate COSY, DEPT and 
HMQC sequences. 
 
 
3.1. Chemical Synthesis of SLMP53-1 
2-Acetyl-benzoic acid (0.19 g, 1.16 mmol, 1.1 eq.) was added to a stirred solution of 
(S)-tryptophanol (0.2 g, 1.05 mmol, 1.0 eq.) in 10 mL of toluene. The mixture was heated at 
reflux under inert atmosphere using Dean-Stark conditions during 16 h. The solvent was 
removed under reduced pressure and the residue obtained was purified by flash 
chromatography (Ethyl Acetate/n-Hexane 2:1). The product was obtained as a white solid 
(81% yield) after recrystallization in Ethyl Acetate/n-Hexane. SLMP53-1: IR (KBr): 3283 (N-
H); 1697 (C=O) cm-1; mp: 182 – 184 °C; [α]D20=+23.7 (c 0.43 g/100 ml, CH2Cl2); 1H NMR 
(DMSO-d6) δ 10.92 (s, 1H, NH), 7.74 – 7.65 (m, 3H, H-Ar), 7.59 (m, 2H, H-Ar), 7.38 – 7.34 
(m, 2H, H-Ar), 7.08 (t, J = 7.1 Hz, 1H, H-Ar), 7.01 (t, J = 7.4 Hz, 1H, H-Ar), 4.41 – 4.29 (m, 
2H, CH e OCH2), 4.14 (dd, J = 8.0, 6.1 Hz, 1H, OCH2), 3.25 (dd, J = 14.5, 5.1 Hz, 1H, CH2-
indole), 3.12 (dd, J = 14.6, 8.1 Hz, 1H, CH2-indole), 1.67 (s, 3H, CH3); 13C NMR (DMSO-d6) 
δ 173.76 (C=O), 147.55 (Cq), 136.63 (Cq), 133.93 (CH-Ar), 131.40 (Cq), 130.81 (CH-Ar), 
127.85 (Cq), 124.04 (CH-Ar), 123.87 (CH-Ar), 123.25 (CH-Ar), 121.49 (CH-Ar), 118.86 (CH-
Ar), 118.70 (CH-Ar), 111.88 (CH-Ar), 110.60 (Cq), 98.87 (Cq), 74.65 (OCH2), 55.95 (CH), 
30.84 (CH2), 22.79 (CH3); Anal. calcd. for C20H18N2O2•0.15H2O: C 74.81, H 5.67, N 8.73, 
found: C 74.86, H 5.67, N 8.75. 
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3.2. Chemical Synthesis of SLMP53-1 enantiomer 
Following the same procedure used for the synthesis of SLMP53-1, to a solution of 
(R)-tryptophanol (0.1 g, 0.53 mmol) in toluene (15 mL) was added 2-acetylbenzoic acid 
(0.10 g, 0.58 mmol). The product was obtained as a white solid (76% yield) after 
recrystallization in EtOAc/n-Hexane. [α]D20= -27.1 (c 0.43 g/100 ml, CH2Cl2) 1H NMR spectra 
was found to be identical to the one obtained for compound SLMP53-1. 
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3.3. 1H NMR and 13C NMR data for compound SLMP53-1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
